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Nuclear Factor kappa B (NFO) is an ubiquitous primary transcription factor that plays 
a central regulating role in many immune and inflammatory responses. 
Using immunohistochernistry, significantly increased numbers of cells positive for 
activated NFKB were demonstrated in all layers of inflamed Crohn's disease bowel, 
compared to non-inflamed bowel from controls. A significant increase in the number of 
positive cells was also demonstrated in the submucosa, of non-inflamed areas of 
Crohn's disease bowel, which may therefore be the site of the first changes of Crohn's 
disease. Cells positive for activated NFO were identified by morphological criteria as 
mostly macrophages, with some lymphocytes. 
While developing a method to study activation of NFicB using in situ hybridisation 
(ISH), non-specific binding of oligonucleotide probes to eosinophils in sections of 
bowel was demonstrated. Binding was sequence-dependent, and was prevented by 
blocking agents followed by high stringency post-hybridisation washes. Hybridisation 
of poly-dM probe to mRNA was demonstrated with low stringency washes, but 
binding to eosinophils returned under these conditions despite blocking measures. 
In vitro binding of oligonucleotide probes to eosinophilic cationic protein (ECP), 
isolated from eosinophil granules, was demonstrated, and this effect was shown not to 
be due to the unusually high pI of ECP. 
Finally, a relationship between probe hydrophobicity, measured by reverse phase ion- 
pair high performance liquid chromatography, and in situ binding of individual probes 
to eosinophils was demonstrated. Effective tissue penetration by hydrophobic probes 
and subsequent strong probe-ECP interactions therefore make ISH, at least with 
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oligonucleotide probes, impractical in eosinophil-containing tissues, such as bowel. 
Previous work using oligonucleotide ISH on bowel has not recognised this difficulty 
and so apparently positive results are likely to have been compromised by this binding 
of probes to eosinophils. 
In conclusion, activation of NFKB, a key event in the inflammatory response, is 
increased in all layers of inflarned Crohn's disease bowel and in the submucosa of non- 
inflamed areas, which may therefore be the site of the first changes of Crohn's disease. 
ECP differentiaRy binds oligonucleotide probes during ISH and the magnitude of this 
binding is determined by probe hydrophobicity. 
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Chapter 2 
Figure 1. Photomicrographs (above x 100, below x 400) of a frozen section of normal 
large bowel from a patient with carcinoma, with ISH using an oligonucleotide probe 
cocktail for mRNA for IkBot, showing positive cells within the lamina propria 
(appearances similar with probe cocktail for mRNA for TNFc0. 
Figure 2. Photomicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis), with ISH using an oligonucleotide antisense probe cocktail for mRNA for 
IkBot, showing a greater number of positive cells than seen in normal bowel (Figure 1) 
widiin the lamina propria (appearances similar with probe cocktails for mRNA for 
TNF(x, IL-4 and IL- 10). 
Figure 3. Photornicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis) with ISH using poly-d(T) probe showing a pattern within the lamina propria 
similar to that seen with probes for cytokine mRNAs (Figure 2), and not positivity of 
all cells, as is expected if poly-d(T) probe remains hybridised to the poly-riboadenosine 
tail present on all mRNA. 
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Figure 4. Photomicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis), pre-treated with RNase, with ISH using an oligonucleotide antisense probe 
cocktail for mRNA for IKB(x, showing a similar pattern of positive cells, at reduced 
levels to that seen without pre-treatment with RNase (Figure 2) (appearances similar 
with probe cocktails for mRNA for TNFot and poly-d(T) probe). 
Figure 5. Photornicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis), with ISH using an oligonucleotide antisense probe cocktail for mRNA for 
insulin, showing a pattern of positive cells similar to that seen with all other probes; 
insulin mRNA should not be present in bowel, and therefore the pattern suggests 
binding of probes to another element. 
Figure 6. Photomicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis), with ISH using an oligonucleotide sense probe for mRNA for IKBcc, showing a 
pattern of positive cells within the lamina propria similar to that seen with the antisense 
cocktail (Figure 2), but with fewer positive cells and each positive cell with fewer 
overlying granules. The concentrations of probe in the sense and antisense 
hybridisation solutions were equal. 
Figure 7. Photomicrograph (x 1000) of a frozen section of inflamed large bowel from 
a patient with inflammatory bowel disease (ulcerative colifis) with ISH using an 
oligonucleotide antisense probe cocktail for mRNA for IKBcc. The cell with overlying 
positive granules has a bilobed nucleus and granular cytoplasm, suggesting it to be an 
eosinophil. Many similar cells had denser overlying positive granules, but this cell was 
chosen for photography as the underlying cell morphology was easily seen. 
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Figure 8. Photomicrograph (x 400) of a frozen section of inflamed large bowel from a 
patient with inflammatory bowel disease (ulcerative colitis) pre-stained with eosin, with 
subsequent ISH using an oligonucleotide antisense probe cocktail for mRNA for IlcB(x; 
all cells with overlying positive granules, indicating binding of probes during ISH, also 
stained with eosin, suggesting them to be eosinophils (appearances similar with probe 
cocktails for mRNA for TNF(x, IL-4, IL-10 and insulin, and with poly-d(T) probe). 
Figure 9. Photomicrograph (x 1000) of a frozen section of inflamed large bowel from 
a patient with inflammatory bowel disease (ulcerative colitis) stained with 15 % carbol 
chromotrope for 30 minutes; only the granular cytoplasm of eosinophils, stains red. 
Figure 10. Photornicrograph (x 400) of a frozen section of nasal polyp from a patient 
with allergic rhinitis, with ISH using an oligonucleotide probe cocktail for mRNA for 
IKBoc, showing numerous positive cells within the lamina propria (appearances similar 
with probe cocktail for mRNA for TNFot and insulin, and with poly-d(T) probe). 
Figure 11. Photomicrograph (x 400) of a frozen section of rat cerebral cortex, with 
ISH using an oligonucleotide antisense probe cocktail for mRNA for IO(x, showing no 
positive cells (appearances similar with probe cocktails for mRNA for TNF(x and 
insulin, and with poly-d(l) probe). 
Figure 12. Photomicrograph (x 400) of a section of paraffin-embedded, inflamed large 
bowel from a patient with inflammatory bowel disease (Crohn's disease), with ISH 
using an oligonucleotide antisense probe cocktail for mRNA for IKB(x, showing a 
pattern of positive cells within the lamina propria similar to that seen in frozen sections 
(appearances similar with probe cocktails for mRNA for TNFoc and insulin, and with 
poly-d(T) probe). 
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Figure 13. Photomicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis) pre-treated with dithiothreitol and iodoacetamide, with ISH using poly-d(T) 
probe, showing no positive cells, indicating successful blocking of non-specific binding 
of probe to cosinophils (appearances similar with probe cocktails for mRNA for TNRX 
and insulin, and with poly-d(T) probe). 
Figure 14. Photornicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis) pre-treated with dithiothreitol and iodoacetamide, with ISH using poly-d(T) 
probe, followed by reduced stringency washes (5 x SSQ, showing positive signal 
overlying all cells, indicating retention of poly-d(T) probe hybridised to the poly- 
riboadenosine tail on all mRNA. 
Figure 15. Photomicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis) pre-treated with RNase, thus removing all mRNA, and then pre-treated with 
dithiothreitol and iodoacetamide, with ISH using poly-d(T) probe, followed by reduced 
stringency washes (5 x SSQ, showing recurrence of non-specific binding of probe to 
eosinophils. 
Chapter 3 
Figure 1. Principle of total internal reflection. Total internal reflection at the interface 
between two media of different refractive indices causes an evanescent wave in the 
medium of lower refractive index on the non-illuminated side (adapted from BIA 
technology handbook (Pharmacia Biosensor, Uppsala, Sweden)). 
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Figure 2. Principles of biomolecular interaction analysis using a BiacoreX-Tm instrument. 
1. SPR at the sensor chip surface results in a sharp reduction in the intensity of reflected light 
at a specific angle of reflection (A). 
2. The angle (B) changes when analyte binds to ligand on the sensor chip surface. 
3.71be angles A and B are recorded as changes in 'resonance signal' in RU and plotted against 
time as a 'sensorgrarn' (adapted from BIA technology handbook (Pharmacia Biosensor)). 
Figure 3. A representative example of one of five injections of antisense 1 probe over 
ECP and myoglobin in chip A, displayed as overlaid sensorgrams. Similar sensorgrams 
were plotted for the three other oligonucleotide probes. The large negative deflection 
of both sensorgrams that occurs at the start of injection represents a combination of the 
bulk refractive effect and any binding of oligonucleotide probe to ECP or the control 
protein, myoglobin. A smaller negative deflection of the ECP sensorgram than the 
control protein sensorgrarn is observed, due to the expected binding of oligonucleotide 
probe to ECP, but not to the control protein. The sensorgrams are precisely 
superimposed but a slower, as well as smaller, negative deflection of the ECP 
sensorgram is observed (see section 3.6.2 for explanation). 
Figure 4. Subtracted sensorgrams (ECP-myoglobin) representing net binding to ECP 
in chip A for all four oligonucleotide probes. 'Me sensorgrams are representative 
examples of one of five cycles of injections of probes. They were created by 
subtraction of the sensorgrams for injection over myoglobin from the sensorgrams for 
simultaneous injection over ECP for each probe, and represent on-off curves for the 
interaction between ECP and oligonucleotide probes. The association and dissociation rate 
constants were calculated using the data contained in the areas of the graphs marked 'A' and 
'13' respectively, while the magnitude of binding was measured at an arbitrary point, 80 
seconds after the start of injection, marked 'C'. The genesis of the initial large peak at the start 
of injection and the subsequent large trough at the end of injection is explained in the legend to 
Figure 3, and their meaning discussed in section 3.6. 
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Figure 5. Reproducibility of subtracted sensorgrams (ECP-myoglobin) representing 
five successive bindings of antisense I to ECP in chip A. Sensorgrams were created by 
subtraction of the sensorgrams for injection of probes over the control protein, 
myoglobin, from the sensorgrams for simultaneous injections over ECP. The graphs 
demonstrate that the data were highly reproducible, and that the initial large peak at the 
start of injection and large trough at the end of injection were conserved between 
injections. 
Figure 6. A representative example of one of four injections of antisense 1 probe over 
ECP and lysozyme in chip B, displayed as overlaid sensorgrams. in contrast to Figure 5, 
there is no delay in the deflection of the two sensorgrams at the start and end of injection, and in 
this chip, the bulk refractive effect of the injection solution is negligible. 
Figure 7. Subtracted sensorgrams (ECP-lysozyme) representing net bindings to ECP 
in chip B of all four oligonucleotide probes to ECP. Sensorgrams were created by 
subtraction of the sensorgrams for injection over the control protein, lysozyme, from 
the sensorgrams for simultaneous injections over ECP, for each probe. The curves 
represent smooth on-off curves for the interaction between ECP and the four tested 
oligonucleotide probes, and are the only complete cycle of injections of all four probes 
in chip B. 
Figure 8. Graph displaying means and standard deviations of magnitudes of bindings of 
different oligonucleotide probes to ECP (x) and to myoglobin (-) in chip A in RU (data 
displayed in tabulated form in Table 2). 
16 
Chapter 5 
Figure 1. Photornicrographs (magnification x 1000) of unstimulated (above) and 
stimulated (below) HeLa Ohio cells grown onto cover slips and immunostained for 
activated NFKB. Cells were stimulated with TNFa and PMA and fixed in 
ethanol/formaldehyde. The stimulated cell shows dense nuclear staining (brown, 
peroxidase-based detection system). The results show, together with results displayed 
in Figures 2 and 3, that the antibody binds to the nuclei of stimulated cells, which is 
consistent with its proposed specificity for activated NFicB. 
Figure 2. Photomicrographs (magnification x 1000) of negative controls of 
unstimulated (above) and stimulated (below) HeLa Ohio cells grown onto cover slips 
and immunostained with substitution of PBS for the primary (anti-p65 NFicB) antibody 
(brown, peroxidase-based detection system). Cells were stimulated with TNF(x and 
PMA and fixed in ethanol/formaldehyde. The absence of staining confirms that the 
staining in Figure 1, with use of the primary antibody, is not due to non-specific 
binding of secondary or tertiary layers of immunostaining, or due to endogenous 
peroxidase activity. 
Figure 3. Photomicrographs (magnification x 400) of a frozen section of mouse 
cerebral cortex immunostained for activated NFicB (above) showing nuclear staining, 
and negative control (below) immunostained in the same manner with PBS substituted 
for the . primary antibody (brown, peroxidase-based detection system) and 
counterstained with Mayer's haernatoxylin. Neurones in mouse cerebral cortex are 
known to constitutively express activated NPKB, and so the results are consistent with 
the proposed specificity of the primary antibody. 
Figure 4. Photomicrographs of the mucosa of a frozen section (above, magnification x 
100; below, magnification x 400) of inflamed CD bowel (patient 10) immunostained 
for activated NFKB and counterstained with Mayer's haernatoxylin, showing scattered 
cells positive for activated NFO (red, alkaline phosphatase-based detection system). 
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Figure 5. Photomicrographs of the submucosa of a frozen section (above, 
magnification x 100; below, magnification x 400) of inflamed bowel from a patient 
with CD (patient 10) immunostained for activated NFkB and counterstained with 
Mayer's haematoxylin, showing scattered cells positive for activated NFKB (red, 
alkaline phosphatase-based detection system). 
Figure 6. Photomicrographs of the muscle layer of a frozen section (above, 
magnification x 100; below, magnification x 400) of inflamed bowel from a patient 
with CD (patient 10) immunostained for activated NFO and counterstained with 
Mayer's haematoxylin, showing scattered cells positive for activated NFO (red, 
alkaline phosphatase-based detection system). 
Figure 7. Photornicrographs (magnification x 200) of a frozen section (above, mucosa; 
middle, submucosa; below, muscle) of inflamed bowel from a patient with CD (patient 
10) immunostained for activated NFxB with PBS substituted for the primary antibody 
as a negative control. The sections were not counterstained with Mayer's haernatoxylin 
to ensure background staining was not obscured. No positive cells and minimal 
background staining is observed (red, alkaline phosphatase-based detection system). 
The results demonstrate that the positive cells, in Figures 4,5 and 6 were not due to 
non-specific binding of the secondary or tertiary layers of immunostaining, or due to 
endogenous alkaline phosphatase activity. 
Figure 8. Photomicrograph of a frozen section (magnification x 100) of normal bowel 
from a control patient (control 6) immunostained for activated NFKB and 
counterstained with Mayer's haematoxylin, showing few cells positive for activated 
NFKB (red, alkaline phosphatase-based detection system). 
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Figure 9. Number of cells positive for activated NFYJB per mm 2 in the three layers of 
normal bowel from control patients, non-inflamed CD bowel and inflamed CD bowel. 
The levels of significance of comparisons between groups using the Mann-Whitney test 
are displayed. Horizontal bars indicate median values. Red data points represent 
patients receiving corticosteroid therapy. The data on which these graphs are based are 
displayed in Appendix III. The results demonstrate significantly increased tissue- 
densities of positive cells in all layers of inflamed CD bowel in comparison to normal 
bowel from controls. In only the submucosa of non-inflamed CD bowel was there a 
significantly increased tissue-density of positive cells in comparison to normal bowel 
from controls. 
Figure 10. Graph of number of cells positive for NFrJB per mm2 in the mucosa of CD 
patients against the inflammatory score of sections taken from the same biopsy 
specimen. Specimens taken simultaneously from non-inflamed areas of five patients 
were included (allocated an inflammatory score of 0) and hence in five patients there 
are two specimens within this graph. A regression line is fitted and the Spearman's rank 
correlation coefficient displayed. 
Figure 11. Graph of number of cells positive for NFO per nun 2 in the submucosa of 
CD patients against the inflammatory score of sections taken from the same biopsy 
specimen. Specimens taken simultaneously from non-inflamed areas of five patients 
were included (allocated an inflammatory score of 0) and hence in five patients there 
are two specimens within this graph. A regression line is fitted and the Spearman's rank 
correlation coefficient displayed. 
Figure 12. Graph of number of cells positive for NFicB per nun 2 in the muscle layer of 
CD patients against the inflammatory score of sections taken from the same biopsy 
specimen. Specimens taken simultaneously from non-inflamed areas of four patients 
were included (allocated an inflammatory score of 0) and hence in four patients there 
are two specimens within this graph. A regression line is fitted and the Spearman's rank 
correlation coefficient displayed. 
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Figure 13. Photomicrographs of formaldehyde-fixed, paraffin-embedded sections of 
mouse cerebral cortex pre-treated by microwaving, and then immunostained for 
activated NFKB (above and middle), showing cytoplasmic staining of neurones within 
an area of the section (above, magnification x 400), and nuclear staining in another 
area of the section (middle, magnification x 200), (brown, peroxidase-based detection 
system). Negative control section (below, magnification x 200) immunostained in the 
same manner with PBS substituted for the primary antibody showing no positive cells. 
Sections were counterstained with Mayer's haematoxylin. Results are difficult to 
interpret, but suggest that when used in microwave pre-treated, paraffin-embedded 
tissue, the primary antibody is not specific for activated NFKB. Alternatively, the 
microwave pre-treatment may have altered cytoplasmic stores of NFO, such that the 
antibody then binds to them. 
Figure 14. Photomicrographs (magnification x 400) of formaldehyde-fixed, paraffin- 
embedded sections of HeLa S3 cells pre-treated by microwaving, and then 
immunostained for activated NFKB (brown, peroxidase-based detection system). Cells 
treated with PMA to activate NFO (above) show nuclear staining most likely to 
represent artefact, as suggested by the irregular contour of the nuclear staining and 
difficulty in reproducing these appearances. Unstimulated cells (middle) show 
cytoplasmic staining, but no nuclear staining. Negative control section (below) of 
stimulated cells immunostained in the same manner, but with PBS substituted for the 
primary antibody, showing no staining. Sections were counterstained with Mayer's 
haernatoxylin. 
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Figure 15. Photomicrographs (magnification x 400) of formaldehyde-fixed, paraffin- 
embedded sections of inflamed small bowel from a patient with CD, pre-treated by 
microwaving and then immunostained for activated NFYB (above), showing 
cytoplasmic staining of large mononuclear cells, but no nuclear staining (brown, 
peroxidase-based detection system). Exclusive cytoplasmic staining suggests that in 
sections of bowel prepared in this way, staining of cells containing nuclear- 
translocated, activated NFicB did not occur. Negative control section (below) 
immunostained in the same manner with PBS substituted for the primary antibody 
showing no positive cells. Sections were counterstained with Mayer's haernatoxylin. 
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Chapter 6 
Figure 1. An example of a dotplot of forward scatter versus side scatter characteristics 
of HeLa cells, showing a gated area, Rl, that is designated as representing whole cells. 
Similar dotplots were obtained for Jurkat T cells. 
Figure 2. An example of a DNA histogram. A plot of number of nuclei versus PI 
fluorescence for a suspension of HeLa cell nuclei. A region, Ml, is gated and used for 
subsequent analysis. Similar histograms were obtained for Jurkat T cell nuclei. 
Figure 3. An example of a histogram of number of HeLa cells versus log FITC- 
fluorescence. Population A is stained with anti-p65 NFO antibody (Boehringer 
Mannheim) and population B with isotype control antibody. The region MI represents 
fluorescence intensity above the 95th centile of fluorescence intensity of the isotype 
control antibody-stained population. Similar histograms were obtained for whole Jurkat 
T cells and suspensions of nuclei of both cell types. 
Figure 4. Overlaid histograins of number of cells versus FITC-fluorescence intensity 
for Boehringer Mannheim anti-p65 NFKB antibody staining of stimulated and 
unstimulated suspensions of nuclei from HeLa cells prepared and fixed by fixation 
method A and stained by immunostaining method 1. 
Figure 5. Graph displaying integrated percentage of the total analysed population of 
stimulated and unstimulated suspensions of nuclei from HeLa cells, prepared and fixed 
by fixation method A, and stained by immunostaining method 1, versus the FITC- 
fluorescence intensity of anti-p65 NFicB antibody staining. Subtraction of these curves 
results in the graph displayed in Figure 6. 
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Figure 6. Graph displaying the result of subtraction of the curve for unstimulated 
nuclei from the curve for stimulated nuclei in Figure 5. Thus, difference in cumulative 
percentage of nuclei is plotted against FITC-fluorescence intensity of anti-p65 NFKB 
antibody staining. The curve may represent measurement of activation of NFO (see 
section 4.2). 
Chapter 7 
Figure. Measured hydrophobicity (retention time in RP-IP HPLC columns in minutes) 
versus calculated hydrophobicity score of the four oligonucleotide probes for IKB(x. 
Correlation coefficient (r) calculated by Pearson's method. 
A12IRendix I 
Figure. Establishing regeneration conditions. Effect of different volumes of 
regeneration solutions A to C (regeneration injections 1-20, see Table) on the 
magnitude of binding (displayed in black in RU) of oligonucleotide I to ECP (above) 
and myoglobin (below), and on regeneration of the dextran-ligand surface, as assessed 
by change in the sensorgram. from before injection of probe to after regeneration 
(displayed in red in RU). The data plotted in these graphs are also displayed in the 
Table: the graphs allow easy identification of trends, particularly the approximately 
exponential decay in magnitude of binding of probe to ECP with successive bindings, 
at least until regeneration solution C is used (starting at regeneration injection 9), while 
the numerical data in the Table explain conclusions drawn below. Regeneration 
injections 12-20 are repeated injections of the same volume of the same regeneration 
solution to verify its properties. 
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inflammatory score was calculated by adding the scores from four categories, namely 
enterocytes, mononuclear cells, crypts and neutrophils. Four sections from each biopsy 
specimen were examined and scored, and the mean of these scores allocated as the fmal 
inflammatory score for the specimen. 
Table 4. Conversion of histological scores to grades, and categorisation into infl=ed 
and non-inflamed specimens. 
Chapter 6 
Table 1. Results of experiment where whole HeLa cells were fixed in 70 % ethanol 
(fixation method B) and then immunostained with anti-p65 NFKB antibody (Boehringer 
Mannheim) and isotype control antibody (immunostaining method 3, two-layer 
technique). MFIs are displayed. None of the different types of analysis of the data (far 
left column) produced the expected order of ranking of magnitude for different cell 
treatments, and it was therefore concluded that the protocol had not resulted in 
successful staining of activated NFKB. 
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Table 2. Results of experiment where whole Jurkat T cells were fixed in 100 % 
methanol (fixation method Q and then immunostained with anti-p65 NFKB antibody 
(Boehringer Mannheim) and isotype control antibody (immunostaining method 3, two- 
layer technique). MFIs are displayed. None of the different types of analysis of the data 
(far left column) resulted in the expected order of ranking of magnitude for different 
cell treatments, and it was therefore concluded that the protocol had not resulted in 
successful staining of activated NFKB. 
Table 3. Results of experiment where whole HeLa cells were fixed in 100 % methanol 
(fixation method Q and then immunostained with and-p65 NFO antibody (Boehringer 
Mannheim) and isotype control antibody (immunostaining method 3, two-layer 
technique). MFIs are displayed. None of the different types of analysis of the data (far 
left column) resulted in the expected order of ranking of magnitude for different cell 
treatments, and it was therefore concluded that the protocol had not resulted in 
successful staining of activated NFicB. 
Table 4. Results of experiment where whole HeLa cells were fixed in PFAfrriton-X 
(fixation method D) and then immunostained with anti-p65 NFicB antibody 
(Boehringer Mannheim) and isotype control antibody (immunostaining method 2). 
MFIs are displayed. None of the different types of analysis of the data (far left column) 
resulted in the expected order of ranking of magnitude for different cell treatments, and 
it was therefore concluded that the protocol had not resulted in successful staining of 
activated NFO. 
Table 5. Results of experiment where whole Jurkat T cells were fixed in Triton-X/PFA 
(fixation method E) and then immunostained with anti-p65 NFkB antibody (Boehringer 
Mannheim) and isotype control antibody (immunostaining method 3, two-layer 
technique). MFIs are displayed. None of the different types of analysis of the data (far 
left column) resulted in the expected order of ranking of magnitude for different cell 
treatments, and it was therefore concluded that the protocol had not resulted in 
successful staining of activated NFicB. 
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TabIe 6. Results of experiment where whole HeLa cells were fixed in Ortho Permeafix 
(fixation method F) and then immunostained with anti-p65 NFO antibody (Boehringer 
Mannheim) and isotype control antibody (immunostaining method 3, two-layer technique). 
MFIs are displayed. None of the different types of analysis of the data (far left column) 
resulted in the expected order of ranking of magnitude for different cell treatments, and it 
was therefore concluded that the protocol had not resulted in successful staining of activated 
NFO. 
Table 7. Results of experiment where whole Jurkat T cells were fixed in Ortho Permeafix 
(fixation method F) and then immunostained with anti-p65 NFKB antibody (Boehringer 
Mannheim) and isotype control antibody (immunostaining method 3, two-layer technique). 
MFIs are displayed. None of the different types of analysis of the data (far left column) 
resulted in the expected order of ranking of magnitude for different cell treatments, and it 
was therefore concluded that the protocol had not resulted in successful staining of activated 
NFKB. 
Table 8. Results of experiments where HeLa cells were fixed and enucleated in 100 % 
methanol (fixation method A) and then immunostained with anti-p65 NFkB antibody 
(Boehringer Mannheim) and isotype control antibody (immunostaining method 1, three- 
layer technique). MFIs are displayed. All the analyses (far left column) of the data from 
experiment A, except the '% positive cells' analysis, are consistent with the expected order 
of ranicing of magnitude for different cell treatments. However, when the experiment was 
repeated in B, the order was no longer as expected, with the largest ME being the 
'inhibited' cell population (see section 3.2). 
Table 9. Results of experiments where Jurkat T cells were fixed and enucleated in 100 % 
methanol (fixation method A) and then immunostained with anti-p65 NFkB antibody 
(Boehringer Mannheim) and isotype control antibody (immunostaining method 1, three- 
layer technique). MFIs are displayed. The experiment was repeated four times (A, B, C and 
D), but none of the different types of analysis of the data (far left column) consistently 
resulted in the expected order of magnitude for different cell treatments, and it was 
therefore concluded that the protocol had not resulted in successful staining of activated 
NFKB. 
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Table 10. Results of experiment where HeLa cells were fixed and enucleated in 100 % 
methanol (fixation method A) and then immunostained with anti-p65 NFicB antibody 
(Santa Cruz) and isotype control antibody (immunostaining method 1, three-layer 
technique). MFIs are displayed. None of the different types of analysis of the data (far 
left column) resulted in the expected order of ranking of magnitude for different cell 
treatments, and it was therefore concluded that the protocol had not resulted in 
successful staining of activated NFKB. 
Appendix I 
Table. Establishing regeneration conditions. Effect of injection of different volumes of 
regeneration solutions A to C on the magnitude of binding, in RU, of oligonucleotide I 
to ECP and myoglobin in chip A, and on regeneration of the dextran-ligand surface in 
each ceH of the chip. Magnitude of binding is calculated as the change in the level of 
the sensorgram ftorn before injection of probe to 80 seconds after injection. 
Regeneration is assessed by change in the baseline sensorgram. from before injection to 
after regeneration. The results represent a step-wise evolution of the constitution of the 
regeneration injection, where the constitution of the next regeneration injection (see 
section 3.5, Chapter 3 for constitution of solutions A, B and C) to be tested was 
chosen after assessing the results obtained from the previous regeneration injection. 
Injections 12-20 are repeated injections of the same volume of the same regeneration 
solution to verify its effects. Conclusions drawn from these data are discussed below, 
and the same data are displayed in graphs in the Figure, to allow easy identification of 
trends. 
Appendix III 
Table I. Number of hits counted per MM2 using a Lennox graticule on sections of 
inflamed bowel immunostained for activated NF1cB (+ve) and the negative control with 
PBS substituted for the primary antibody (-ve). In patients with CD, the differences 
between these counts (A) are displayed in a scattergrarn in Figure 9, Chapter 5. 
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Table H. Number of hits counted per mm 2 using a Lennox graticule on sections of 
non-inflamed bowel immunostained for activated NFicB (+ve) and the negative control 
with PBS substituted for the primary antibody (-ve). The differences between these 
counts (A) are displayed in a scattergram in Figure 9, Chapter 5. 
Table HI. Number of hits counted per nim 2 using a Lennox graticule on sections of 
bowel from control patients immunostained for activated NFKB (+ve) and the negative 
control with PBS substituted for the primary antibody (-ve). The differences between 
these counts (A) are displayed in a scattergram in Figure 9, Chapter 5. 
A1212endix IV 
Table. Assessment of reproducibility of counts of cells immunostaining positive for 
activated NFO. 
Appendix V 
Table. Hydrophobicity scores calculated from sequences for oligonucleotide antisense 
and sense probes used in previous publications. 
Appendix VI 
Table. Mean percentage nucleotide base content of human liver, sperm and thymus. 
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Abbreviations and common names 
A adenine 
AIDS acquired immunodeficiency syndrome 
BSA bovine serum albumin 
C cytosine 
CD Crohn's disease 
CD cluster differentiation factor 
DEPC diethylpyrocarbonate 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
DTT dithiothreitol 
ECP eosinophil cationic protein 
EDTA ethylenediaminetetraacetic acid 
FITC fluoroscein isothiocyanate 
9 gram 
G guanine 
HBS HEPES-buffered saline 
HEPES N-2-hydroxyethylpiperazine-N-2-ethanesulphonic acid 
HIV human immunodeficiency virus 
IBD inflammatory bowel disease 
ICAM intercellular cell adhesion molecule 
IEL intraepithelial lymphocyte 
IL interleukin 




WOS inducible nitric oxide synthase 
IP-RP HPLC ion-pair reverse-phase high performance liquid chromatography 
ISH in situ hybridisation 
KCI potassium chloride 
kDa kiloDaltons 
KOH potassium hydroxide 
I litre 
LPS lipopolysaccharide 





MFI mean fluorescent intensity 
MHC major histocompatibility complex 
min minute 
mRNA messenger ribonucleic acid 
MW molecular weight 
n nano- 
NaCl sodium chloride 
NaOH sodium hydroxide 
NFx]B nuclear factor ic of B cells 
32 
NHS/EDC hydroxysuccinimide and N-ethyl-N'- 
(dimethylaininopropyl)carbodiimide 
PBS phosphate buffered saline 
PC personal computer 
PCR polymerase chain reaction 
PDTC pyrrolidine dithiocarbamate 
PI isoelectric point 
PI propidium iodide 
PMN polymdrphonuclear leucocyte 
PMA phorbol 12-myristate 13-acetate 
RNA ribonucleic acid 
RNase ribonuclease 
ROI reactive oxygen species 
rpm revolutions per minute 
RPMI Roswell Park Memorial Institute 
RU resonance units 
SD standard deviation 
SPR surface plasmon resonance 
T thymidine 
TCM tissue culture medium 
TGF transforming growth factor 
TNFcc tumour necrosis factor cc 
IL interleukin 
SSC standard saline citrate 
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UC ulcerative colitis 
UK United Kingdom 
VCAMvascular cell adhesion molecule 
ZnCl2 zinc chloride 
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Aims of the thesis 
The initial aim of this thesis was to develop a method of detecting in situ activation of 
the transcription factor NFxB within cells in sections of tissue, and to use this method 
to study the activation of NFKB in normal and diseased bowel. No such method existed 
at the start of the work, and it would be used to determine whether activated NFKB is 
expressed within cells in nonnal bowel, and whether activation of NFKB is increased in 
inflammatory bowel disease. In addition, the site of activation widiin the bowel wall, 
for instance, surrounding the vasculature or within Peyer's patches, would be 
investigated, and the cell type containing activated NFO determined. 
Study would be particularly focused on apparently normal, non-inflamed areas of 
bowel taken from patients with Crohn's disease, to use the properties of NFKB, which 
is a factor that plays a central, early role in co-ordinating gene expression of numerous 
inflammatory mediators in response to many pathological stimuli, to determine the site 
and nature of the first inflammatory events in Crohn's disease. This should improve 
I 
understanding of the pathophysiology of the disease, and perhaps provide clues to its 
cause. Furthermore, a potential potent target for new treatments of Crohn's disease 
would be identifled. 
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Summarl of main findings 
The main findings of this thesis are: 
1. Oligonucleotide probes non-specifically bind to eosinophils, widiin sections of bowel 
during in situ hybridisation (ISH). 
2. Non-specific binding of oligonucleotide probes to eosinophils is blocked by pre- 
treating sections with dithiothreitol and iodoacetamide in ISH experiments using high 
stringency post-hybridisation washes that remove probe hybridised to target mRNA. 
3. Non-specific binding of oligonucleotide probes to eosinophils is not blocked by pre- 
treatment with dithiothreitol and iodoacetamide when the stringency of post- 
hybridisation washes is reduced to a level that allows retention of oligonucleotide 
probe bound to target mRNA. This strongly suggests that the successful blocking of 
non-specific binding to eosinophils using dithiothreitol and iodoacetamide in ISH 
experiments with high stringency washes was in part due to the effect of high 
stringency washes removing probe bound to eosinophils. 
4. The magnitude of oligonucleotide probe binding to eosinophils varied with probes of 
differing sequences. 
5. Oligonucleotide probes bind in vitro to eosinoPhilic cationic protein (ECP), but not 
to control proteins. The property of ECP that is responsible for this effect is not its 
unusually high isoelectric point (pI), as probes did not bind to a control protein with a 
similar pI. 
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6. The dissociation constant at equilibrium, indicating affinity, of the interaction 
between oligonucleotide probes and ECP is of the order 10" M, indicating moderate 
affinity, although the interaction is likely to be of high capacity because of the 
abundance of ECP. 
7. Measured parameters of the in vitro interaction between individual oligonucleotide 
probes and ECP, namely magnitudes of binding, association rate constants, dissociation 
rate constants and dissociation constants at equilibrium, did not explain differential 
magnitudes of in situ binding of the same Probes to eosinophils. 
8. Hydrophobicities of individual probes, measured by ion-pair reverse-phase high 
performance liquid chromatography, correlated with differential magnitudes of in situ 
binding of the same probes to eosinophils. Hydrophobicity of oligonucleotide probes 
limits tissue penetration and so limits the amount of probe available to bind to ECP in 
eosinophils in sections of bowel during ISH. 
9. Cells containing activated NFidB were demonstrated by immunohistochernistry in the 
lamina propria of normal bowel from control patients. 
10. The tissue-density of cells containing activated NFKB was significantly increased in 
all layers of inflamed bowel from patients with Crohn's disease (CD) compared to 
normal bowel from controls. 
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11. The tissue-density of cells containing activated NFKB was significantly increased in 
only the submucosa of macroscopically and microscopically non-inflamed bowel from 
patients with CD compared to normal bowel from controls, which suggests that the 
apparently non-inflamed bowel in CD may be more immunologically active than 
completely normal bowel from controls, and that the first molecular inflammatory 
events of CD may occur in the submucosa. 
12. Activation of NFkB was restricted mainly to large mononuclear cells, 
morphologically suggestive of macrophages, suggesting these to be a major cell-type 
involved in propagating inflarnmation in CD. 
13. Activation of NFrB may be measured in large populations of cells using flow 
cytometry with a protocol using fixation in 100 % methanol followed by 
immunostaining with a triple layer technique. 
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Chapter 1. General introduction 
Part A: The NFicB and IicB roteins 
1. Discoverl of NFicB 
In 1986, Sen and Baltimore (1) described aB cell nuclear factor that bound to a site in 
the immunoglobulin ic enhancer, and this later became known as NFKB. NFKB was 
soon demonstrated in other ceH types (2) and is now known to be ubiquitous (3). 
Binding sites were found in the promoters and enhancers of many genes, most of which 
were not B-cell specific, but were generally involved in immunological processes, 
inflammatory reactions and cell growth and death. In addition, multiple factors were 
demonstrated to activate NFicB, and so NFKB was identified as a transcription factor 
that played a central, orchestrating role in many inflammatory and immunologically- 
mediated events. Activation of NFO does not require protein synthesis (2), because 
NFicB exists in a pre-formed state bound to an inhibitory molecule, IKB, within the 
cytoplasm and is hence described as a 'primary' transcription factor. Several subtypes 
of NF1cB are now recognised that, together with many levels of control of activation 
and interaction with other transcription factors, allow it to play multiple, diverse roles. 
2. Molecular Biology of NFiCB 
The active forms of human NFKB are dirners, most commonly of a protein of 50 kDa, 
termed p5O, and a protein of 65 kDa, termed p65 or Rel A, which both bind to DNA. 
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Both subunits contain the same DNA-binding domain of 300 amino acids that are 
called the NRD domain (4) (NFrB/Rel/dorsal, as it is also found in the related Rel 
oncoproteins and Drosophila factor, dorsal) or Rel homology domain (5). p5O contains 
little additional sequence, but p65 contains three independent transcription activating 
domains that bind with high affinity to decameric consensus sequences in the target 
genes (commonly 5'-GGGA=CC-3', although multiple other similar sequences 
with reduced affinity are described (6)), usually leading to transcription of the gene. 
Both subunits can be independently transported into the nucleus and contain a cluster 
of positively charged amino acid residues within the NRD that serve as nuclear location 
signals (NLS). 
p50 exists also as a precursor molecule, p105 (also termed NFKB-1), which is 
essentially a p50 molecule joined to an IicB molecule (7). In addition, three other 
subunits of NFicB have been described: NFkJ3-2 (plOO), which consists of a p52 
subunit, with similar properties to p50, joined to an IlcB-Hke molecule (8); Rel. B, 
which appears to be an altemative to p65 (Rel A) (9), and c-Rel which appears also to 
be an alternative to p65, but with reduced transcription activating potential (10). 
Various hetero- and horno-dimers of these subunits have been described, but the most 






























activation of gene expression 
Figure 1. Generalised scheme of activation of NFicB. Following exposure of a cell 
to an inducer of activation of NFicB, NIB (ficIla, IicBP or one of the precursor proteins 
with DcB-like activity, such as p105) is phosphorylated (step 1) by an IicB kinase. DcB 
is then ubiquitinated (step 2), and finally degraded by the proteasome (step 3). In the 
case of p105, the degradation is partial, yielding p50. NF1cB then translocates to the 
nucleus (step 4), where it activates a variety of genes (Table 1) including Iaa and 
p50/plO5 (with permission from the Annual Review of Immunology (5). Copyright 
1996 by Annual Reviews). 
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3. Retiulation of activation of NFicB 
The mechanism of activation of NFKB, and its regulation, are described below and 
surnmarised in Figure 1. 
3.1 Regulation of activation of NFicB b3: accessor3: proteins 
Cytoplasmic NFicB is bound to an inhibitory protein, 10, that prevents its nuclear 
translocation (11) and transcription activating capacity (12) by direct protein-protein 
interactions that stericafly inhibit interaction of the NLS and NRD domains with their 
receptors. Furffiermore, 10 can dissociate nuclear NFicB-DNA complexes (13) by an 
allosteric, rather than competitive, mechanism, and removes NFKB from the nucleus. 
An amino acid sequence that is responsible for its export from the nucleus, termed the 
&nuclear export sequence', has been discovered in IKB(x (14). Although the 
predominant form of NPrJ3, p50-p65 (ReIA), is exclusively cytoplasmic until activated, 
there is evidence that other forms of NFKB may be found constitutively within the 
nucleus: NFO-1 (p105) homodimers are found at low levels widiin the nucleus of 
many cell types in the unstimulated state (although there is conflicting evidence about 
the transcription activating potential of this homodimer), and nuclear p50-c-rel 
heterodimers are found in mature B-cell lines (15). 
3.2 Subt3: pes of licB 
Two main, similar fonns of 10 have been described in humans: IrB(x (16), a 37 kD 
protein previously known as MAD-3, and IOP, a 46 kD protein (17) that is 
immunologically distinct. However, both contain the distinctive motif of IKB proteins 
of multiple, closely adjacent, homologous 33 amino acid sequences called 'ankyrin 
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repeats'. As described below in more detail, as soon as NFO is activated, there is a 
rapid response in transcription of the IKB genes, and newly-synthesised IkB enters the 
nucleus, removes activated NFO from DNA and transports the complex back into the 
cytoplasm. IkJ3a is produced when cells, are stimulated with TNF(x and phorbol 12- 
myristate 13-acetate (PMA), but IxBP is produced when cells are stimulated with IL-1 
or lipopolysaccharide (LPS) (5). 
A third IKB protein, IKBy (18), appears to be limited to mouse B-cells. 
FinaUy, as described above, p105 (NFKB-1) and plOO (NFO-2), the precursor 
molecules for p50 and p52 respectively, contain IKB-like sequences that appear to be 
functionally active in cytoplasmic retention and prevention of activation of 
transcription. 
3.3 Post-transcriptional regulation of activation 
Activation of NFO, described below, is primarily post-transcriptional and, indeed, 
post-transladonal. 
NFO is activated when IKB dissociates from NFO in the cytosol, allowing nuclear 
translocation of the activated form. The first evidence for this came from a study that 
demonstrated in vitro activation of cytosolic NFO by treatment with a dissociating 
agent, the detergent desoxycholate (19) and, from another study, when deactivation of 
NFlcB occurred when purified 10 was added to a preparation of activated NFKB. 
Dissociation of IKB occurs by proteolytic degradation, suggested by the rapid 
disappearance of DcB on stimulation of cells with agents known to activate NFKB, with 
a half-life for IlcB, in these circumstances, of 1.5 minutes. In contrast, in cells in which 
IlcB is experimentally over-expressed, and are not stimulated with agents known to 
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activate NFKB, the half-life of IKB is over two hours (20). Thus, IxB disappears from 
cells in which NFO is activated at a greatly increased rate, which can only be due to 
proteolytic degradation. Furthermore, a proteolytic enzyme for IkB(x has now been 
identified and found to be a non-lysosymal, ATP-dependent 26S proteolytic complex 
composed of a 700 kDa proteasome (21-23). 
3.4 Proteolytic degradation of licB is preceded by its phosphoEllation 
and then ubiguitination 
The event that initiates eventual activation of NFO appears to be phosphorylation of 
IicBa (and probably IOP) (24), and in particular, phosphorylation of two serine 
residues at the N-terminus of IicBct, ser32 and ser36 (25). Phosphorylation of these 
residues is followed by ubiquitination (addition of a short polypeptide termed 
'ubiquitin') of two nearby lysine residues, presumably because phosphorylation results 
in a change in secondary or tertiary structure that exposes the lysine residues to 
ubiquitination (26). Ubiquitination of IicBcc is followed by its proteolytic degradation 
(20). 
3.5 Control of phosphorylation of licBcc 
The events that connect signals at the cell surface to phosphorylation of 10 are the 
subject of intense investigation. Several protein kinases that control phosphorylation of 
IYJB(x in response to different stimuli have been identified, but more may exist: 
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9 Double-stranded RNA activated kinase phosphorylates 10a in vitro (27), and in 
vivo inactivation of this kinase inhibits the ability of double-stranded RNA to 
activate NFicB (28), but does not block activation of NFrJB by TNFa; 
e Casein kinase II has also been demonstrated to phosphorylate the C-terminus of 
IkBa (29,30), and 
s mammalian mitogen activated protein 3 kinase-related kinase (MAP3K-related 
kinase) has recently been shown to participate in the phosphorylation of IKBcc in 
response to stimulation of some TNFcc receptors (CD120a and b, also known as 
p55 and p75 respectively) and type I IL- 1 receptor (3 1). 
Thus, in response to different stimuli, different kinase cascades may participate in 
phosphorylation of IKIBot, which explains how, perhaps together with other 
mechanisms as yet unknown, a single transcription factor can play multiple, diverse 
roles in mammalian cells. 
3.6 Role of reactive ox1gen intermediates in the activation of NFicB 
InitiaRy, reactive oxygen intermediates (ROIs) were thought to be one of the Tmal 
common pathways' by which different NFO-activating stimuli activated NFk. B, 
perhaps by causing an intracellular rise in hydrogen peroxide, which in some way led to 
activation of protein kinases. Evidence to support this hypothesis came from the ability 
of micromolar quantities of hydrogen peroxide to activate NFO (32), and from 
inhibition of NFrJB activation by certain antioxidants, such as N-acetyl-L-cysteine (33) 
and pyrrolidine dithiocarbarnate (34). This property of antioxidants was conserved 
despite use of different activators of NFlcB. 
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However, there is evidence that casts doubt on this theory of ROIs as a final common 
pathway, as in tumour cell lines, experimental over-expression of catalase, which 
degrades hydrogen peroxide, does not block PMA- and TNF(x-induced activation of 
NFY. B (35,36). In addition, the discovery of IxB kinases sensitive to differing NFO- 
activating stimuli argues against the existence of a 'final common pathway' preceding 
the phosphorylation of IrJB. 
3.7 Transcriptional regulation of activation of NFicB 
3.7.1 Transcril2tion of the IKBcc gene 
Although activation of NFKB is primarily by a post-translational mechanism, 
deactivation of activated NFrB occurs by re-synthesis of IKB protein, which then 
displaces activated NFicB from its binding sites to DNA, and transports it back into the 
cytoplasm. Surprisingly, the transcription of the bdBa gene is primarily controlled by 
activated NF1cB itself, and when Iic]B(x is subsequently translated, a negative feedback 
loop is completed. Evidence for control of IKBcc transcription by activated NFrJ3 
comes from four sources: 
e IKBcc mRNA is constitutively expressed at only very low levels in human T-cells and 
monocytes, and levels are strongly enhanced by stimuli that activate NF-KB (37); 
e geneticaRy-coded over-expression of p65 (which is the major transcription 
activating subunit of NFrJ3), but not p50 (which has little transcription activating 
potential), increases levels of IkBa mRNA (37,38); 
e inhibitors of activation of NFrB, such as pyrrolidine dithiocarbarnate (PDTC), 
prevent an increase in IKB(x mRNA (38), and 
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9 activation of the promoter of the porcine IicBcc gene is dependent on the presence 
and integfity of two ldB sites to which activated NFO can bind (39). 
3.7.2 Transcription of the genes encoding Che subunits of NFicB 
As stated above, transcriptional regulation of IKBcc by activated NFxB controls 
deactivation of NFkB. However, there is also evidence that maintenance of NFO 
activation is dependent on transcription, in this case of the subunits of NFKB itself. In a 
study in T-cefls (40), continued activation of NFKB required new protein synthesis, 
suggesting that proteolysis of NFO subunits is a further way in which activated NFkB 
is deactivated. It is therefore of interest to review how transcription of the genes 
encoding the various subunits of NFicB are regulated. 
R105 (R50) and R100 (j252 
The genes for p105 (p50) and plOO (p52) are constitutively expressed, but levels of 
their mRNAs rise in response to agents that activate NFrB (41); as with the gene for 
Ir, B, there are two KB binding motifs in the promoter of the gene for p105 (42), and 
similar findings are expected for the promoter of the gene for pl. 00 (3), and so 
activated NFKB appears to play a major role in regulating production of its subunits. 
Furthermore, transcription of the subunits of other types of NFKB, such as c-rel and 
Rel B, are also controlled by activated NFY. B (9,43). 
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1265 (Rel A) 
In contrast, the gene for p65 (Rel A) is not under transcriptional regulation by 
activated NFY. B, as agents that activate NFKB do not cause a rise in the level of its 
mRNA (44), and there is simply a low-level constitutive expression of its mRNA, and 
hence protein. As stated previously, p65 is the most potent transcription-activating 
subunit of NFKB, and this continuous, constitutive, low-level expression of its mRNA 
renders its transcription-activating potential easily controlled by the rapidly-induced 
IKB, and, to a lesser extent, by p105 and plOO, which have IKB-like activity (3). 
3.8 Summarl of regulation of activation of NFicB 
In summary, NFicB is kept in an inactive, dormant state in the cytosol as a pre-formed 
complex bound to an inhibitory protein, WB, and control of its activation occurs at 
both the transcriptional and post-translational levels, which is unique amongst 
transcriptional activators (3). 
4. Genes activated by NFicB 
The target genes of NFxB are numerous (Table 1) and most share the common feature 
of being quickly induced in response to extracellular stimuli. Furthermore, NFkJ3 is 
activated in response to many different agents (see section 5), and so a rise in activated 
NFicB is not necessarily informative about a program of gene expression in response to 
a particular inducing agent. Most of the target genes are involved in immunological 
activity, and the roles of NFO in particular contexts have been extensively studied, 
and are discussed below. 
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Table 1. Genes activated by NF-kB (6) 
CLASS TARGET GENES 
Viruses Human immunodeficiency virus I (HIV-1) (45) 
Cytornegalovirus (46) 
Adenovirus (47) 
Simian virus 40 (48) 
Immunoreceptors lirununoglobulin ic light chains (2) 
T cell receptor 0 chain (49) 
Major histocompatibility complex class 1 (50) 
Major histocompatibility complex class 11 (5 1) 
Tissue factor (52) 
Cell adhesion molecules Endothelial leucocyte adhesion molecule-I (53) 
Vascular cell adhesion molecule- 1 (54) 
Intercellular cell adhesion molecule-I (55) 
Cytokines and haematopoetic P-Interferon (56) 
growth factors Granulocyte/macrophage colony-stimulating factor (57) 
Granulocyte colony-stimulating factor (58) 






Transcription factors and subunits IicBcc (37,38) 
p105 (p50) (41) 
plOO (p52) (41) 
c-rel (9) 
Rel B (43) 
Others NO-synthase (65) 
50 
4.1 Genes transcribed in response to activation of NFKB during T-cell 
activation 
Over one hundred genes are transcribed in T-ceRs after stimulation by antigen in the 
context of the appropriate major histocompatibility complex molecule, or by agents 
that mimic this interaction (66). NFicB, in combination with other transcriptional 
regulators, is involved in the expression of many of these genes, especially in the early 
phase of the response to T-cell receptor stimulation (67). 
One of the most important of these genes is that encoding IL-2, which requires NFkB 
activation for its transcription in response to antigen stimulation of T-cells, but not in 
response to other T-cell activators such as anti-CD3 (68). However, NFKB plays only 
one part in an ensemble of regulatory factors involved in initiation of its transcription, 
and the promoter for IL-2 contains binding sites for multiple transcription activating 
factors, including NFKB (60), nuclear factor of activated T-cells (NF-AT) (69), 
activated protein-I (AP-1) (70), octamer factors (71), purine-rich binding factors (72) 
and a CD-28 responsive complex (73), and many of these sites must be simultaneously 
occupied to allow full IL-2 promoter activity (69). 
The gene encoding IL-2 receptor (IL-2R) (x chain is another important example of a 
gene whose transcription during T-ceH activation is often dependent on NFicB 
activation. As seen with the gene for IL-2, NFO participates in IL-2R cc chain gene 
transcription only when T-cells are activated by some mechanisms (by antigen (74-76)_ 
and by TNFoc (77)), but not by others (phorbol ester (76)). 
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4.2 Genes in B cells transcribed in response to activation of NFicB 
NFicB was first described as a factor that activated the immunoglobulin (Ig) ic light 
chain gene in B cells (1), and so acquired its name 'nuclear factor ic of B cells'. It was 
noted that NFxB was constitutively active in mature B cells and plasma cells, but not in 
pre-B cells, unless stimulated with cytokines or LPS. The constitutively active, nuclear 
form of NFO in mature B cells has been shown to be largely the p5O-c-Rel 
heterodimer (15,78), and the p50-p65 fonn has been found at low levels only in the 
cytoplasm. The mechanism of this increased activity of the p50-c-Rel form is not clear, 
but may relate to reduced stability of 10(x and increased transcription of the c-Rel 
gene (78,79). The function of constitutively active p50-c-Rel and the absence of 
constitutively active p50-p65 is unproven, but is thought to be maintenance of the 
mature B ceU state with capacity to produce immunoglobulin (3). 
NFicIB has also been implicated in the transcriptional regulation of a variety of other 
genes in B cells including those encoding major histocompatibility complex (MHQ 
class I and Id molecules (50,5 1) and 02 microglobulin (80). 
4.3 Function of NFicB in neurones 
NFr, B has been shown by immunohistochernistry to be constitutively activated in 
neurones of mouse cerebral cortex and hippocampus, and in primary neuronal cultures 
derived from rat cerebral cortex by gel shift assay (8 1). The physiological significance 
of this finding is unknown, but it may relate to the expression of vascular cell adhesion 
molecule-1 (VCAM-1), which is involved in neural differentiation and is an NFrB- 
controlled gene, as a correlation between expression of VCAM-1 and activation of 
52 
NF1cB has been demonstrated in P 19 embryonic carcinoma cell cultures, which act as a 




Unlike other transcription factors, such as heat shock factor or steroid receptors, which 
are specifically activated by only one agent, NFxB is activated by numerous agents 
(Table 2). Such agents can originate from different sites within the cell: 
e from the ceH surface, such as receptors for cytokines (e. g. IL-1 (83), IL-2 (84), 
TNF(x (83) and lymphotoxin (85)); 
e from elements of second messenger pathways that are associated with events at the 
cell membrane, such as phorbol esters and calcium ionophores (2,86); 
* from cytoplasmic events such as kinase induction by dsRNA (56) and the inhibition 
of protein synthesis (2), and finally 
e by intranuclear proteins such as the tax transactivator of the human T-ceH 
lymphotropic virus I (HTLV1) (87). 
As discussed above in section 3, the mechanisms by which such diverse stimuli can all 
activate NFO is only partially understood, but relates to the complex control of its 
activation. Furthermore, activation of NFO by these stimuli does not produce a 
uniform response, as different types of NFxB can be activated and the eventual gene 
transcription often depends on interaction with other transcriptional regulators. 
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TabIe 2. Conditions activating NF-r, ]B. 
CLASS INDUCING CONDITIONS 
Bacterial products Lipopolysaccharide (2) 
Viruses HIV-1 (88) 
Adenovirus (89) 
Viral products Double-stranded RNA (56) 
X protein of hepatitis B virus (90) 
Latent membrane protein- 1 of Epstein-Barr virus (9 1) 
Human T-cell lymphotrophic virus tax protein (87) 




T-cell nýdtogens Antigen (84) 
Lectins (phytohaemaggludnin (2), concanavalin A (92)) 
Calcium ionophores (86) 
Anti-CD2 (93) 
Others UV light (94) 
Hydrogen peroxide (95) 
Drugs Phorbolesters (2) 
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6. The relationship between NFlcB and TNF(x 
TNFoc is a potent and rapid activator of NFO (40,83). Binding of TNFoc to ceH 
surface receptors activates a phoshatidylcholine-specific phospholipase C to produce 
I 
1,2-diacylglycerol, which then induces an acidic sphingomyelinase to release ceramide 
from sphingomyelin (96,97). Ceramide is thought to control the activity of specific 
protein kinases and phosphatases, which then act on mitochondrial membrane proteins 
and alter mitochondrial production of ROIs resulting in activation of NFO, perhaps by 
induction of IidB(x kinases (see section 3.5). 
Conversely, activated NFicB controls transcription of TNF(x (63), but its exact role is 
unresolved. Three sites homologous to NF1cB consensus sequences can be identified in 
the human TNFa promoter, but are involved in TNFa transcription by only some 
stimulators of TNF(x production. For instance, none are involved in PMA-induced 
TNFa transcription in human T and B ceRs (98) and monocytic ceRs (99), but all are 
involved in LPS- and virus-induced TNF(x transcription in aB cell line (100), and LPS- 
induced TNFa transcription in monocytic cell lines (101). 
Thus, TNFoc activates NFkB, and activated NFKB controls transcription of TNFa, 
forming a positive feedback loop that may augment immune responses. 
7. NFlcB and disease 
Because of its direct role in regulating responses to inflammatory cytokines and 
endotoxin, the activation of NF1cIB plays a role in the development of chronic diseases 
such as atherosclerosis, rheumatoid arthritis, Alzheimer's disease, HIV infection and 
inflammatory bowel disease (IBD), or in acute situations such as septic shock (studies 
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relating to rheumatoid arthritis, atherosclerosis and IBD are discussed in greater detail 
in Chapter 5, section 4.2). Activation of NFicB also plays a role in oncogenesis and 
apoptosis. 
Atherosclerosis 
Initiation and progression of atherosclerosis is related to the oxidation of lipids in low 
density lipoproteins that become trapped in the extracellular matrix of the 
subendothelial space and apparently activate NFicB, leading to transcriptional 
activation of genes involved in the inflammatory process (102). Interestingly, mice 
that are susceptible to atherosclerosis exhibit activation of NFKB when fed an 
atherogenic diet (103). Tbrombin, a serine protease that serves several important roles 
in inflammatory cells, as well as in cells within vessel walls, stimulates the 
proliferation of vascular smooth muscle cells through the activation of NFrB (104), 
and hence may contribute to atherosclerosis. Furthermore, activated NFxB has been 
demonstrated by immunohistochernical methods in macrophages, endothelium and 
smooth muscle cells of human atherosclerotic lesions (105). Overall, these data 
provide substantial evidence that NFKB activation is an important contributor to 
events leading to atherosclerosis. 
Rheumatoid arthritis 
Activation of NFxB has been demonstrated by immunohistochernistry in the 
endothelium and cells of macrophage lineage (type A synoviocytes) in the synovial 
lining of patients with rheumatoid arthritis (106). 
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Alzheimer's disease 
Alzheimer's disease may also involve chronic activation of NFicB, since the arnyloid P 
peptide causes production of ROIs and activates gene expressi 
, 
on through KB sites 
(107). 
HIV infection 
As described previously, NFKB plays an important role in the activation of HIV gene 
expression. Both HIV-1 and HIV-2 have NFicB binding sites close to their 
transcription start sites within the long tenninal repeat (LTR) (108-110) and several 
studies have documented activation of HIV LTR by activation of NFrJ3 (45,111,112). 
NFKB may therefore play a role, in concert with other transcriptional activators, in the 
induction of active viral replication that characterises progression of HIV infection 
from the early, latent stage to acquired immunodeficiency syndrome (AIDS). 
Inflammatory bowel disease 
At the start of the investigations described in this thesis, there were no published data 
concerning the activation of NFKB in IBD. Some studies have been published since 




The systemic inflammatory response associated with septic shock is initiated by LPS 
and other microbial products that stimulate expression of various inflammatory 
cytokines. It has recently been proposed that the production of nitric oxide in response 
to LPS regulates important aspects of septic shock (113). These experiments showed 
that iNOS-deficient mice were protected from septic shock. Since NFrB activates 
transcription of the NOS gene (Table 1), activation of NFkB by LPS may play a role 
in the development of septic shock. Other activators of NF0, such as TNF(x, may also 
mediate septic shock and augment the inflammatory response through activation of 
NFr, B (114). 
Oncogenesis and apoRtosis 
Evidence for involvement of NFKB or DcB members in oncogenesis is based on several 
observations (3,115): 
e NFrJ3 proteins are members of a proto-oncogene family, and one of its members, v- 
rel is an altered transcription factor coded for by an avian retrovirus that is forcefully 
and consistently oncogenic (116); 
9 the NFicB gene and the Bcl-3 gene, which encodes a protein with IO-like 
properties, are translocated in certain lymphomas (117); 
* NFKB is activated by several viral transforming proteins (Table 2) and this effect is 
thought to be related to the oncogenic properties of these proteins, for instance: 
1. HTLV- 1 tax that is involved in induction of leukaernia in HTLV- I infection (87); 
2. latent membrane protein-1 of Epstein-Barr virus which is implicated in the 
pathogenesis of Burkitt's lymphoma and nasopharyngeal carcinoma (91), and 
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3. the X protein of hepatitis B virus which is implicated in the development of 
hepatocellular carcinoma in chronic hepatitis B infection (90); 
* exposure of cells to IkBa antisense results in oncogenic transformation (118), and 
9 antisense to ReIA blocked development in vivo of turnours induced by HTLV-1 tax 
(119). 
There is also evidence that activation of NFKB may protect against apoptosis, which 
may explain the oncogenic effect of some members of the NRD family. Of particular 
interest are recent reports that indicate that inhibiting activation of NFO renders ceU 
lines, which were previously insensitive, acutely sensitive to the apoptotic effects of 
TNFa (120,121). Furthermore, knockout mice, deficient of p65, die of massive 
apoptosis of hepatocytes during embryonic development (122). 
8. NFicB as a target for anti-inflammatory and 
immunosuppressive agents 
NFKB has multiple functions in immunological and inflammatory processes and is 
therefore an attractive target for anti-inflammatory and immunomodulatory therapy. 
Early experimental evidence suggests agents that prevent activation of NFkB may be 
effective in inflammatory disorders. A study in mice of p65 antisense oligonucleotide, 
administered as either a single intravenous bolus or locally via a catheter, improved 
2,4,6-trinitrobenzene sulphonic acid-induced colitis as assessed by clinical signs, 
histological inflammation and cytokine production by isolated lamina propria 
macrophages (123). In another study, chronic granulornatous colitis induced by 
intramural injection of peptidoglycan polysaccharide was ameliorated, as judged by 
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macroscopic inflammatory scores, by intravenous administration of a selective inhibitor 
of the IKB proteasome (124). 
Furthermore, agents already established in the treatment of inflammatory disorders 
have been found to inhibit activation of NFicB (see below). 
Corticosteroids 
a 
Corticosteroids bind in vitro to cytoplasmic glucocorticoid receptors which 
directly interact with, and inhibit, activated NFKB (125,126). In addition, 
corticosteroids increase production of IKB(x (127,128) and hence reduce activation of 
NFr, B. These in vitro effects may explain their diverse anti-inflammatory effects in 
vivo. 
ClcloslRorin A 
The immunosuppressants, cyclosporin A and tacrolimus (FK506), are 
known to suppress T-cell activation by inhibiting calcineurin, a calcium- 
dependent phosphatase, which is involved in the activation of the 
transcription factor, nuclear factor of activated T-cells (NF-AT). Although 
this is thought to be their predominant mode of action, they also block 
activation of NFrB (129,130), which, as described in section 4.1, is also 
critically involved in the activation of T-cells. This suggests that calcium- 
dependent mechanisms may be involved in activation of NFKB, which is 
consistent with the finding of activation of NFO by calcium ionophores 
(Table 2). 
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Salicylates, aminosalicylates and gold 
Salicylates inhibit the activation of NFY. B at concentrations used to treat arthritis (13 1) 
and also inhibit activation of NFrB in stimulated endothelial cell cultures (132). 5- 
aminosalicylic acid (5-ASA) inhibits activation of NFrB in cultured CaCo-2 cells 
(133), an action probably mediated by the known anti-oxidant effects of 5-ASA. 
Furthermore, gold, used in the treatment of rheumatoid arthritis, inhibits activation of 
NFKB (134). 
9. Methods of detectinLy activation of NFicB 
NFx1B is a primary transcription factor that is ubiquitously present in an inactive state 
in the cytosol, and so methods to study the functional importance of NFKB must detect 
only the activated, nuclear-translocated, IKB-dissociated form. 
9.1 Electrophoretic mobility shift assav (EMSA) (135) 
Transcription factors interact and bind to specific sequences of DNA and activate 
transcription of a gene. Only activated NFxB, and not inactive, cytosolic NF0, binds 
to DNA, and this property is utilised in EMSAs to detect only the activated form. 
In brief, protein extracts from whole cells, or from nuclear fractions of cells (an 
additional step that ensures only activated, nuclear-translocated NFKB is detected), are 
incubated with radioactively-labelled oligodeoxynucleotides of the same sequence as 
the DNA binding site of NFicB. ElectroPhoresis through a non-denaturing 
polyacrylamide gel separates free oligodeoxynucleotide from oligodeoxynucleotide 
bound to NFKB protein, which migrates more slowly and appears as a discrete band on 
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an autoradiograph. Use of control oligodeoxynucleotides and an excess of unlabelled 
probes allows confirmation of formation of sequence-specific complexes. 
Furthennore, the identity of the oligodeoxynucleotide-binding protein can be 
confirmed by 'supershifting' the assay by addition of antibody specific to the 
oligodeoxynucleotide-binding protein, for instance, anti-p65 NFic. B antibody. Binding 
of the antibody to the oligodeoxynucleotide-binding protein complex further slows 
migration in the gel and results in a 'supershifted band'. 
9.2 Western blotting 
Traditional Western blotting can detect only activated NFKB, and it requires either 
successfid extraction of nuclear proteins (83) and use of a non-discriminating 
antibody, or alternatively, use of total cellular protein with an antibody that detects 
only the activated form of NFKB. At the start of this thesis, no such antibody existed. 
9.3 Immunohistochemistr-v 
As for Western blotting, no antibody that detects only the activated forin of NFKB 
existed at the start of the studies contained in this thesis. 
9.4 In situ hvbridisation (ISH) 
No studies exist that use ISH to detect activation of NFKB, but as described in Chapter 
2, a method to detect activation of NFr. B using ISH was explored. 
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Part B: Crohn's disease 
Crohn's disease (CD) is a chronic inflammatory condition affecting any part of the 
gastrointestinal tract, but most commonly the terminal fieurn and colon, that is usually 
characterised by a chronic remitting clinical course. Its clinical features, pathology and 
treatment are weH documented, and in the fbHowing sections, discussion is mostly 
limited to areas directly relevant to this thesis. 
10. Epidemiology and aetiolog 
CD appears to be increasing in incidence, with one study documenting a six-fold 
increase in incidence from the 1960s to the 1980s (136). This increase is unlikely to be 
accounted for solely by improved case detection or by assignment of a diagnosis of CD 
to patients with colitis whom may previously have been labelled as suffering from 
ulcerative colitis (UC). 
The aetiology is unknown, but there is evidence to support a genetic component with a 
clear familial link demonstrated by twin and population studies. In a family with an 
incident case and an affected first-degree relative, the chance of a second first-degree 
relative developing CD is increased to between one in ten and one in fifteen, fifty times 
the population prevalence (137). In a study of twins, 8 of 18 individuals with an 
affected monozygotic twin developed CD themselves, compared to only I of 26 with 
an affected dizygotic twin (138), which is an equivalent level of concordance to that for 
insulin-dependent diabetes mellitus, and strongly suggests a genetic component to its 
aetiology. 
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There is additional evidence of a genetic component to the aetiology of CD with a 
weak human leucocyte antigen (HLA) class II association (DRI Dqw5 (139) and 
DRB1*07 (140)) with no class I associations, although these associations are generally 
weaker than for UC. Furthermore, there are indications that chromosome 16 may bear 
a susceptibility locus for CD, with this site being close to that coding for several cell 
adhesion molecules (CD 11 integrin cluster, including complement receptor type 3, CD 
19 involved in B cell function, and sialophorin involved in leucocyte adhesion) and for 
interleukin-4 receptor, which suggests that the specific protein coded for by the 
susceptibility locus, that at present is unknown, is likely to be involved in immune and 
inflammatory responses. However, the relative risk of this linkage is low at 1.3, and is 
documented only in families with multiple affected members (14 1). In another study of 
sibling-pairs with IBD, linkage at statistically significant levels was reported to marker 
sites at the same locus on chromosome 16, as well as at loci on chromosomes 3,7 and 
12 for both UC and CD (142). 
There have been many hypotheses postulated for the aetiologies of CD, but none is 
proven, and some of the hypotheses currently under investigation are described below. 
10.1 Hypotheses of infective aetiology 
An infective cause for CD has been sought since its first description by Crohn in 1932 
(143). However, there is epidemiological evidence against an infective aetiology, such 
as a study that examined childhood socio-economic circumstances of patients with 
IBD, when access to running hot water and a separate bathroom were associated with 
increased risk of CD (relative risk 5.0 and 3.3 respectively) (144). Furthermore, the 
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incidence and prevalence of IBD is probably reduced in developing countries compared 
to that in developed countries, which is contrary to the usual pattern of infectious 
diseases, and immigrant populations appear to acquire the same incidence as that of the 
general population of the resident country. 
Mcobacterium izarartuberculosis 
Johne's disease in cattle is caused by Mycobacterium paratuberculosis and shares 
many characteristics with CD, but the bacteria are rarely detectable in CD (145). One 
study found 65, % of specimens from CD patients positive for Mycobacterium 
paratuberculosis DNA using polymerase chain reaction (PCR), compared to 13 % of 
controls, and 4% with UC, but the study was too small for these differences to achieve 
statistical significance (146). Immunohistochernistry fails to detect Mycobacterium 
paratuberculosis in tissue sections of affected bowel, and serological studies have 
found conflicting evidence of antibodies to Mycobacterium paratuberculosis antigens 
(147,148). Furthermore, antituberculous, chemotherapy has produced inconsistent 
results in the treatment of CD (149). 
Measles 
Drawing on the precedent of persistent measles virus causing subacute sclerosing 
panencephalitis, an hypothesis for persistent measles virus causing CD has been 
postulated. A study using ISH and immunohistochernistry has demonstrated measles 
RNA and nucleocapsid protein respectively in CD tissue (150). This finding has been 
linked to pathological studies that have demonstrated vascular injury, focal arteritis, 
fibrin deposition and arterial occlusion in the intestinal microcirculation of affected 
areas of CD (151), with granulornata associated with this vasculitis (152), by the 
65 
demonstration of paramyxovirus-like particles by transmission electron microscopy 
within these granulomata (153). 
There is epidemiological data to support a link between measles infection and CD, with 
infants born during a measles epidemic being significantly more likely (relative risk 1.5) 
to develop CD in the next 30 years than those born in non-epidemic periods (154). 
Furthermore, in the same population, four pregnancies were complicated by clinically 
proven measles infection, and of the four individuals born from these pregnancies, three 
subsequently developed CD (155). In addition, measles vaccination may increase the 
risk of developing CD (156), and this has been proposed to explain the apparently 
conflicting observations of declining measles infections and rising incidence of CD. 
10.2 Smokin 
Patients with CD who smoke have more aggressive disease and suffer more frequent 
relapses, and there is a higher prevalence of smoking in patients with CD than in 
controls (157-160). Furthermore, patients with CD who stop smoking after surgery 
have a reduced rate of recurrent disease compared to those who continue smoking 
(161), and these findings provide support for the vascular aetiology of CD. Conversely, 
there is a reduced prevalence of smoking in patients with UC, with a particularly high 
incidence in ex-smokers (162,163). 
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11. Pathology of Crohn's disease 
The pathology of CD is well described. The classic description of transmural 
inflammation, thickened bowel wall and narrowed lumen represents advanced disease, 
but the first changes of CD are more relevant to this thesis. 
Originally described as the first macroscopic change, the aphthoid ulcer is an area of 
ulceration overlying a Peyer's patch, and with the subsequent recognition of colonic 
involvement in CD, also overlying colonic lymphoid patches (164). Specialised cells, 
termed membranous epithelial cells ('M' cells), overlie these lymphoid. aggregates, and 
transport antigens from the lumen to the underlying lymphoid tissue, and may process 
and present the antigens to macrophages (165,166). This suggests that luminal antigens 
are important in the pathogenesis of aphthoid ulcers, which is consistent with the 
clinical observations of the importance of the faecal stream in the recurrence of CD 
(167). 
More recently, endoscopy has allowed identification of more subtle early macroscopic 
changes that may precede aphthous ulceration, such as patchy erythema and fliable 
mucosa (168), a 'worm-eaten' mucosal pattern (169), and pin-point haemorrhages of 
the size of a single villus (170). Histological examination of these areas shows 
inflammatory changes and granulornata suggesting that the disease process is weH 
established at this stage (171). A study using a magnifying colonoscope demonstrated 
red halos surrounding colonic lymphoid patches that preceded frank aphthous 
ulceration in CD patients, and scanning electron microscopy of these lymphoid patches 
showed small erosions of the overlying specialised epithelium (172). These red halos 
can also be seen using a standard colonoscope in some patients with early CD (Figure 
2). 
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Abnormalities that may reflect events which occur earlier in the pathogenesis of CD are 
found by histological examination of areas of bowel that are 
macroscopically/endoscopically normal. Indeed, microscopic infl=matory changes 
occur in 45 % of biopsy specimens of sigmoidoscopically non-nal rectum (173), and in 
patients with CD undergoing upper GI endoscopy, granulomata are seen in 7% and 
non-specific inflammatory changes in 25 % of biopsy specimens taken from 
macroscopically normal gastric antrurn and duodenal bulb, although some of the non- 
specific changes might now be attributed to Helicobacter pylori infection (174). 
Furthermore, areas of CD bowel that are passed as histologically normal on routine 
examination, are abnormal when studied using additional histopathological methods 
(see Chapter 5, section 4.2). Thus, microscopic changes often occur in macroscopically 
normal CD bowel, and study of early molecular events that may precede the first 
inflammatory changes, such as the activation of NFKB, should be focused on bowel 
that is both macroscopically and microscopically normal (see Chapter 5). In such 















12. Immunology of Crohn's disease 
Inflammatory bowel diseases (IBD) in general, and CD in particular, are thought to 
result from a complex interaction of susceptibility genes (141), environmental factors 
and the immune system. The immune system is the final pathway through which 
inflammation results, and it is possible that susceptibility genes may code for inherent 
alterations in the immune system that are fundamental to pathogenesis, and the extreme 
expression of this hypothesis is that there is an abnormal response to a 'normal' 
stimulus in a genetically susceptible individual (see section 1). Thus, immunological 
changes that occur in CD are of interest, but interpretation is hampered by the 
complexity of the gastrointestinal environment, where there is an abundance of food 
and bacterial antigens. These antigens not only result in a highly complex and brittle 
immunological state of tolerance in the normal bowel, but also, when the mucosal. 
barrier is breached, may result in a profound secondary inflammatory response that may 
obscure the initiating abnormality. For these reasons, the immunological features of 
IBD, described in brief below, are difficult to interpret, and discussion is therefore 
often restricted to a comparison of the differences in these features between UC and 
CD. 
12.1 Abnormalities of humoral immunitv 
12.1.1 Immunoglobulins and B cells 
The normal protective mucosal immune response is a selective, controlled and localised 
response of B cells. These properties are to a large extent mediated by the 
immunoglobulin A response, which is the major immunoglobulin (Ig) produced by the 
normal intestine. IgA protects by passive aggregation and exclusion of antigen rather 
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than by activation of the complement cascade or by induction of an intense 
inflammatory response. In IBD there is a marked increase in total immunoglobulin 
production, with a relative increase in mucosal IgG production over IgA (175). The 
relative reduction of IgA production may also be associated with defective IgA 
function as the subtypes change from polymeric to monomeric forms, and from IgA2 to 
IgAi (176). In CD, even histologically unaffected jejunum produces significantly less 
polymeric IgA compared to jejunum from patients with UC. This defect in mucosal 
humoral immunity may allow increased entry of antigens to the mucosa. 
There are differences in the predominant subtypes of IgG produced by the mucosa in 
UC and CD. In UC, IgGi predominates, which is usually produced in response to 
protein antigens, while in CD IgG2 predominates, and this is usually produced in 
response to carbohydrate and bacterial antigens (177), a difference that has led to 
speculation about environmental triggers for the two diseases. 
The changes in lamina propria B cells mirror the changes in Ig production, with total 
numbers of cells increased in both UC and CD (178,179), but with the relative increase 
in IgG-producing cells greatest in UC (179). 
12.12 Autoantibodies 
There are associations between UC and several true autoimmune diseases, namely 
thyroid disease, haemolytic anaemia and vitiligo, and consequently there has been 
interest in identifying an autoantibody associated with UC. Several candidates have 
been proposed, but none are sufficiently disease-specific to term a true autoantibody. 
Epithelial cell associated component antibodies are detected in 70 % of patients with 
IBD compared to 8% of controls (180), and in 50 % of healthy relatives of patients 
with IBD (18 1) and therefore may represent a marker of genetic susceptibility to IBD. 
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Colitis colon-bound antibody (CCA-IgG) has been identified in resected, washed UC 
colon in most patients, but not in CD (182). The antigen for this antibody is now 
known to be a 40 kD protein belonging to the tropomyosin family and is present in the 
skin, the eye, on colonic epithelial cells and on bile duct epithelial cells (183). Indeed, a 
subsequent study identified the antibody in the serum of 13 out of 14 patients with 
primary sclerosing cholangitis (PSC) associated with UC, but in not one control (184). 
Thus, this antigen and antibody may in some way be linked to the extra-intestinal 
features of IBD, but its significance in the aetiology of IBD is unclear. 
Perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) has been identified in 20- 
90 % of patients with UC and less frequently in CD (185-188). It is particularly 
prevalent in patients with both UC and PSC (189), is rarely found in patients with UC 
limited to the rectum, and has been linked with a more aggressive clinical course of UC 
and with the occurrence of pouchitis after restorative proctocolectomy. It may also be 
present in a significantly increased proportion of first-degree relatives of patients with 
UC compared to controls, but studies are conflicting (189-191). 
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12.2 Abnormalities of cell-mediated immunitv 
12.2.1 T-cells 
T-cells in intestinal lesions assessed by immunohistochemistry 
In the lamina propria, the numbers of T-cells are increased in both UC and CD, but the 
CD4: CD8 ratio remains unchanged at 2: 1, as does the proportion of cells expressing 
HLA-DR (192,193). The proportion expressing activation antigens such as the IL-2 
receptor (CD25) (194,195), 4F2 (196) and transferrin receptor (197) is increased. 
There is no increase in intra-epithelial lymphocytes (IELs) in CD or UC, except 
perhaps in CD ileitis (192). 
Isolated lamina propria T-cells 
Surprisingly few differences have been found in the proportions of subsets of isolated 
lamina propria T-cells from inflamed areas compared to non-inflamed areas and 
control specimens, perhaps because the 'normal' intestinal mucosa is in a constant 
state of activation, held in control by, as yet, undefined mechanisms. However, lamina 
propria T-cells show an activated phenotype in both UC and CD, such as expression of 
the IL-2 receptor, transferrin receptor (CD7 1) and 4F2 antigen (198). 
Greater differences have been found between isolated lamina propria T-cells and 
circulating T-cells in IBD, but this difference may simply reflect the difficulties in 
isolating cells from the lamina propria, as evidenced by the wide variation in the 
proportions of subsets of immunological cells in lamina propria isolates in different 
studies. 
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Mucosal cvtotoxic T-cells 
When mucosal mononuclear cells are activated in vitro with IL-2, CD cells, despite 
producing low levels of IL-2, show equal cytotoxicity to control cells, whereas UC 
cells, which produce substaritially less IL-2, show remarkably low cytotoxic activity 
(199). This suggests that although T-cells are activated in both UC and CD, this does 
not imply similar function. 
Circulating T-cells 
T-cells of yS receptor phenotype are rare in the peripheral blood of nonnal controls, 
but are found in large numbers in normal bowel. An increase in circulating T-cells of 
this phenotype has been demonstrated in IBD (200), and interpreted as the appearance 
of 'gut-like' T-cells in the peripheral circulation. However, immunohistochernical 
analysis shows a reduction in these cells among IELs and lamina propria lymphocytes 
compared to controls (201), probably reflecting a relative increase in the alternative 
phenotype of aP receptor cells in inflamed bowel. 
12.2.2 Monocytes and macrophages 
There is increased production of monocytes in IBD (202), probably related to 
increased demand for macrophages in inflamed bowel due to increased antigen 
stimulation because of epithelial damage, and indeed there are increased numbers of 
CD68+9 Ll+ monocytes in active IBD lesions, a phenotype implying recent recruitment 
from the circulation (203). 
Normal intestinal macrophages are a heterogeneous cell population, but two main 
categories are identified: scavenger or mature tissue macrophages, (RFD7 antibody 
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positive) are found predominantly below the epithelium, and interdigitating dendritic 
antigen-presenting cells are found predominantly in organised lymphoid tissue such as 
Peyer's patches. This distribution is unsurprisingly disturbed in IBD, and the 
heterogeneity is accentuated. Thus, there are abundant interdigitating antigen- 
presenting cells as well as mature tissue macrophages throughout inflamed areas in 
both UC ýhd CD, and clusters of epithelioid cells are seen in CD (204). 
12.2.3 PollmoERhonudear neutrol2hils, eosinophils and mast cells 
There is marked infiltration by polymorphonuclear neutrophils (PMNs) in IBD which 
are the main source of ROIs and reactive nitrogen metabolites. Chemiluminescence 
probes detect large quantities of ROIs in the mucosa of patients with CD and UC that 
correlate with disease severity (205). Elevated levels of nitric oxide and synthase 
activity have also been demonstrated in both UC and CD colonic tissue (206), and 
inflamed epithelium shows expression of iNOS that is not seen in normal colonic 
epithelium (207). IBD mucosa is relatively depleted of antioxidant defences (208), 
rendering it susceptible to injury by oxidative injury, and aminosalicylates have 
scavenger activity for superoxide radical formation (209,210). 
Increased levels of eosinophils are found both in early and in more established CD 
lesions (211,212). Eosinophils secrete eosinophilic cationic protein and major basic 
protein that, in vitro, are directly cytotoxic to epithelial cells (213), and secrete IL-5, 
which activates eosinophils and stimulates production of immunoglobulin by B cells 
(see section 12.3.1). 
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12.3 Abnormalities of cytokines 
In section 4, abnormalities of cells of the immune system in IBD are described. These 
cells produce cytokines that activate and stimulate other inflammatory cells, and 
recruit further cells to the site of inflammation. Consequently, cytokine expression in 
IBD has been extensively studied to understand the mechanisms that initiate and 
propagate inflammation in IBD, to identify targets for new anti-inflammatory 
therapies, and to investigate for a primary abnormality of cytokine production or 
function that might be important in the aetiology or the mechanisms of the 
pathogenesis of CD. As discussed in section 4 in relation to abnormalities of cells of 
the immune system in IBD, it is difficult to interpret whether abnormal cytokine 
profiles are of primary importance, or whether they are simply secondary to the 
inflammatory process. 
12.3.1 Immunostimulatory cytokines 
Interleukin-1 
IL-I is a powerful pro-inflammatory cytokine that is produced predominantly by 
monocytes/macrophages but can be produced by a variety of immune and non-immune 
cell types. Two isoforms exist, a membrane-bound form, termed IL- I cc, and a secreted 
form, termed IL- 1 P, and both mediate the same biological activities (214). The first 
study of IL-I in IBD showed no significant increase in production as assessed by a 
biological proliferation assay of stimulated PBMNCs (215). However, a subsequent 
study, using a similar bioassay, showed increased spontaneous production by 
PBMNCs from CD patients (216) and this was confirmed in subsequent studies using 
immunoassays on stimulated PBMNCs (217,218). Furthermore, significantly 
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increased levels of IL-lp immunoreactivity were found in supernatants of 
unstimulated and stimulated lamina propria mononuclear cells (LPNWCS) taken from 
active lesions of both UC and CD, compared to control samples (219). The cellular 
source of these proteins has been shown by immunocytochernistry to be endothelial 
cells and colonocytes (220), but this was not confirmed in a study using ISH (221). In 
another study investigating IL- I bioactivity and protein and gene expression, LPMNCs 
were demonstrated to be a source of IL-1 (222). As might be expected, increased 
levels of IL- I are not specific to 1131) and are found in other forms of gut inflammation 
(223). 
The biological activity of IL-I is now recognised to be determined by the balance 
between levels of IL- I and its antagonist, IL- I receptor antagonist (IL- 1 ra), and tissue 
levels of IL- I ra are elevated in IBD (224), but with a relative deficiency of IL- I ra in 
comparison to IL-1, in IBD compared to controls (225). 
IntpripitUn-A 
IL-6 has many pro-inflammatory effects and is produced by a range of cells of the 
immune system. Levels in peripheral blood are raised in CD but not in UC, and 
correlate well with other assessments of disease activity such as C-reactive protein 
(226). However, high levels of IL-6 mRNA in inflamed tissue were demonstrated in 
both UC and CD by PCR (227), with similar findings in supernatants of cultured 
LPNWCs (228). The significance of this difference in circulating and tissue levels 
between the two diseases is uncertain. 
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TNF 
TNFa is produced predominantly by macrophages, although it can be produced by 
lymphocytes and, like IL-I and IL-6, it induces a wide range of pro-inflammatory 
effects and is a prime mediator of the systemic host response (229). Although it is 
thought to play an important role in UC and probably a larger role in CD, results of 
studies are conflicting. One study demonstrated significantly elevated serum levels in 
children with active UC and colonic CD (230), while another found no increase over 
normal controls (23 1). As with IL- I and IL- I ra, a better assessment of TNFcc activity 
may be made by assessing levels of both TNFa and its receptors, p55 and p75, which 
have neutralising capacity, and circulating levels of both receptors are elevated in CD 
compared to controls (232). 
The concentration of TNFa in stools of children with both active CD and UC is 
elevated (233). TNFcc mRNA measured by PCR was detected with similar frequency 
in mucosal biopsy specimens from patients with IBD and controls (227), but use of 
ISH to detect TNFa mRNA in IBD mucosa yielded positive results in macrophages in 
II of 15 patients with IBD and 4 of 9 controls (221). 
Despite the conflicting evidence for involvement of TNF(x in IBD, treatment of 
patients with refractory CD with chimeric monoclonal anti-TNF(x antibody appears to 
be effective, although the mechanism is unclear (234). 
Interleukin-5 
IL-5 stimulates B cells to produce immunoglobulin and activates eosinophils. Again, 
evidence is conflicting concerning its role in IBD with increased levels of mRNA 
detected by ISH in CD (212), but no increase was found when IL-5 mRNA was 
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assessed by quantitative reverse transcriptase PCR performed on homogenates of 
mucosal biopsy specimens (235). Another study reported reduced IL-5 protein 
production by cultured LPMNCs in CD, and increased production in UC (236). The 
discrepancy in IL-5 mRNA levels measured by different techniques and IL-5 protein 
production in CD may be explained by, as yet, undetected methodological problems 
that are explored in Chapter 2. 
Cell adhesion molecules 
There is evidence of dysregulation of cell adhesion molecule expression in IBD with 
increased expression of ICAM-1 on mucosal mononuclcar phagocytes (237) and 
increased ICAM-1, leucocyte function antigen-1 and E-selection on venules in 
involved mucosa (238,239). However, expression of VCAM-l is not increased in 
inflamed 1131) mucosa (239). 
12.3.2 Immunoregulatory cytokines 
Interleukin-2 
IL-2 is the prototypical immunoregulatory cytokine and is produced by T-cells and 
modulates almost every step of T-cell function as well as function of many other cells 
of the immune system, and has consequently been widely studied in IBD. Circulating 
IL-2 is generally not detectable in health or disease, but IL-2 bioreactivity in cultures 
of LPMNCS was first reported to be reduced in both UC and CD (240). Subsequently, 
increased levels of IL-2 mRNA in active CD, but not UC, was detected by reverse- 
transcriptase PCR (241). Moreover, cultured T-cells from patients with UC and CD 
respond differently to IL-2, with a weak response in UC and a hyper-reactive response 
in CD. Furthermore, patients with CD given IL-2 for treatment of malignancies suffer 
79 
relapses of CD (242), and patients with AIDS often develop remission of CD, perhaps 
because of loss of IL-2-secreting cells (243). Consistent with the hypothesis that in UC 
there is IL-2 hyporeactivity and in CD, IL-2 hyper-reactivity, is the finding of a 
spontaneous UC-like disease in IL-2 gene knockout mice (244). 
Elevated levels of soluble IL-2 receptor (slL-2R) have also been demonstrated in IBD 
(245). In another study, these elevated levels correlate with LPMNC production in 
CD, but with PBMNC production in UC (246), and in a separate study by the same 
group, levels of mRNA for IL-2Ra and IL-2RP (subunits of the receptor) in LPMNCs 
were elevated in CD but not UC, supporting the concept of T-cell hyper-reactivity in 
CD (247). 
Interferon 
IFN-y is produced by T-cells and natural killer cells and mediates a wide range of 
immunomodulatory effects, including the induction of MHC class II molecule 
expression on antigen-presenting cells, a function particularly relevant to the bowel. 
Although initial reports suggested reduced production in IBD (248), subsequent 
reports suggested increased production may occur in CD, as indicated by spontaneous 
release of IFN-y and increased mRNA in LPMNCs, and the presence of IFN-y- 
secreting cells in inflamed mucosa (249,250). Induction of IFN-y production is 
dependent on IL-12 production by monocytes/macrophages, and a recent study has 
shown increased spontaneous and mitogen-induced production of IL-12 by mucosal 
cells in CD (25 1), but not in UC or controls, which strengthens the hypothesis of aT 
helper 1 -type (Th- 1) cytokine pattern in CD (IL- 12- and transfornling growth factor 0- 
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induced predominant production of IL-2, IFN-y and lymphotoxin by T helper cells) 
(252). 
Interleukin-4 
IL-4 is produced by T-cells and has predominantly anti-inflammatory 
immunoregulatory effects on B-cells. Studies of its role in IBD are conflicting, with 
production by LPMNC cultures reported to be reduced in both UC and CD (236,253), 
but with elevated tissue levels of IL-4 mRNA in UC, but not CD (235). However, a 
recent study reported increased tissue levels of IL-4 mRNA in early post-surgical 
recurrences of CD (254). 
12.3.3 Growth factors 
Transforming growth factors (TGF) a and P are important mediators of intestinal 
epithelial restitution and defence, and levels of TGFP, but not of TGF(x, arc increased 
in active CD and UC lesions, whereas in quiescent IBD the reverse is found (255). 
This has led to the hypothesis that enhanced TGFP may promote healing, whilst 
increased TGFcc production may cause epithelial hyperproliferation and contribute to 
the increased risk of intestinal malignancy in IBD. 
12.4 Abnormalities of eicosanoids 
There is evidence documenting increased levels of prostaglandins in IBD that fall with 
successful treatment (256,257), and other arachadonic acid derivatives such as 
thromboxanes, prostacyclins and leukotriene B4 are all also elevated in 1131) (258,259). 
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12.5 Abnormalities of complement 
Unsurprisingly, there is evidence of increased complement activation in IBD, which is 
likely to mediate tissue destruction and chemoattraction of inflammatory cells (260). 
12.6 Animal models of IBD induced by immune dysregulation 
There are now many animal models of IBD induced by immune dysregulation, which 
illustrate that chronic intestinal inflammation can be the result of a primary 
immunoregulatory defect, with the more recent models demonstrating the central role 
of T-cells and their immunoregulatory cytokines. One of the first studies demonstrated 
gut inflammation by transfer of CD45RBh'gh, CD4 T-cells (a functionally distinct 
subset of T helper cells) into mice with severe combined immunodeficiency, and the 
resulting colitis was characterised by high levels of IFN-y and TNFa (261). 
A feature of several models is the importance of microbial antigens in the 
pathogenesis of gut inflammation, and this supports indirect clinical evidence of a 
similar effect in CD (167). In HLA-1327 transgenic rats, inflammation is seen in many 
organs, but inflammation in the intestine is spared when the rats are bred in a germ- 
free environment (262). Similar observations were made in IL-2 (244) and IL- 10 (263) 
gene knockout models of IBD. Furthermore, when the microbial intestinal 
environment is restored, particularly with Bacteroides species, to gerinfree HLA-1127 
transgenic mice, gut inflammation recurs (264). 
The central role of T-cells in the pathogenesis of experimental IBD is demonstrated by 
experiments in which IL-2-deficient mice were crossed with either B cell-deficient 
mice or B cell- and T-cell-deficient mice, when colitis was prevented only when T cell 
function was restored, with no improvement in the colitis on re-introduction of B cells 
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(265). Abnormalities in T-cell function may not have to be primary, congenital 
abnormalities to affect the mucosal immune system, as demonstrated in a study where 
appendicectomy at one month prevented the subsequent development of the colitis that 
is usually seen in T-cell receptor a-mutant mice (266), which is in keeping with the 
observations regarding the protective effect of appendicectomy against the onset of 
UC in man (267). 
Although there are many animal models in which interference with the immune 
system by gene knock-out results in intestinal inflammation, there are also other 
genetically-altered animal models of colitis, such as mice with 'dominant negative N- 
cadherin' genes, which develop IBD because of increased intestinal permeability 
associated with reduced levels of cadherin-complexes that mediate cell polarity and 
formation of junctional complexes (268). This model supports the hypothesis of 
altered gut permeability as a primary abnormality in 1131), with inflammation 
developing as a secondary immune response to translocated luminal antigens. 
12.7 Conclusions from studies of the immunolo0cal abnormalities in 
Crohn's disease 
As with most organs, the range of reactions of the bowel to injury is limited. In the 
bowel, this limited reaction to injury is compounded by a stereotyped reaction to 
luminal antigens once the integrity of the epithelial barrier is breached. Thus, there is a 
'final common pathway' of intestinal inflammation, and it is difficult to distinguish 
observations on immunological responses that may be of primary importance in the 
pathophysiology of CD from this complex final common pathway of inflammation. 
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However, described in a simplistic manner, the evidence presented above suggests a 
primary state of T-cell activation with a predominantly Th-I pattern of cytokine 
activation, with a bystander effect of injury to the epithelium, rather than a primary 
autoimmune abnormality directed against the epithelium. Macrophages appear to be 
important in the response to luminal antigens and tissue damage is effected by 
recruited PMN's. Whether this primary state of T-cell activation is a purely 
genetically-determined effect, or whether, more likely, environmental factors act on a 
background of genetic susceptibility, is unclear. 
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Part C: Introduction to the results chapters 
The original aim of this thesis was to determine the site within the bowel wall of early 
inflammatory events in CD by studying the site of activation of NFicB within 
macroscopically and microscopically unaffected CD bowel. The central, early role of 
NFKB in co-ordinating gene expression of numerous' inflammatory mediators in 
response to many pathological stimuli would be utilised to determine the site of early 
events of CD and the cell type involved. 
At the start of the studies contained in this thesis, no method existed to study in situ 
activation of NFO, and so in Chapter 2, a method using ISH is explored. These 
experiments led to important observations on methodological problems in using 
oligonucleotide ISH in sections of bowel, and in Chapters 3 and 4, the mechanisms of 
these problems are determined. In Chapter 5, an antibody that recognises only the 
activated form of NFic]B, which became available during the course of these studies, is 
used successfully to study the activation of NFKB in normal bowel, and in both 
uninflarned and inflamed CD bowel. In Chapter 6, the same antibody is used to develop 
a method of measuring activation of NFicB in cultured cells using flow cytometry. 
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Chapter 2 
Measurement of activation of NFicB in sections of 




The aim of the work presented in this chapter was to develop a method of detecting in 
situ activation of NFrB within cells in sections of tissue, and to use this method to 
study the activation of NFKB in normal and diseased bowel, as further discussed in 
Aims of Thesis. 
1.2 Established methods to detect activation of NFKB 
NFO is a pre-formed complex that is present in an inactive state in the cytosol of 
many different ceU types. Study of its activation requires a method of distinguishing the 
inactive, cytosolic complex from the activated, nuclear-translocated form. 
There are established methods that measure activation of NFrJ3 in homogenised tissue, 
such as electrophoretic mobility shift assay (EMSA) and Western blotting, and 
distinguish active from inactive forms by separation of nuclear and cytosolic fractions. 
An additional method for detecting only the activated form of NFO is provided by the 
detection method used in EMSA, which is a radiolabelled oligonucleotide whose 
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sequence is complementary to the NFKB consensus binding sequence. Thus, the 
radiolabelled oligonucleotide binds only to activated NFKB. 
However, when investigations were started, there was no method to detect activated 
NFk, B in situ. Antibodies that bind to the p65 and p50 subunits of NFic]B were 
commercially available, but when used for immunocytochemistry, these bind to both 
inactive and activated NF1cB, and no antibody that recognised only the activated form 
of NFkB had then been developed. 
1.3 Basis of a new method to detect activated NFlcB in situ 
When cells are stimulated with agents that activate NFkJB, the inactive, dormant, 
cytoplasmic p50-p65-1rB(x complex is activated by proteolytic degradation of the 
IKBcc protein, allowing nuclear translocation of the p50-p65 (together termed NFicB) 
complex, which is subsequently deactivated, and transported back to the cytoplasm, by 
synthesis of new IKB(x protein. IKBa mRNA transcription is initiated by binding of the 
active p50-p65 heterodimer to 0 consensus sequences in the promoter of the IKBa 
gene, thus completing a feedback loop. Thus, IicBcc is degraded and requires re- 
synthesis, whereas p50 and p65 are recycled by deactivation by newly-synthesised 
DdBoc and subsequent transportation back into the cytoplasm. 
Separate studies have demonstrated rises of mRNA for p50 and p65 (269) and of 
mRNA for IKB(x (37) when NFO is activated by stimulation of tumour cell lines, such 
as U937 and Jurkat T cells, with agents known to activate NFKB (TNFot and PMA), 
but there is no published study directly comparing their concurrent appearance. When 
comparing these two studies, mRNA for IKB(x appears sooner (at twenty minutes) 
after stimulation than mRNA for p50 and p65, but methodological differences between 
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the studies prevent conclusions about the magnitude of the responses. However, the 
postulated mechanism of activation of NFO would suggest a larger rise in IkBot 
mRNA, to allow physiological repletion of degraded IKB(x protein, in contrast to the 
conserved p50 and p65 proteins. 
Thus, presence of IkBa mRNA in a cell implies activation of NFO in that cell, as all 
stimuli that initiate IKBa transcription do so by activating NFrB (270), and 
development an in situ hybridisation (ISH) method for detecting IicB(x mRNA as an in 
situ marker of activation of NFKB was proposed. 
1.4 In situ hybridisation 
ISH is used for detecting specific sequences of nucleic acid, most commonly messenger 
RNA (mRNA), in intact cells or tissue sections using complementary nucleic acid 
probes. It has several advantages over other techniques for localising gene expression. 
First, the half-life of mRNA is short, usually ranging from one to sixty minutes (271) 
and thus detection suggests recent transcription of a gene, in contrast to 
immunocytochernistry that cannot usually distinguish between newly-produced and 
stored protein. Second, combination of different visualisation systems allows 
simultaneous identification of several mRNA species within the same tissue section. 
Finally, ISH may also be combined with immunocytochernistry to identify cells 
currently containing both a particular nucleic acid sequence and the corresponding 
transcribed protein. 
Different types of probe can be used to hybridise to and detect mRNA: 
1. complementary, single-stranded RNA probes (riboprobes) derived from 
transcription vector plasmids, typically 0.1 - 1.0 kbases in length (272); 
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2. complementary single-stranded deoxyribonucleic acid (cDNA) probes prepared by 
polymerase chain reaction (PCR) (273), 
3. double-stranded DNA probes, prepared by nick translation, random priming or 
PCR, that are less sensitive than single stranded probes since the two strands can re- 
anneal in the hybridisation solution, thus reducing the concentration of probe available 
to the target (274), and 
4. synthetic complementary oligodeoxyribonucleotides (oligonucleotide) probes, 
typically 20-35 bases long (275). 
Riboprobes are most often used for detection of mRNA (276,277), although synthetic 
oligonucleotide probes are also widely used and offer advantages of rapid and 
inexpensive synthesis of sequences selected from published DNA databases, effective 
penetration of fixed and unfixed. tissue sections (278) and resistance to ubiquitous 
ribonucleases (RNases), since they are DNA strands. Thus, oligonucleotide ISH was 
chosen as the method. 
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2. Methods 
All solutions were made using RNase-free 'Q' water (one litre of deionised water with 
1 ml of diethylpyrocarbonate (DEPQ (Sigma Chemical Company), left overnight and 
then autoclaved). 
2.1 Biopsv specimens 
Gastrointestinal biopsy specimens were obtained from macroscopically inflamed areas 
from patients with inflammatory bowel disease undergoing routine colonoscopy and 
specimens of normal control large bowel from patients undergoing colonoscopy for 
follow-up of colonic polyps. Normal control small bowel biopsy specimens (distal 
duodenum) were obtained from patients undergoing oesophagogastroduodenoscopy 
for investigation of dyspepsia or anaemia, and nasal polyp was obtained from a patient 
undergoing polypectomy for allergic rhinitis. Specimens were orientated using 
watchmaker forceps (Raymond A Lamb Ltd., London, UK) a dissecting microscope 
A (Zeiss, Zurich, Switzerland) and frozen in Optimum Cutting Temperature (OCT) 
compound (BDH, Poole, UK) over thawing isopentane (BDH) and stored in liquid 
nitrogen (British Oxygen Company, Guildford, UK). 
2.2 Preparation of microscope slides 
Microscope slides (Sigma Chemical Company) were washed twice in 'Q' water and 
then dried at 60 "C in an oven. Slides were then immersed in a 10 % (v/v) solution of 
poly-L-lysine (Sigma Chemical Company) for ten minutes, air-dried and stored at -70 
'C for up to two weeks. 
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2.3 Sectioning of biol2sy sRecimens 
Biopsy specimens were transported from the liquid nitrogen storage cylinder (BDH) to 
the cryotome (Cryotome 620M, Anglia Scientific Instruments, Cambridge, UK) in a 
portable liquid nitrogen container (BDH). Biopsy specimens were orientated and then 
fixed to a1xI cm cork square (BDH) with OCT compound, which was then frozen 
widlin the cryotome. The cork square was then fixed to the mounting plate of the 
cryotome with frozen water. Sections of 8 gm thickness were cut onto poly-L-lysine- 
coated slides, air-dried for ten minutes, then fixed in a4% (w/v) solution of 
paraformaldehyde (Sigma Chemical Company) in phosphate buffered saline (PBS), pH 
7.3 (Oxoid, Unipath Ltd., Basingstoke, UK) for fifteen minutes followed by immersion 
in a 15 % (w/v) solution of sucrose (Sigma Chemical Company) for fifteen minutes, 
twice, and then stored at -70 OC. 
2.4 Probes and radioactive labellin 
2.4.1 Probes 
Sequences for the three different exon-specific oligonucleotide (30-mers) probes 
(Table 1) for the mRNA for IkBa, the inhibitory protein of the transcription factor 
NFKB, were chosen by Dr. Steve Jones (Retinitis Pigmentosa Research Unit, The 
Rayne Institute, St. Thomas' Hospital) using the published sequences of the gene for 
IkBa (16). Sequences were analysed using the Genetics Computer Group (Wisconsin, 
USA) Version 7 Program, made available through the Human Genome Mapping 
Project Resource Centre (Hinxton, UK) and a PC, to ensure there was no significant 
likelihood (defined as > 60 % matching of bases) of cross-hybridising with other 
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known sequences. For closely related genes, a direct homology search was performed 
using the DNAsis program (Hitachi Europe Ltd., Maidenhead, UK) and a PC. 
Sequences were chosen that provided a near even mix of A/T and G/C base pairs and 
also minimal self-complimentarity, to prevent hairpin formation by internal base- 
pairing, using the DNAsis secondary structure analysis program. The three 
oligonucleotides, for IKBoc mRNA, together with three previously documented (279) 
oligonucleotide probes for TNFa mRNA (Table 1), were manufactured according to 
the chosen sequences (Pharmacia Biotech UK Ltd., St. Albans, UK). A poly- 
deoxyribothymidine (poly-d(T)) probe (Pharmacia Biotech UK Ltd. ), which hybridises 
to the poly-riboadenosine tail present on all mRNA (280), and equimolar cocktails of 
three oligonucleotide probes for each of the mRNAs for insulin, IL-4 and IL-10 (R & 
D Systems, Abingdon, UK) were also used (see section 3, for rationale for use of these 
additional probes). All probes were thirty bases long. 
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Table 1. Sequences of oligonucleotide probes for IxBoc mRNA and TNFa mRNA. 
Protein Probe Sequence (5' -ý 3') 
IKBa antisense 1 TCC TTG ACC ATC TGC TCG TAC TCC TCG TCT 
IKB(x antisense 2 CCC CTT TGC ACT CAT AAC GTC AGA CGC TGG 
IKBa antisense 3 ACA AAG GTG AGG Trr AAA AGA AGT Trr CTC 
IKB(x sense AGA CGA GGA GTA CGA GCA GAT GGT CAA GGA 
TNFa antisense 1 GCT GGG CTC CGT GTC TCA AGG AAG TCT GGA 
TNFa antisense 2 CGG GGT TCG AGA AGA TGA TCT GAC TGC CTG 
TNFa antisense 3 AGT AGG CCG ATT ACA GAC ACA ACT CCC TGG 
Oligonucleotide antisense probe cocktails for insulin, IL-4 and IL-10 were obtained 
from commercial sources (sequences not released). 
93 
2.4.2 Radioactive labellin 
For each mRNA target, three antisense probes, in an equimolar cocktail, were labelled 
at the 3' termini with deoxyadenosine 5' S35-thiotriphosphate (35S-dATP) (Pharmacia 
Biotech UK Ltd. ), catalysed by overnight incubation with tenninal deoxynucleotidyl 
transferase solution (Promega, Southampton, UK) (15-30 units gr, in 50 nM 
potassium phosphate pH 7.4,1 mM mercaptoethanol and 50 % (v/v) glycerol, where 1 
unit is the amount of enzyme required to catalyse transfer of 1 nmol deoxyadenosine 
triphosphate to poly-d(T)5o in 60 minutes at 370C). To 4 pmol of probe (3 ýd of a 1.6 
ng rnl-1 solution) was added 3.2 gl of a 370 MBq rnl-' (10 mCi rnl-') solution of S35_ 
dATP, 2.5 gI of terminal deoxynucleotidyl transferase solution and 8 gl of terminal 
deoxynucleotidyl transferase buffer (Promega) (500 mM cacodylate buffer, pH 6.8,5 
mM cobalt chloride, 0.5 mM dithiothrietol, 500 gg rrd" bovine serum albumin), and 
made up to 40 gl with 'Q' water and incubated at 37 'C overnight. 
2.4.3 Purifleation of labelled probes 
NICK spin columns (Pharmacia Biotech UK Ltd. ) (containing Sephadex G-50 fine, 
DNA grade) were prepared according to the manufacturer's instructions. First, the gel 
was resuspended by inverting the columns and then excess fluid allowed to drain. 
Second, to each column was added 1 ml elution buffer (0.1 M Tris (Sigma Chemical 
Company), 50 mM EDTA (BDH), pH 7.5), which was allowed to drain, and finally, 2 
ml elution buffer was added to each column which were then centrifuged at 500 xg at 
room temperature for four minutes in an IEC 6000B centrifuge (International 
Equipment Company, Dunstable, UK). The labelled oligonucleotide solutions, with 40 
gI of elution buffer added to each sample, were pipetted carefully onto the prepared 
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columns and centrifuged at 500 xg at room temperature for four minutes, and the elute 
collected in microcentrifuge tubes. The specific activity of each purified, labelled probe 
was then measured in triplicate by pipetting 1 ýtl aliquots, of the recovered probe into 
three scintillation vials, followed by addition of 3 ml Betaplate Scint scintillation buffer 
(Fisons Chemicals, Loughborough, UK) to each vial and the P-emission in one minute 
measured using a scintillation counter (Wallac 140g liquid scintillation counter, Wallac, 
Turku, Finland). The specific activity of the labelled, purified probes was greater than I 
x 108 counts per minute gg-1 . 
2.5 In situ hvbridisation 
ISH was performed according to the method of Hamid et al (281) including standard 
steps to reduce non-specific binding, namely: 
e acetylation 
'pre-hybridisation' with hybridisation solution containing Denhardt's solution and 
excluding probe 
incorporation of non-complementary DNA sequences in the hybridisation solution 
to compete with probe for non-specific binding sites. 
In general, microscope slides were removed from storage at -70'C and were allowed 
to come tp room temperature whilst still within their protective covering of aluminium 
foil (BDH) within sealed polythene storage bags (BDH), to minimise condensation of 
water onto the sections. Sections were air-dried and then permeabilised in a 0.3 % 
(v/v) solution of Triton X-100 (Sigma Chemical Company) in PBS for 10 minutes 
followed by a solution of proteinase K (1 [tg ml-1) (Sigma Chemical ComPany) in 0.1 M 
Trizma base (Sigma Chemical Company), pH 7.4, containing 50 mM 
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ethylenediaminetetraacetic acid (EDTA) (Sigma Chemical Company) at 37 *C for thirty 
minutes. In some experiments as a negative control (see Results), slides were then 
treated with 100 gg ml-1 deoxyribonuclease-free RNase (Pharmacia Biotech UK Ltd. ) 
for thirty minutes to remove target mRNA. Sections were post-fixed in a 0.4 % (w/v) 
solution of paraformaldehyde in PBS for ten minutes, acetylated in a freshly prepared 
0.25 % (v/v) solution of acetic anhydride (Sigma Chemical Company) in OAM 
triethanolamine (Sigma Chemical Company) for ten minutes, and then pre-hybridised in 
a solution containing 50 % (v/v) formamide (Sigma Chemical Company), Ix 
Denhardt's solution (Sigma Chemical Company) (0.02 % (w/v) bovine serum albumin, 
0.02 % (w/v) Ficoll, 0.02 % (w/v) polyvinylpyrolUdone) and 2x standard saUne citrate 
(SSQ (Sigma Chemical Company) (0.15 M sodium chloride, 0.0 15 M sodium citrate), 
for thirty minutes at 37 OC. 
Overnight hybridisation was performed at 39 OC with 50 [tl of a solution containing 
0.12 gg ml"' probe (6 ng of probe), 2x SSC, 50 % (v/v) formarnide, 0.4 mg ml-1 
denatured, sheared (by immersion of vial in boiling water for three minutes) salmon 
sperm DNA (Sigma Chemical Company) and 10 % (w/v) dextran sulphate (Sigma 
Chemical Company). Three consecutive post-hybridisation washes were performed for 
thirty minutes each at 39 OC in solutions of 2x SSC, 1x SSC plus 50 % (v/v) 
formamide and 0.1 x SSC. In later experiments (see results), the effect of graded 
reductions in stringency of washes was investigated. 
Sections were then dehydrated in a 95 % (v/v) solution of absolute alcohol (BDH) in 
DEPC-treated water, followed by a 99 % solution, for 30 seconds each, and then dried 
at room temperature for 30 minutes. 
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For autoradiography, sections were dipped in nuclear track emulsion, namely Ilford K5 
photographic gel emulsion (Ilford Scientific Products (Ceiba-Geigy), London) 
diluted 1: 1 with distilled water at 43 *C, dried in a darkroom for two hours, and then 
incubated at 4 OC in a light-proof container containing silica gel (Sigma Chemical 
Company) for five days. Slides were developed in a 4.4 % (w/v) solution of Dektol 
(Kodak, via Sigma Chemical Company) for two minutes, washed briefly in distilled 
water and fixed in a 30 % (w/v) solution of sodium thiosulphate (Sigma Chemical 
Company) at 4 OC for five minutes, and then washed in running water for five minutes 
and counterstained with filtered Mayer's haernatoxylin (Sigma Chemical Company) for 
three minutes, followed by 'blue-ing' in tap water for one minute. Sections were 
dehydrated in serial, graded alcohols (70,90 and 99 % (v/v) solutions of alcohol in 
distiHed water for 30 seconds each) and then immersed in xylene (BDH) for 30 
seconds, twice, air-dried for 15 minutes and then mounted in kalmount (BDH) and 
covered with a cover-slip (Sigma Chemical Company). 
In addition, ISH experiments with single probes were performed with each of the three 
antisense probes and the sense probe for IkBa mRNA, when quantitation of positive 
cells containing hybridised oligonucleotide probe was undertaken. Positive cells were 
arbitrarily defined as cells with at least 25 overlying positive granules, and positive cells, 
in the lamina propria were counted in ten high-powered (x 400) microscope fields 
avoiding the epithelium, by an observer who was blinded to the identity of the slide, 
and quantitation expressed as number of positive cells per microscope field. 
Variations in the above protocol were made, as indicated in Results, during attempts to 
optimise specific staining. 
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2.6 Photoaraphv 
Photomicrographs were taken using an Axioscop microscope (Zeiss, Zurich, 
Switzerland) fitted with an HE photofilter (Nikon, Tokyo, Japan) and a Canon AV-1 
camera (Canon UK, London, UK), using Ektachrome 64 tungsten photographic film 
(Kodak via Sigma Chemical Company) 
2.7 Statistical anaivsis 
In the experiments with individual probes, the number of positive cells per microscope 
field were compared for different probes using a Student t-test with a Bonferroni 
correction for multiple comparisons (Tables 2 and 3). 
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3. Results 
3.1 ISH on sections of bowel using probes for mRNA for IKB(x, TNF 
and insulin, and pOll-d(T) probe 
ISH using oligonucleotide probe cocktails for both TNF(x and IidB(x mRNA targets 
showed apparently positive cells within the lamina propria of sections of both normal 
large (n = 8) and small (n =5) bowel from control patients (Figure 1). Findings were 
similar for patients with inflammatory bowel disease (n =7 for large bowel, n=3 for 
small bowel), but with a greater number of positive cells (Figure 2). The positive 
control probe, poly-d(T) (Figure 3), showed a pattern of positive cells shilar to that 
seen with both probe cocktails for TNFa and IkBa mRNA, and not, as was expected, 
a positive signal over all cells. Staining with probe cocktails for TNFa and IKB(x 
mRNA and with poly-d(T) probe was only partially abolished by pre-treatment of 
sections with RNase (Figure 4), and a similar pattern was observed with a probe 
cocktail for insulin mRNA (Figure 5) that should not be present in bowel. Furthermore, 
a similar pattern, but with fewer positive cells (see section 3.9) was also observed using 
a sense probe for ýKB(x mRNA as a negative control (Figure 6). 
All experiments were repeated at least three times using sections from different patients 
with the same findings on each occasion, and together suggested probes were not 
hybridised to target mRNA but were bound non-specifically to scattered cells within 
the lamina propria (see section 4.1 for detailed explanation of this deduction) with 
bilobed nuclei and granular cytoplasm, that were provisionally identified by these 
morphological criteria (282) as eosinophils (Figure 7). 
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Figure 1. Photomicrographs (above x 100, below x 400) of a frozen section of normal 
large bowel from a patient with carcinoma, with ISH using an oligonucleotide probe 
cocktail for mRNA for IKBot, showing positive cells within the lamina propria 
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Figure 2. Photornicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis), with ISH using an oligonucleotide antisense probe cocktail for mRNA for 
IKBoc, showing a greater number of positive cells than seen in normal bowel (Figure 1) 
within the lamina propria (appearances similar with probe cocktails for mRNA for 
TNFa, IL-4 and IL- 10). 
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Figure 3. Photomicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis) with ISH using poly-d(T) probe showing a pattern within the lamina propria 
similar to that seen with probes for cytokine mRNAs (Figure 2), and not positivity of 
all cells, as is expected if poly-d(T) probe remains hybridised to the poly- 
riboadenosine tail present on all mRNA. 
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Figure 4. Photomicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis), pre-treated with RNase, with ISH using an oligonucleotide antisense probe 
cocktail for mRNA for IKBa, showing a similar pattern of positive cells, at reduced 
levels to that seen without pre-treatment with RNase (Figure 2) (appearances similar 
with probe cocktails for mRNA for TNFcc and poly-d(T) probe). 
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Figure 5. Photomicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis), with ISH using an oligonucleotide antisense probe cocktail for mRNA for 
insulin, showing a pattern of positive cells similar to that seen with all other probes; 
insulin mRNA should not be present in bowel, and therefore the pattern suggests 
binding of probes to another element. 
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Figure 6. Photomicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis), with ISH using an oligonucleotide sense probe for mRNA for IKB(x, showing 
a pattern of positive cells within the lamina propria similar to that seen with the 
antisense cocktail (Figure 2), but with fewer positive cells and each positive cell with 
fewer overlying granules. The concentrations of probe in the sense and antisense 






Figure 7. Photomicrograph (x 1000) of a frozen section of inflamed large bowel from 
a patient with inflammatory bowel disease (ulcerative colitis) with ISH using an 
oligonucleotide antisense probe cocktail for mRNA for IKBcc. The cell with overlying 
positive granules has a bilobed nucleus and granular cytoplasm, suggesting it to be an 
eosinophil. Many similar cells had denser overlying positive granules, but this cell was 
chosen for photography as the underlying cell morphology was easily seen. 
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3.2 Identirication of cells binding olig-onucleotide probes 
3.2.1 Staining with eosin 
The identity of cells binding probes during ISH was confirmed as eosinopl-Als by pre-staining 
the sections before ISH with a1% (w/v) solution of alcoholic eosin (Sigma Chemical 
Company) in a 95 % (v/v) solution of alcohol in DEPC-treated water. Eosin stains eosinophils 
bright orange, but also stains other polymorphonuclear neutrophils (PMNs) to a lesser extent 
(283) and is therefore not specific. 
The strength of the eosin stain was considerably reduced by subsequent ISH, and to prevent 
this, the following modifications to the method were made: 
1. it was noted that the hybridisation solution covering sections pre-stained with eosin turned 
orange and was therefore leaching eosin from the section, so to prevent this, the strength of 
the 'post-fixation step' of ISH, immediately prior to covering the section with hybridisation 
solution, was increased to 4% (w/v) paraformaldehyde to fix the eosin stain; 
2. repeating the eosin stain after hybridisation, but, as eosin stains the emulsion yellow, prior 
to coating with photographic emulsion. 
However, neither of these modifications increased the intensity of the stain, and although the 
reduction of the eosin stain by ISH reduced visualisation for photography, it resulted in a more 
specific staining of eosinophils than occurs with stronger eosin stains, with only cells that 
appeared morphologically to be eosinophils staining orange, with no discernible staining of 
PMNs. 
Ibus, all cells that bound Oligonucleotide probes during ISH were confirmed as eosinopl-dls by 
staining with eosin (Figure 8). However, some cells that stained with eosin after ISH, and had 
morphological appearances of eosinophils, did not bind oligonucleotide probes, suggesting that 
not all eosinophils bound probes, or did not bind them sufficiently strongly to prevent their 




Figure 8. Photomicrograph (x 1000) of a frozen section of inflamed large bowel from 
a patient with inflammatory bowel disease (ulcerative colitis) pre-stained with eosin, 
with subsequent ISH using an oligonucleotide antisense probe cocktail for mRNA for 
IKBoc; all cells with overlying positive granules, indicating binding of probes during 
ISH, also stained with eosin, suggesting them to be eosinophils (appearances similar 
with probe cocktails for mRNA for TNF(x, IL-4, IL- 10 and insulin, and with poly-d(T) 
probe). 
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3.2.2 Carbol chromotrope 
Chromotrope 2R is a specific bright red stain for eosinophils. The method described by 
Lendrum in 1944 (284) uses carbol chromotrope, a 0.5 % (w/v) solution of 
chromotrope 2R in a1% (w/v) solution of phenol (Sigma Chemical Company) in 
distilled water, applied to formalin-fixed intestinal sections for 30 minutes and washed 
off with tap water. To optimise this staining method for identification of eosinophils in 
paraformaldehyde-fted frozen sections of bowel, a range from 0.5 to 15 % carbol 
chromotrope (Sigma Chemical Company) concentrations were applied for a range from 
15 to 60 minutes. Optimum staining of eosinophils with minimum background staining 
in sections of normal and inflamed large bowel, that had not undergone ISH, was 
achieved with 15 % carbol chromotrope for 30 minutes (Figure 9), and this was 
therefore used in subsequent attempts to stain eosinophils during ISH. 
Because carbol chromotrope pre-staining has been used in a previous study to block 
binding of long DNA probes to eosinophils in bone marrow smears (285) (see section 
3.6 for application of the blocking properties of carbol chromotrope to the present 
study), to identijý eosinophils in ISH sections in the present study, carbol chromotrope 
was applied after hybridisation and prior to coating slides with photographic emulsion. 
This method did not result in a clear staining of eosinophils, presumably because the 
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Figure 9. Photornicrograph (x 1000) of a frozen section of inflamed large bowel from 
a patient with inflammatory bowel disease (ulcerative colitis) stained with 15 % carbol 
chromotrope for 30 minutes; only the granular cytoplasm of eosinophils stains red. 
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3.3 Other tissues 
3.3.1 Small bowel 
To determine whether binding of oligonucleotides to eosinophils in the gastrointestinal 
tract occurred in areas other than the colon, ISH experiments were repeated on 
sections of distal duodenal biopsy specimens, when an oligonucleotide probe cocktail 
for IKB(x mRNA and poly-d('I) probe bound in a pattern similar to that seen in the 
colon. 
3.3.2 Nasal polyp 
To confirm binding of oligonucleotide probes to eosinophils, and to investigate 
whether this is an effect isolated to bowel, oligonucleotide ISH was performed on 
Paraforrnaldehyde-fixed, frozen sections of nasal polyp taken from a patient with 
allergic rhinitis, that are known to contain large numbers of eosinophils. Findings were 
identical to those in bowel, with cells identified as eosinophils by staining with eosin, 
binding all probes tested, namely probe cocktails for IKBcc mRNA, TNF(x mRNA and 
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Figure 10. Photornicrograph (x 400) of a frozen section of nasal polyp from a patient 
with allergic rhinitis, with ISH using an oligonucleotide probe cocktail for mRNA for 
IKB(x, showing numerous positive cells within the lamina propria (appearances similar 
with probe cocktail for mRNA for TNFcc and insulin, and with poly-d(T) probe). 
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3.3.3 Rat cerebral cortex 
Rat cerebral cortex was used as a control tissue as it contains no eosinophils. In 
addition, NFKB is constitutively activated in neurones of rat cerebral cortex (8 1), and, 
according to studies in tumour cell lines (see section 1.2 and Chapter 1), is therefore 
likely to be accompanied by an increase in IKB(x mRNA. The cerebral cortices of 
Sprague-Dawley rats, that had been freshly killed for harvesting of hearts for use in 
isolated perfusion experiments in another laboratory, were dissected, set in OCT 
compound, frozen in liquid nitrogen and processed in the same manner as specimens of 
bowel. No positive cells were seen in ISH experiments performed with all probes 
(Figure 11), which is consistent with the hypothesis that positive ceRs in previous 
experiments using sections of bowel were due to non-specific binding of probes to 
eosinophils, which are absent in cerebral cortex, and not due to hybridisation to specific 
mRNA, confirmed, in this case, by the absence of cefls expected to be positive for 
IicB(x mRNA. 
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Figure 11. Photomicrograph (x 400) of a frozen section of rat cerebral cortex, with 
ISH using an oligonucleotide antisense probe cocktail for mRNA for IKBa, showing 
no positive cells (appearances similar with probe cocktails for mRNA for TNF(x and 
insulin, and with poly-d(T) probe). 
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3.4 Rel2roduction of findings by other investigators 
To ensure that the observed binding of oligonucleotide probes to eosinophils was not a 
phenomenon confined solely to my ISH experimental technique and skills, sections of 
colonic biopsy specimens from patients with inflammatory bowel disease were given to 
an independent investigator within The Rayne Institute who was conducting similar 
oligonucleotide ISH experiments based on the same protocol, except using different 
probe cocktails, namely for mRNA for IL-10 and IL-4, and a fixation technique that 
differed slightly from that used in this project with sections being initially fixed in 
acetone for 30 seconds, before storage at -70'C, and finally, as in the protocol used in 
this project, fixed in a4% (w/v) solution of paraformaldehyde in PBS immediately 
prior to ISH. A similar pattern of staining was observed, with binding of probes only to 
ceRs staining with eosin, confmning their identity as eosinophils. Thus, this 
phenomenon is not due to my experimental ISH technique or skills, and also does not 
appear to be dependent on fixation technique, as is also demonstrated by similar 
findings in formaldehyde-fixed, paraffin-embedded specimens (see section 3.5). 
Similarly, to ensure that the observations were not due to mistakes in collection and 
sectioning of specimens, ISH was performed on sections prepared by another 
investigator, when findings were identical. 
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3.5 Form aidehyde-fixed, paraffin-embedded specimens 
ISH experiments were also conducted on formaldehyde-fixed, paraffm-embedded 
specimens from small bowel resection specimens from patients with Crohn's disease 
stored in the Histopathology Department at St. Thomas' Hospital. Sections of seven 
gm thickness were cut into 'Q' water, and then dried onto microscope slides. Paraffin 
was removed from the sections in a standard manner by immersion in xylene for two 
minutes, twice, 100 % alcohol for one minute, twice, and then successive solutions of 
reducing concentrations of alcohol for one minute each (95 %, 70 % and 50 % (v/v) 
solutions of alcohol in 'Q' water), and finally washed in 0.5 x SSC for one minute. All 
solutions used for removing paraffin contained I% DEPC to destroy RNases. ISH was 
then conducted using the same protocol as for frozen sections. However, a range of 
concentrations from 0- 40 gg ml-1 of proteinase K were used to establish the ideal pre- 
digestion of sections, as is recommended for ISH on paraffin-embedded sections (272). 
Probes for mRNA for IicBa and insulin, and poly-d(T) probe were tested and all bound 
to eosinophils in a manner similar to that observed with frozen sections, with most 
binding seen with no pre-digestion with proteinase K (Figure 12). Thus binding of 
oligonucleotide probes to eosinophils occurred in paraffin-embedded sections as well 







Figure 12. Photomicrograph (x 400) of a section of paraffin-embedded, inflamed large 
bowel from a patient with inflammatory bowel disease (Crohn's disease), with ISH 
using an oligonucleotide antisense probe cocktail for mRNA for IKBcc, showing a 
pattern of positive cells within the lamina propria similar to that seen in 
frozen 
sections (appearances similar with probe cocktails for mRNA for TNF(x and insulin, 
and with poly-d(T) probe). 
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3.6 Blocking of non-specific binding of oligonucleotide 12robes to 
eosinophils 
Thus far, it has been demonstrated that when using standard conditions for 
oligonucleotide ISH, probes bound non-specifically to eosinophils but did not appear to 
hybridise to specific target mRNA. 
I hypothesised that the stringency of washes used in this protocol was set at a level that 
removed probe hybridised to target mRNA but allowed persistence of probe bound 
non-specifically to eosinophils. To test this hypothesis, the ability of blocking 
manoeuvres to prevent non-specific binding of probe to eosinophils, together with 
differing stringencies of washes to allow persistence of probe hybridised to specific 
mRNA, was then investigated. 
3.6.1 Blocking of non-specific binding of oligonucleotide probes to eosinophils 
using carbol chromotroj2e 
In a previous report by others, binding of longer DNA probes (200-mers) to 
eosinophils in bone marrow smears was completely blocked by pre-staining with carbol 
chromotrope (a 1.25 % (w/v) solution of chromotrope 2R in a1% (w/v) solution of 
phenol in 'Q' water) prior to ISH (285). 
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Thus, in the present study, pre-staining was investigated with a range of concentrations 
of carbol chromotrope from 1.25 to 15 % (w/v), in combination with a range of 
incubation times from 30 to 120 minutes, and, in contrast to the previous report by 
others, only a reduction, but not elimination, of non-specific binding of probe to 
eosinophils was achieved, with maximal blocking achieved by 15 % for 30 minutes, 
with no additional benefit from longer incubation periods. 
3.6.2 Competitive inhibition of non-speciric binding of oliggonucleotide 12robes to 
eosinophils 
To determine if non-specific binding sites within eosinophils could be saturated with 
excess unlabeRed oligonucleotide, thus preventing non-speciflc binding of labeHed 
oligonucleotide probe, an unlabefled, irrelevant probe (a 30-mer oligonucleotide for 
mRNA for IL-6) was added at excess concentration (800 times the concentration of 
labelled probe) to the hybridisation solution to competitively inhibit non-specific 
binding to eosinophils. Reduction, but not elimination, of non-specific binding to 
eosinophils was achieved 
Pre-treatment with carbol chromotrope and competitive inhibition by an unlabelled, 
irrelevant probe were combined, and led to a further reduction, but not complete 
elimination of non-specific binding to eosinophils. 
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3.6.3 Blocking of non-sl2ecific binding of oligonucleotide 12robes to eosinol2hils by 
pre-treatment with dithiothreitol and iodoacetamide 
Pre-treatment of sections with 0.2M dithiothreitol (DTT) (Sigma Chemical Company) 
for twenty minutes to maintain thiols in the reduced state and to reduce disulphide 
groups, followed by a solution of OAM iodoacetamide (Sigma Chemical Company) in 
OAM triethanolamine at pH 8.2, for thirty minutes has been previously used to block 
non-specific binding of riboprobes to eosinophils in sections of bowel (286), and was 
therefore explored with oligonucleotide ISH: it resulted in a complete loss of positive 
ceRs in different experiments with all probes (Figure 13), confirming that all positive 
ceUs were eosinophils. 
Furthermore, as successful blocking of non-specific binding to eosinophils resulted in 
no positive cells, the hypothesis that probe hybridised to target mRNA was not 
persisting after washes was confirmed, or, alternatively, hybridisation was not 
occurring because, for instance, of prior destruction of target mRNA by contamination 
with RNases. 
Excessively stringent post-hybridisation washes were hypothesised to be the most likely 
explanation for the absence of hybridised probe, and experiments to test this hypothesis 
are described below. The stringencies of washes were taken from previous publications 
that developed the methodology (281,287-291), and were, in retrospect, excessively 
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Figure 13. Photomicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis) pre-treated with dithiothreitol and iodoacetamide, with ISH using poly-d(T) 
probe, showing no positive cells, indicating successful blocking of non-specific 
binding of probe to eosinophils (appearances similar with probe cocktails for mRNA 
for TNFa and insulin, and with poly-d(T) probe). 
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3.7 Reducing wash stringencl to retain hybridised probe 
To prove this hypothesis and to determine the ideal stringency of post-hybridisation 
washes to allow retention of hybridised probe, further experiments were performed 
with washes of reduced stringency, after binding sites within eosinophils had been 
blocked by pre-treatment of sections with DTT and iodoacetamide. Poly-d(T) probe 
was used in these experiments, to allow easy distinction between successful retention 
of probe hybridised to mRNA, which, with poly-d(T) probe, would result in a positive 
signal over all cells, and recurrence of binding to eosinophils in bowel and nasal polyp, 
which would result in a positive signal over only scattered cells in the larnina propria. 
For the same reasons, probe cocktails for specific mRNA (e. g. IrJ3(x or TNFa mRNA) 
were not used as successful retention of hybridised probe might then have resulted in a 
pattem of scattered positive cells within the lainina propria that would be difficult to 
distinguish from the similar pattern, which would result if binding to eosinophils, in 
bowel and nasal polyp recurred. 
Thus, ISH experiments were performed on sections of normal human bowel, rat 
cerebral cortex and human nasal polyp. Sections were pre-treated with DTT and 
iodoacetamide, to prevent binding to eosinophils, and ISH with poly-d(T) probe was 
then followed by reduced stringency washes at 5x SSC, thrice. Positive signal was 
observed over all cells indicating successful retention of hybridised probe to mRNA in 
all cells (Figure 14). 
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Figure 14. Photomicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis) pre-treated with dithiothreitol and iodoacetamide, with ISH using poly-d(T) 
probe, followed by reduced stringency washes (5 x SSC), showing positive signal 
overlying all cells, indicating retention of poly-d(T) probe hybridised to the poly- 
riboadenosine tail on all mRNA. 
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To ensure that some of the observed many positive cells in the above ISH experiments 
with reduced stringency washes using poly-d(T) probe on sections of bowel and nasal 
polyp were not due to recurrence of binding of probes to eosinophils, despite the 
blocking measures with DTT and iodoacetamide used to prevent this, some sections 
were first treated with RNase (see section 2.5) to remove target mRNA and prevent 
hybridisation. Thus, if any positive cells occurred in this experiment, they would be due 
to recurrence of non-specific binding of probes to eosinophils. 
Unfortunately, despite blocking measures, re-appearance of non-specific binding of 
probes to eosinophils was demonstrated (Figure 15). It was therefore postulated that 
the previous success in removing non-specific binding of probes to eosinophils was due 
to a combination of the blocking effects of DTT and iodoacetamide and the subsequent 
high stringency washes, and that when wash stringency was reduced to a strength that 
allowed retention of probe hybridised to target mRNA, non-specific binding of probes 
to eosinophils recurred, despite pre-treatment with DTI' and iodoacetamide. 
3.8 Further attempts to eliminate eosinophil binding at low stringencv 
washes 
In an attempt to eliminate the recurrence of non-specific binding of probes to 
eosinophils when low stringency washes were used, pre-treatment of sections with 
carbol chromotrope and with DTT and iodoacetamide were combined, but proved to 
be unsuccessful. 
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Figure 15. Photomicrographs (above x 100, below x 400) of a frozen section of 
inflamed large bowel from a patient with inflammatory bowel disease (ulcerative 
colitis) pre-treated with RNase, thus removing all mRNA, and 
then pre-treated with 
dithiothreitol and iodoacetamide, with ISH using poly-d(T) probe, 
followed by 
reduced stringency washes (5 x SSQ, showing recurrence of non-specific 
binding of 
probe to eosinophils. 
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3.9 Quantitation of binding of single oligonucleotide probes for TicBcc 
mRNA to eosinophils 
At the start of the investigations, fewer 'positive cells' (later identified as non-specific 
binding to eosinophfls) were noted with use of a cocktail of antisense probes for IKB(x 
mRNA than with use of a single sense probe (see section 3.1), used at an equivalent 
concentration as a negative control. Furthennore, each 'positive cell' had fewer 
overlying black granules of photographic emulsion with the sense than with the cocktail 
of antisense probes. This observation, with, the sense negative control being 'less 
positive' than the antisense cocktail, might have falsely suggested successful 
hybridisation of the antisense probe cocktail to target mRNA, rather than the correct 
observation of non-specific binding of probes to eosinophils. To explore further this 
finding of differential non-specific binding of probes to eosinophils, ISH experiments 
were performed with each single individual probe for IrBcc mRNA (three antisense 
probes, one sense probe) at identical concentrations, rather than with the cocktail of 
antisense probes, when the number of positive cells for all three individual antisense 
probes was significantly greater than for the sense probe (Tables 2 and 3), and when 
Bonferroni corrections for multiple comparisons were made, these differences remained 
significant. Thus, differential binding of probes to eosinoPhils was confirmed, and 
possible explanations for this phenomenon are explored in the Discussion. 
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Table 2. Number of positive cells in the lamina propria of a section of inflamed bowel 
in an ISH experiment with individual oligonucleotide probes for IkBa mRNA. 
Probe Mean number of positive 
cells per microscope field 
Standard 
deviation 
Antisense 1 27.3 10.6 
Antisense 2 28.6 12.3 
Antisense 3 36.7 8.2 
Sense 16.2 6.3 
Table 3. Comparison of number of positive ceRs in the lamina propria of a section of 
inflamed bowel in an ISH experiment with individual oligonucleotide probes. 
comparison difference between 95 % confidence p-value' adjusted 
means of numbers intervals of the p-value* 
of positive cells per difference* 
microscope field 
antisense 1 vs 11.1 (2.9,19.3) 0.011 0.032 
sense 
antisense 2 vs 12.4 (3.2,21.6) 0.011 0.033 
sense 
antisense 3 vs, 20.5 (13.6,27.4) <0.001 <0.00 I 
sense I 
# values compared to values for sense using an unpaired Student's t-test, 
* p-values adjusted using Bonferroni corrections for multiple comparisons 
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4. Discussion 
4.1 Non-specific binding of 12robes to eosinophils 
I have shown that oligonucleotide probes bind to eosinophils in the larnina propria of 
sections of bowel, a conclusion based on the following observations: 
1. all tested probes (probes for IKBcc, TNFcc, insulin, IL-10 and IL-4, and poly-d(T) 
probe) bound to scattered cells within the lamina propria of large bowel; 
2. the cells that bound these probes have morphological appearances of eosinophils; 
3. probes for insulin mRNA, which should not be present in bowel, bound in a similar 
pattem; 
4. poly-d(T) probe bound in a similar pattern and not to all cells, as would be expected 
if hybridisation to the poly-riboadenosine tail present on all mRNA had occurred; 
5. the sense probe for 10(x, a negative control, bound in a similar pattern, albeit at a 
slightly reduced level; 
6. binding was not prevented by pre-treatment of sections with RNase to destroy target 
mRNA; 
7. cells binding probes stained with eosin; 
8. binding of all probes to the putative eosinophils, which had not been prevented by 
standard methods of reducing non-specific binding included in the protocol, namely 
acetylation, pre-hybridisation with Denhardt's solution and addition of non- 
complementary DNA sequences (salmon sperm DNA) to the hybridisation solution, 
was reduced by pre-treatment of sections with carbol chromotrope, and by competitive 
inhibition by addition of a high concentration of unlabelled, irTelevant probe to the 
hybridisation solution; 
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9. binding of all probes to the putative eosinophils was completely blocked by pre- 
treatment of sections with DTT and iodoacetamide. 
Findings were similar in sections of small bowel and sections of nasal polyp, which is 
rich in eosinophils, but no binding was observed in sections of rat cerebral cortex, 
which contains no eosinophils. 
Non-specific binding to eosinophils was not due to personal experimental technique, as 
findings were similar when experiments were performed by a different investigator in 
another laboratory where the technique was in use. Furthermore, non-specific binding 
to eosinophils was not isolated to sections fixed only in paraformaldehyde, and was 
seen when sections were initially fixed in acetone followed by parafonnaldehyde, and in 
sections fixed in formaldehyde and then embedded in paraffin wax. 
Non-specific binding of oligonucleotide probes to eosinophils in bowel and nasal polyp 
was only partially inhibited by pre-staining with carbol chromotrope, unlike in a 
previous report, when non-specific binding of longer DNA probes to eosinophils in 
bone marrow smears was completely blocked by the same measure (285), and this 
difference may be due to the additional effect of higher stringency washes allowed by 
use in the previous report of longer probes, as high stringency of washes may have an 
additive effect to pre-hybridisation manoeuvres in blocking non-specific binding (see 
below). 
Complete inhibition of non-specific binding of probes to eosinophils was achieved by 
pre-treatment with dithiothreitol followed by iodoacetamide, a method used previously 
to block non-specific binding of riboprobes to eosinophils in sections of bowel (286), 
and when the stringency of post-hybridisation washes was reduced, hybridisation of 
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poly-d(T) probe to mRNA in all cells was observed. This suggests a stronger 
interaction between probes and eosinophils than between poly-d(T) probe and mRNA. 
When the stringency of washes was reduced so that poly-d(T) probe hybridised to 
mRNA was no longer removed, non-specific binding to eosinophils returned, and could 
not be prevented despite combining carbol chromotrope with DTT and iodoacetamide 
pre-treatments. 
4.2 Melting temperature of nucleic acid hybrids in hybridisation 
solutions and post-hybridisation washes 
Specific binding of oligonucleotide probes to target mRNA in sections involves 
formation of RNA-DNA hybrids and is termed hybridisation. The strength of 
hybridisation is reflected by the stability of the RNA-DNA hybrid. The stability of 
nucleic acid hybrids is determined by several factors including the temperature of the 
solution in which the hybrids form. The melting temperature (T, ) of identical hybrids in 
a solution is defined as the temperature of the solution at which half the hybrids would 
dissociate if left to equilibrate, and is influenced by: 
1. the nature of the hybrid: RNA-RNA hybrids are more stable than RNA-DNA 
hybrids, which in tum are more stable than DNA-DNA hybrids; 
2. the length of the probe: longer nucleotides form more stable hybrids; 
3. the base composition of the probe: increasing GC content of the nucleotide results in 
more stable hybrids, and 
4. the composition of the hybridisation solution: higher concentrations of monovalent 
cations, such as sodium, increase the stability of hybrids, while increasing 
concentrations of formamide reduce stability. 
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A formula for RNA-DNA hybrids has been derived to calculate the T. of hybrids in 
hybridisation solutions and post-hybridisation washes (272): 
T. = 81.5 + 16.6 log (molarity of monovalent cations) + 0.41 (% GC content) - 
500/length of probe in bases - 0.5 (% (v/v) formamide) 
Using this formula, the following values for T. of hybrids in the hybridisation solution 
and the post-hybridisation washes are calculated using mean % GC content (0.47) of 
all oligodeoxynucleotide probes for specific mRNA used (for IkBa and TNFa, but not 
for insulin, IL-4 or IL-10, as base composition was not released by manufacturers), 
excluding poly-d(T) probe (see section 4.2), and the appropriateness of the actual 
temperatures used in ISH experiments is discussed. 
Calculated melting temperatures for hybrids in the hybridisation solution in ISH 
experiments using probes for speciflc target mRNA 
The calculated Tm of hybrids in the hybridisation solution is 52.3 "C. The optimum 
temperature for hybridisation to occur maximally at 5-6 hours is 25 T below the T,. of 
hybrids in the hybridisation solution. However, if hybridisation is performed overnight, 
as in the protocol described above, more stringent conditions can be used (276), and 
thus the hybridisation temperature of 39 IC used in the protocol described above was 
appropriate. 
131 
Calculated melting temi2eratures for h3: brids in the IRost-hybridisation washes in 
ISH exj2eriments using probes for s]2ecifle target mRNA 
The calculated T. s of hybrids in the post-hybridisation washes are: 
* first post-hybridisation wash (2 x SSQ: 77.3 T 
9 second post-hybridisation wash (I x SSC, 50 % formamide): 47.3 IC 
o third post-hybridisation wash (0.1 x SSQ: 55.7 "C 
Thus, as is commonly practised, the second wash was the most stringent, with the final 
wash being of reduced stringency and containing no formamide with the aim of simply 
washing formamide from the tissue section. The ideal temperature for the most 
stringent post-hybridisation wash is several degrees Centigrade below the calculated 
Tm of hybrids in the wash solution (272), and so 39 `C was not theoretically over- 
stringent, although the results of ISH experiments described above suggest it, in fact, 
to be over-stringent, as there was complete removal of hybridised probe. The 
alternative hypothesis, that hybridisation had not initially occurred, is unlikely, as the 
temperature of the hybridisation solution was appropriate to the calculated T. of 
hybrids in the hybridisation solution, and results of later experiments with poly-d(T) 
probe and reduced stringency washes indicated that hybridisation was occurring, at 
least to the poly-riboadenosine tail on all mRNA, and must therefore have been 
removed by the more stringent washes used in early experiments (see below). 
Experiments using specific oligonucleotide probe cocktails, for instance for IKBoc 
mRNA, as opposed to poly-dCI) probe, with reduced stringency washes were not 
performed. This was because it would be difficult to distinguish the recurrence of 
binding of probe to eosinophils, that was shown to occur with reduced stringency 
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washes, from true, persisting hybridisation of probe to IxBoc mRNA, which both would 
result in scattered positive cells in the lamina propria. Indeed, a few cells containing 
probe hybridised to specific target mRNA may have been present amongst the 
numerous eosinophils that bound probe in the early experiments with stringent washes. 
However, this is unlikely because only eosinophils, as identified by pre-staining with 
eosin, displayed overlying positive signal and it is unlikely that only eosinophils would 
contain mRNA for IkBa and TNFcc. 
Calculated melting temperatures for hybrids in 12ost-hlbridisation washes in 
experiments using polv-d(T) probe 
As indicated in the formula to calculate T., G-C bonds are stronger than A-T bonds, 
and thus poly-d(T) probe forms hybrids with a lower T, than mixed-base 
oligonucleotide probes, such as the probes within the cocktails for specific mRNA 
(Ir, B(x, TNFa). Would calculated T. s for hybrids in the initial high stringency and 
subsequent lower stringency washes explain the experimental findings and fit with the 
hypothesis that the initial high stringency washes removed hybridised poly-d(T) probe, 
leaving only probe bound non-specifically to eosinophils, and the subsequent lower 
stringency washes did not remove poly-d(T) probe hybridised to mRNA in all ceRs? 
Early ISH exl2eriments with strinLent post-hybridisation washes 
The T, for poly-d(T) probe in the most stringent post-hybridisation wash used in early 
experiments (1 x SSC, 50 % formamide) is 28 T, and so a wash temperature of 39 T 
would remove hybridised poly-d(T) probe, as was concluded from the results of the 
experiments. Indeed, this apparent error in the initial methodology taken from previous 
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reports was fortuitous, as it resulted in removal of poly-d(T) probe hybridised to 
mRNA in all cells and left only probe bound non-specifically to eosinophils, and this 
surprising result, of only scattered cells with overlying positive signal widiin the lamina 
propria in experiments with poly-d(T) probe, contributed to the realisation that probes 
were, in fact, binding non-specifically to eosinophils. 
Later ISH experiments with less stringent post-hlbridisation washes 
The T, of hybrids in the less stringent post-hybridisation washes (5 x SSQ used in 
later experiments with poly-d(T) probe is 64.7 OC, indicating very low stringency of the 
wash at 39 OC, appropriate to the aim of ensuring that hybridised poly-d(T) would not 
be removed during washing. This aim was achieved when the predicted result of 
positive signal over all cells was observed. 
In conclusion, the ISH methods used previously by others (281,287-291), and modified 
in this project, do not allow successful blocking of non-specific binding of 
oligonucleotide probes to eosinophils as well as successful hybridisation of probe to 
target mRNA, and the technique of ISH using oligonucleotide probes cannot be used 
to investigate gene expression in the lamina propria of bowel unless other blocking 
manoeuvres are developed, as non-specific binding of probe to eosinophils appears 
identical to probe genuinely hybridised to target mRNA. Furthermore, this 
phenomenon occurred in sections of nasal polyp that is rich in eosinophils, and 
therefore probably occurs in other eosinophil-containing tissues, such as lung and Ever. 
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Investigation of the epithelium with ISH using oligonucleotide probes may stil. 1 be 
possible as few eosinophils are present. 
Interestingly, there was greater non-specific binding of the antisense probe cocktail for 
IxBoc to eosinophils than of an equivalent concentration of a single sense probe. This 
might have been due to different probes occupying different binding sites within 
eosinophils, but later experiments with individual IKB(x probes still showed 
significantly less non-specific binding of sense than antisense probes to eosinophils. 
This effect, of greater non-specific binding of antisense than sense probes to 
eosinophi. 1s, might lead to a false conclusion of successful hybridisation to target 
mRNA, and emphasises the importance of strict observation of negative controls, i. e. 
the sense probe should be entirely negative and not only 'less positive'. The 
explanation for the difference in non-specific binding of probes to eosinophils is unclear 
and is further explored in Chapter 3. 
4.3 Review of previous literature 
ISH using oligonucleotide probes has previously been extensively used in bowel using a 
similar pr9tocol, particularly to identify cells containing cytokine mRNA, without 
recognition of binding of probes to eosinophils (221,287-292). Results in these studies 
have shown 'positive' cells within the lamina propria with no staining within other 
expected areas, such as the epithelium. Hence, it may be possible that these apparently 
&positive' ceUs were, in fact, due to probes binding to eosinophils. Furthermore, 
increased numbers of eosinophils, in sections of inflamed specimens result in increased 
numbers of ceUs binding probes, which, when mistaken for hybridisation to target 
135 
mRNA, appears consistent with hypotheses of increased numbers of ceRs expressing 
cytokine mRNAs in inflamed specimens. Other reports, using similar methods in the 
gastrointestinal tract, may also have been subject to this effect (293-296). 
Binding of oligonucleotide probes to eosinophils was also observed in nasal polyp, and 
is therefore likely to occur in other eosinophil-containing tissues such as lung, liver and 
skin, and previous studies using oligonucleotide ISH with these tissues (297-299) may 
have been unknowingly subject to this effect. 
Furthermore, there are studies that suggest that non-specific binding to eosinophils may 
occur with probes other than oligonucleotide probes. A study of expression of 
transforming growth factor-P in nasal polyp using a 640 base-pair cDNA probe, 
demonstrated a positive signal over eosinophils only, and none over fibroblasts, 
macrophages and endothelial ceRs as was expected from in vitro studies (300). In 
another study, riboprobes bound to eosinophils in bowel despite higher stringency 
washes allowed by long probes and the stronger interaction between DNA-RNA 
compared to DNA-DNA hybrids, and despite post-hybridisation treatment with RNase 
to destroy non-hybridised probe (286); this suggests RNase is ineffective in hydrolysing 
RNA bound non-specifically to eosinophil granules. Thus, non-specific binding to 
eosinophils may occur with all types of probe, and so these findings are relevant for all 
types of ISH in eosinophil-containing tissues. 
Furthermore, non-specific binding of nucleotide probes to eosinophils may explain the 
apparently contradictory literature on expression of interleukin-5 (IL-5) mRNA in 
Crohn's disease; a study using ISH with riboprobes, demonstrated increased expression 
of IL-5 mRNA in the lamina propria of inflamed bowel from patients with Crohn's 
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disease (254), but no increase was found when IL-5 mRNA was assessed by 
quantitative reverse transcriptase polymerase chain reaction performed on 
homogenates of mucosal biopsy specimens (235). In addition, it has previously been 
suggested that eosinophil. granules may contain RNA based on localisation of labelled 
nucleic acids to eosinophil granules (301), but this observation may be explained by 
non-specific binding of nucleic acids to eosinophils. 
Another study has identified potential problems when using oligonucleotide probes for 
ISH in the gastrointestinal tract of the rat. An unusually strong signal was noted 
overlying immune cells of the lamina propria using 35S-dATP-labelled probes, which 
was thought to represent an amplification of a specific hybridisation signal due to 
crosslinking of thiosulphate groups on 35S_Iabelled probes, co-ordinated by cobalt ions 
in the hybridisation buffer (302). Specific hybridisation was thought to have occurred 
because experiments with sense probes were negative, and because use of riboProbes 
for the same mRNA produced a similar pattern of positive cells within the lamina 
propria. However, as described above, there may be differential non-specific binding of 
antisense and sense probes to eosinophils, and binding of riboprobes may also occur, 
which may explain these findings. 
Paneth cells in rat stomach and small intestine have also been shown to non-specifically 
bind nucleic acid probes, providing a further potential hazard when using ISH in the 
gastrointestinal tract (303). 
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5. Conclusion 
Eosinophils widiin sections of bowel and nasal polyp non-specifically bind 
oligonucleotide probes. Non-specific binding to eosinophils was prevented by a 
combination of pre-treatment of sections with dithiothreitol and iodoacetamide and 
stringent post-hybridisation washes, but the stringency of these washes resulted in loss 
of hybridised probe. When wash stringency was reduced to a level that allowed 
retention of hybridised probe, non-specific binding to eosinophils returned, despite pre- 
treatment of sections with dithiothreitol and iodoacetamide. It is concluded that these 
methods do not allow successful blocking of non-specific binding to eosinophils as well 
as successful hybridisation, and that the technique of ISH using oligonucleotide probes 
should be used with caution to investigate gene expression in the lamina propria of 
bowel, and probably in other eosinophil-containing tissues, unless other blocking 
manoeuvres are developed. 
Differential non-specific binding of individual oligonucleotide probes to eosinophils 
was observed, which may lead to misinterpretation of non-specific binding to 
eosinophils as successful hybridisation to target mRNA, and the causes of this 
phenomenon are explored in Chapter 3. 
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Chapter 3 




In Chapter 2, non-specific binding of oligonucleotide probes to eosinophils in sections 
of bowel during ISH was demonstrated and methods of blocking this interaction were 
investigated. Furthermore, greater non-specific binding of antisense than of sense 
oligonucleotide probes to eosinophils was observed. 
1.1 Aim 
The aim of the present chapter was to investigate the nature of this binding further 
using in vitro techniques, and to identify the element(s) within eosinophils that binds 
oligonucleotide probes. Eosinophilic cationic protein (ECP), contained within 
eosinophil granules, was hypothesised to be this element for the reasons explained 
below. 
1.2 Eosinophils 
Eosinophils are often considered a subset of PMNs because of similar structure with 
multi-lobed nuclei and prominent cytoplasmic granules, but they have different 
functions and are derived from different progenitor cells. Eosinophils are mainly 
concerned with allergic reactions, parasitic infections and chronic inflammatory 
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responses and are found predominantly in tissues, whereas neutrophils are primarily 
involved in acute bacterial infections, ischaernic lesions and reactions to damaged cells 
and tissues, and defend predominantly intravascular sites. Neutrophils phagocytose 
material whereas eosinophils secrete their granules. Eosinophil granules contain large 
quantities of major basic protein (8.6 gg per 106 cells) that is thought to be an 
important mediator of eosinophil-dependent damage to parasites and host tissues, and 
also of ECP (25 gg per 106 eosinophils) within cytoplasmic granules (304). 
1.3 Biochemistry of ECP 
ECP is a single-chain, highly cationic glycoprotein that contains 2.5 moles of zinc per 
mole of piotein (283). It exists in three molecular weight forms of 18.5,20 and 22 kDa 
and has an isoelectric point (pI) of over 11 (305). It is secreted from eosinophils by 
degranulation and has ribonuclease activity, histamine-releasing properties and 
neurotoxic effects. 
The pI of a protein describes the pH of a solution of that protein at which the protein 
carries no net charge. The unusually high pI of ECP results in ECP bearing a strongly 
cationic charge at physiological pHs, and it was therefore hypothesised that 
oligonucleotide probes, known to be mildly anionic at physiological pHs, were binding 
to ECP within eosinophils. Biornolecular interaction analysis, which is a method that 
records and characterises the real-time interaction between two biomolecules, was used 
as an in vitro method to demonstrate this proposed interaction. 
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2. Description of real-time biomolecular interaction analysis 
using a biosensor approach 
2.1 Backuound 
A biosensor is defined as an instrument that combines a biological recognition 
mechanism with a sensing device or transducer, and is used to monitor interactions 
between biornolecules. Early biosensor methods, such as enzyme-linked 
immunosorbent assay and affinity chromatography, give information about the 
conditions and specificity of such interactions but only provide a snap-shot and are 
unable to continuously monitor the interaction. Spectrophotometric methods are rapid 
and can be used to follow interactions, but require the molecules to contain a suitable 
absorbent or fluorescent group. Alternatively, one of the molecules can be labelled, but 
this may interfere with the interaction and requires the interactants to be purified in 
relatively large quantities. 
A recently developed biosensor method, termed real-time biomolecular interaction 
analysis, continuously monitors the interaction of unlabelled molecules using the optical 
phenomenon of surface plasmon resonance, which is the sharp reduction in intensity of 
reflected light that occurs at a specific incident angle of a light beam that is totally 
internally reflected at a thinly metal-coated surface. 
2.2 Surface plasmon resonance 
At an interface between two transparent media of different refractive indices, light from 
the side of higher refractive index is partly reflected and partly refracted. Below a 
certain critical angle of incidence, no light is refracted across the interface and total 
internal reflection occurs. Although the incident light is totally reflected, an 
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electromagnetic field component, the evanescent wave, penetrates a short distance into 
the medium of lower refractive index (Figure 1). If the interface between the two media 
is coated with a thin layer of metal, the evanescent wave interacts with delocalised 
surface electrons (plasmons) in the metal, resulting in collective resonant oscillation of 
the electrons, termed surface plasmon resonance (SPR). An amplification of 
electromagnetic field strength occurs with SPR and causes a reduction in intensity of 
reflected light, and the angle of reflection at which this reduction occurs is termed the 
SPR angle and is measured by the BiacoreXTM instrument as an SPR signal in resonance 
units (RU) and plotted as a graph against time, the sensorgrarn (Fig. 2). 
glass prism 
incident light reflected light 
Figure 1. Principle of total internal reflection. Total internal reflection at the 
interface between two media of different refractive indices causes an evanescent wave 
in the medium of lower refractive index on the non-illuminated side (adapted from BIA 
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Figure 2. Principles of biornolecular Interaction analysis using a BiacoreXTm Instrument. 
1. SPR at the sensor chip surface results in a sharp reduction in the intensity of reflected light 
at a specific angle of reflection (A). 
2. When analyte binds to ligand on the sensor chip surface, the angle of the reduction in the 
intensity of reflected light changes from A to B. 
3. The angles A and B are recorded as changes in 'resonance signal' in RU and plotted against 
time as a 'sensorgram' (adapted from BIA technology handbook, Pharmacia Biosensor). 
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The SPR angle is determined by three parameters: 
1. the properties (thickness, optical constants etc. ) of the metal film 
2. the wavelength of the incident light, and 
3. the refractive indices of the media on either side of the metal film. 
In the BiacoreXTM instrument, 1 and 2 are constant and therefore the SPR angle is 
determined solely by the refractive indices of the media. The denser medium on the 
illuminated side of the interface is glass with a constant refractive index. The less dense 
medium on the non-illuminated side, into which the evanescent wave penetrates, is a 
carboxymethylated dextran matrix on which one of the molecules under investigation, 
the ligand, is immobilised. The refractive index of this medium is altered by binding of 
the other molecule under investigation, the analyte, to the ligand, and by the ionic 
strength of the overlying aqueous solution (running buffer), which affects the hydration 
of the dextran matrix. Providing that the running buffer is constant, then the sole 
variable determining SPR is binding of analyte to ligand. 
2.3 Components of BiacoreXTM 
A. Light source and sensor. The light source is a high efficiency light-emitting diode 
that produces light nearly in the infrared range. The light is focused on the glass-gold 
interface of the 'sensor chip' in a wedge-shaped beam, giving a range of simultaneous 
incident angles. Reflected light is monitored by a two-dimensional diode array that 
determines the SPR angle to a resolution corresponding to 0.1 RU. 
B. Sensor chip. The sensor chip fonns the interface at which total internal reflection 
and SPR occur. It consists of a glass slide coated with a thin layer of gold, chosen for 
its combination of chemical inertness and good SPR response, that is linked to a 
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surface matrix of carboxy-methylated dextran. The dextran matrix allows covalent 
immobilisation of the ligand using weU-characterised chemistry and provides a 
hydrophilic environment for the interaction between ligand and analyte with a very low 
degree of non-specific binding to the matrix. The dextran matrix is swoRen to 
approximately 100 mn in aqueous media, aaW higher pH and lower ionic strength 
increase the depth of the matrix, and so change the baseline SPR response, by 
increasing electrostatic repulsion between negatively-charged carboxyl groups within 
dextran (306). However, running conditions of high ionic strength (physiological salt 
concentrations of 0.15M or higher) are preferred, so that electrostatic interactions 
between immobilised Hgand and carboxyl groups of the dextran matrix are minimised. 
The analyte is passed over the dextran-ligand surface in free solution and as the 
interaction proceeds, the concentration of analyte binding to ligand in the surface layer 
changes, producing a change in SPR angle that is continuously measured. The dextran- 
ligand surface is then regenerated by stripping off the analyte with a regeneration 
solution. 
3. Flow cells. Analyte is passed through two flow cells, with the dextran surface of the 
sensor chip forming one wall of the cells, while the gold film is illuminated through the 
glass froth outside the cell (Figure 2). The two cells are used in parallel, allowing 
simultaneous binding of analyte to two ligands, one a control that is subtracted from 
the index ligand. Temperature is closely controlled because of its effect on refractive 
index and reaction kinetics. 
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2.4 Immobilisation of Iiiiand 
ECP and control proteins, rather than the oligonucleotide probes, were immobilised on 
the dextran matrix because first, only a single immobilisation of each was required, 
producing a fixed concentration of immobilised ligand over which different analytes 
(oligonucleotide probes) could be repeatedly passed, and second, immobilisation of the 
larger molecules was less likely to interfere with the active site(s) responsible for the 
proposed interaction between ECP (and control proteins if this occurred) and 
oligonucleotide probes. 
The following methods can be used to immobilise ligand to the dextran, matrix: 
9 amine coupling using reactive esters 
* coupling by thiol-disulphide exchange 
e binding biotinylated ligands to immobilised streptavidin 
e aldehyde coupling to a hydrazine-activated surface 
Amine coupling is the most generally applicable immobilisation method (307) and is 
particularly recommended for neutral and basic proteins, such as ECP and the control 
proteins myoglobin and lysozyme. 
Amine coupling comprises the following steps: 
1. activation of the chiP surface by injection of 0.05M N-hydroxysuccinimide and 
0.2M N-ethyl-N'-dimethylarninopropylcarbodiimide, which modifies about 40 % of 
the carboxymethyl groups in the dextran matrix; 
2. injection of ligand in a solution at a pH below the pI of the ligand, resulting in its 
protonation and thus increasing electrostatic attraction to the negatively-charged 
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carboxyl groups of the dextran. matrix, a process termed 'pre-concentration'. 
However, the pH should not be so low that the carboxyl groups of the dextran 
matrix are no longer negatively charged. Electrostatic attraction is further favoured 
by a ligand solution of low ionic strength, and 
3. deactivation of excess reactive groups in the dextran matrix with 1M ethanolamine 
hydrochloride at pH 8.5. In addition, the high ionic strength of this solution removes 
non-covalently bound ligand from the dextran matrix. 
The amount of ligand immobilised is determined by the duration of injection of the 
dextran matrix activator, the concentration of the ligand and the pH and ionic strength 
of its buffer. 
2.5 Regeneration of the dextran-ligand surface 
After each binding study, the surface must be regenerated by removal of the non- 
covalently bound analyte, leaving only the ligand covalently bound to the dextran 
matrix. Ideal regeneration conditions vary with the nature of the ligand-analyte 
interaction and weak interactions simply require return to the running buffer, and so the 
choice of running buffer may be relevant to regeneration. However, for stronger 
interactions, a regeneration solution with a pH different to that of the running buffer is 
usually required, when the temporary change in pH strips the analyte from the ligand. 
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3. Methods 
3.1 Preparation of dextran matrix 
Hvdration of dextran matrix 
The sensor chip CM5 (Pharmacia Biosensor) was docked in the BiacoreXTM instrument 
(Pharmacia Biosensor) and the dextran matrix hydrated by injecting HEPES-EDTA- 
buffered saline (HBS) running buffer (Pharinacia Biosensor) (10 mM N-2- 
hydroxyethylpiperazine-N-2-ethanesulphonic acid (HEPES), 150 mM NaCl and 3 mM 
EDTA, pH 7.4, in a 0.005 % (v/v) soludon of polysorbate 20 surfactant in distiHed 
water) at 5 gI rnin" for forty minutes until the baseline sensorgrarn had stabilised. The 
running buffer was then passed continuaUy at 5 gl min-' over the dextran matrix, and 
between all subsequent injections. 
Activation of dextran matrix 
The dextran matrix was then activated by injecting 35 gl of 0.05M N- 
hydroxysuccinimide (Biosensor Pharmacia) and O. 2M N-ethyl-N'- 
dimethylaminopropylcarbodiimide (NHS/EDC solution, Biosensor Pharmacia) at 5 gl 
min-', followed by return to HBS running buffer. 
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3.2 Immobilisation of li2ands 
3.2.1 Lieands 
Two proteins were used as controls for ECP (MW 18.5 kDa, pI >11), namely 
myoglobin, which has similar MW (18 kDa) and different pI (6.9-7.4), and lysozyme, 
which has similar MW (14.3 kDa) and similar pI (>10) (308). These proteins were 
chosen to define the nature of the proposed interaction between ECP and 
oHgonucleotide probes. 
Myoglobin and lysozyme were obtained from commercial sources and ECP was kindly 
donated by Professor Per Venge, University of Uppsala, Uppsala, Sweden, after 
isolation from human eosinophils (305). 
Two different chips were prepared, the first, chip A, containing ECP and myoglobin, 
and the second, chip B, containing ECP and lysozyme. Thus, in each chip, 
simultaneous binding of oligonucleotide probes to ECP and a control protein were 
compared, and the two resulting sensorgrarns were subtracted (see Figures 3 and 4) to 
remove background changes in the sensorgrams and hence determine true binding to 
ECP. 
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3.2.2 Prel2aration of two chips 
Chip A: ECP was immobilised (net immobilisation 3482 RU, 0.18 8 pmol MM-2) in one 
cell and the control protein, myoglobin from horse heart (Sigma Chemical Company), 
in the other (net immobilisation 3477 RU, 0.193 PMOI MM-2). 
Chip B: ECP was again immobilised in one ceR (net immobilisation 3755 RU, 0.203 
pmol nim -2 ) and in the other the control protein, lysozyme from chicken egg white 
(Sigma Chemical Company) (net immobilisation 981 RU, 0.069 pmol mm-'). 
3.2.3 Immobilisation conditions 
a) Myoglobin 
Myoglobin was immobilised in one of the two flow ceRs of chip A by injecting 10 gl of 
a 500 gg ml-1 solution of myoglobin in 10 mM sodium acetate buffer (BDH) pH 3.0 at 
5 gl min", followed by return to HBS running buffer. 
b) ECP 
ECP was immobilised in one of the two flow ceRs of both chips A and B by injecting 
10 gI of a 500 gg ml" solution of ECP in 200 MM sodium acetate buffer pH 5.5 at 5 gI 
min-', followed by return to HBS running buffer. 
c) Lysozyme 
Lysozyme was immobilised in one of the two flow ceRs of chip B by injecting 10 gl of 
a 500 gg ml-1 solution of lysozyme in 200 mM sodium acetate buffer pH 5.5 at 5 gI 
min-', followed by return to HBS running buffer. To achieve an immobilisation level for 
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lysozyme of equivalent order of magnitude to that achieved for myoglobin and for 
ECP, a further 20 gI followed by 40 gl of a 500 gg ml-1 solution of lysozyme, and then 
finally 35 gI of a 1000 gg ml-1 solution were injected. 
3.3 Deactivation of dextran matrix 
Excess reactive groups were then deactivated by injection of 50 ýtl of ethanolamine 
hydrochloride 1M, pH 8.5 (Sigma) at 5 gI min" followed by return to HBS running 
buffer. 
3.4 Protocol for binding of anal3: tes 
The binding of four oligonucleotide probes to ECP was examined, namely antisense 1, 
antisense 2, antisense 3 and sense probes for IrBoc mRNA (see Chapter 2, Table 1 for 
sequences). These probes were chosen as individual in situ binding of these probes to 
eosinophils had been quantitated in Chapter 2, hence allowing comparison of in situ 
binding to eosinophils with in vitro binding to ECP. 
AU oligonucleotides were at a concentration of 100 pg ml", which was 833 times 
greater than the concentration of probe in the hybridisation solution (0.12 gg ml-1) used 
during ISH. This concentration was chosen arbitrarily, as the concentration of 
immobilised ECP could not be equated to the concentration of ECP in eosinophil 
granules, which is unknown (although it is known that 106 eosinophils contain 26 gg 
ECP (304)). Oligonucleotide probes were injected over the dextran-ligand surface at 
20 gl min". The net binding of probe was measured in RU as the difference in the 
sensorgrarn from immediately pre-injection to a fted interval (80 seconds) after the 
end of injection of the oligonucleotide probe. 
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3.5 Solutions tested to re2enerate the dextran-li2and surfaces 
The following regeneration solutions were tested to obtain optimal conditions (see 
section 4.1 for results of testing): 
solution A. Pierce antibody/antigen buffer (Pierce & Warriner (UK) Ltd., Chester, 
UK) -a regeneration solution widely used to disrupt many interactions (formula not 
released by manufacturer); 
solution B. Pierce antibody/antigen buffer diluted 1 in 10 in the appropriate running 
buffer, and 
solution C. 0.15M KCI (BDH) adjusted to pH 12 with KOH (BDH) -a strong alkali 
to deprotonate ligands, including those with high pI (ECP and lysozyme), resulting in a 
net negative charge on the ligand and thus aiding dissociation of the negatively-charged 
oligonucleotide analytes. To reprotonate the ligand, 10 gl of 200 mM sodium acetate 
with 50 mM NaCl (BDH), adjusted to pH 5.5 with NaOH (BDH), was injected, 
followed by a return to HBS running buffer, pH 7.4, thus returning the ligand to its 
physiological state. 
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3.6 Method of analysis of sensorgrams to obtain data for kinetics of 
bindin 
The proposed interaction between ECP and oligonucleotide probes was assumed to be 
of 1: 1 stoichiometry, and therefore described by the formula: 
k. 
A+B ---I' AB 4- 
kd 
where the association rate, k. in M-1 sý', is defined in the formula: 
d[AB] / dt = k, [A][B] 
and the dissociation rate, kdin s-1, is defined in the formula: 
- d[AB] / dt = Icj [AI[B] 
The dissociation constants at equilibrium (KD in M), which describe the balance 
between complexes and free components at equilibrium and are therefore indices of 
affinity, were calculated using calculated values for k. and kd and the formula: 
KD = kd / k.. 
To examine the kinetics of the association between ECP and oligonucleotide probes, 
standard analysis of the data in sensorgrams was performed using a computer program, 
BIA evaluation (Pharmacia Biosensor), specifically designed for analysis of data 
collected with a BiacoreXTm instrument, and a PC. Using this package, the sensorgrams 
of the simultaneous injection of one probe into both flow cells of a chip, one containing 
ECP, and the other myoglobin or lysozyme, in chips A and B respectively, were 
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precisely superimposed to allow subtraction of the sensorgram for the control protein 
from that for ECP, thus removing bulk refractive effects of solutions and fluctuations 
due to, for example, opening and closing of the valves controlling injection. 
3.6.1 ChiR A containing ECP and m3: oglobin 
A representative example of sensorgrams for one of the five injections of antisense I 
probe into chip A, thus injected simultaneously over ECP and myoglobin, is displayed 
in Figure 3. The large negative deflection of both sensorgrams that occurs at the start 
of injection represents a combination of the bulk refractive effect and any binding of 
oligonucleotide probe to ECP or the control protein, myoglobin. A smaller negative 
deflection of the ECP sensorgrarn than the control protein sensorgrarn is observed, due 
to the expected binding of - oligonucleotide probe to ECP, but not to the control 
protein. 
In chip A at the start of injection (Figure 3), there are small delays in the negative 
deflection of the ECP sensorgrarn in comparison to the myoglobin sensorgram, and, 
similarly, in the return to baseline at the end of injection. These are not due to a 
mismatch in the timings of the injections, which occur simultaneously (with recording 
of sensorgrams to within 0.1 s), as the bulk refractive shift effect of the injection of the 
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Figure 3. A representative example of one of five injections of antisense 1 probe 
over ECP and myoglobin in chip A, displayed as overlaid sensorgrams. Similar 
sensorgrams were plotted for the three other oligonucleotide probes. The large 
negative deflection of both sensorgrams that occurs at the start of injection represents 
a combination of the bulk refractive effect and any binding of oligonucleotide probe 
to ECP or the control protein, myoglobin. A smaller negative deflection of the ECP 
sensorgram than the control protein sensorgram is observed, due to the expected 
binding of oligonucleotide probe to ECP, but not to the control protein. The 
sensorgrams are precisely superimposed but a slower, as well as smaller, negative 
deflection of the ECP sensorgram is observed (see section 3.6.2 for explanation). 
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Thus, when the myoglobin sensorgrams are subtracted from the simultaneous ECP 
sensorgrams for each probe, the sensorgrams in Figure 4 result, with an initial large 
peak and subsequent large trough in the subtracted sensorgrams. Figure 5 
demonstrates the reproducibility these subtracted sensorgrams (ECP-myoglobin) for 
five successive bindings of antisense 1 to ECP and myoglobin in chip A. 
Association rate constants were calculated from the straight line data between the start 
and end of injection in the graphs in Figure 4, during the period when the probes were 
passed over the dextran-ECP surface. Dissociation rate constants were calculated from 















Figure 4. Subtracted sensorgrams (ECP-myoglobin) representing net binding to 
ECP in chip A for all four oligonucleotide probes. 'llie sensorgrams are representative 
examples of one of five cycles of injections of probes. They were created by 
subtraction of the sensorgrams for injection over myoglobin from the sensorgrams for 
simultaneous injection over ECP for each probe, and represent on-off curves for the 
interaction between ECP and oligonucleotide probes. The association and dissociation rate 
constants were calculated using the data contained in the areas of the graphs marked 'A' and 
'13' respectively, while the magnitude of binding was measured at an arbitrary point, 80 
seconds after the start of injection, marked 'C'. The genesis of the initial large peak at the start 
of injection and the subsequent large trough at the end of injection is explained in the legend to 
Figure 3, and their meaning discussed in section 3.6. 
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Figure 5. Reproducibility of subtracted sensorgrams (ECP-myoglobin) 
representing five successive bindings of antisense I to ECP in chip A. Sensorgrams 
were created by subtraction of the sensorgranis for injection of probes over the control 
protein, myoglobin, from the sensorgrams for simultaneous injections over ECP. The 
graphs demonstrate that the data were highly reproducible, and that the initial large 
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3.6.2 Chip B containing ECP and llsozlme 
In chip B, there was no mismatch in the simultaneous sensorgrams of injection of 
antisense 1 over ECP and lysozyme, (Figure 6), and hence the subtraction of the 
sensorgrams results in a sensorgrarn with a smooth on-off curve representing binding 
to ECP (Figure 7, red curve), with no peak and trough at the beginning and end of 
injection, as occurred in chip A with ECP and myoglobin. Similar smooth on-off curves 
were obtained in chip B for antisense 2, antisense 3 and sense probes. The mismatch in 
chip A may be due to the difference in pl of ECP and myoglobin that may have caused 
a charge-related artefact, that was not seen in chip B because of the similarity in the pI 
of ECP and lysozyme. 
3.7 Statistical anallsis 
Statistical analysis was performed using STATA (Stata statistical software, Release 
5.0, Stata Corporation, College Station, Texas, USA) and a PC, and was performed by 















Figure 6. A representative example of one of four injections of antisense I probe 
over ECP and lysozyme in chip B, displayed as overlaid sensorgrams. In contrast to 
Figure 5, there is no delay in the deflection of the two sensorgrams at the start and end of 
injection, and in this chip, the bulk refractive effect of the injection solution is negligible. 
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Figure 7. Subtracted sensorgrams (ECP-lysozyme) representing net bindings to 
ECP in chip B of all four oligonucleotide probes to ECP. Sensorgrams were created 
by subtraction of the sensorgrams for injection over the control protein, lysozyme, 
from the sensorgrams for simultaneous injections over ECP, for each probe. The 
curves represent smooth on-off curves for the interaction between ECP and the four 
tested oligonucleotide probes, and are the only complete cycle of injections of all four 
probes in chip B. 
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4. Results 
4.1 Establishment of conditions for regeneration of dextran-ligand 
surface 
Ideal regeneration of the dextran-ligand surfaces results in reproducible bindings of 
analyte to the ligands (ECP and control protein). For this to be achieved, the 
sensorgram should return after each regeneration injection to the level prior to binding 
of analyte, suggesting complete removal of the analyte from the dextran-ligand surface 
without stripping of any ligand from the dextran. Experiments to establish ideal 
regeneration conditions are described in Appendix I and, based on these findings, 2 gl 
of solution C was chosen as the regeneration injection and HBS was used as the 
running buffer. 
4.2 Binding of different oligonucleotide 12robes to ECP and to 
mloglobin in chip A 
Oligonucleotide probes were injected simultaneously over the two ligands in chip A, 
ECP and myoglobin, and the dextran-ligand surfaces regenerated between bindings. 
The four oligonucleotide probes were injected in succession and the sequence of 
successive injections was changed in each cycle. The changes in the baselines from 
before injection to after regeneration were satisfactory for all four probes and are 
displayed in Table I in relation to the mean binding for each probe. 
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Table 1. Regeneration of dextran-ligand surface in chip A. Regeneradon was 
assessed by change, in RU, in baseline sensorgram from before injection of 
oligonucleotide probe to after regeneration in five successive cycles of simul=eous 
injections of oligonucleotide probes over ECP and myoglobin in chip A. 
antisense 1 antisense 2 antisense3 sense 
ECP MG ECP MG ECP MG ECP MG 
mean binding of 18.4 0.0 12.2 -0.4 2.9 0.0 23.4 0.3 
probe (RU) I I I 
mean A baseline 3.2 -0.5 0.6 -1.8 -1.8 -1.2 -2.1 -1.6 
sensorgram 
(RU) 
SD A baseline 1.1 2.0 1.7 0.9 2.1 2.1 1.0 0.8 
sensorgram 
(RU) 
Where A= change, MG = myoglobin, ECP = eosinophil cationic protein. 
binding = RU of sensorgram 80 seconds after injection - RU immediately before 
injection of oligonucleotide probe 
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4.2.1 Assessment of data for drift between c3: cles of injections of oligonucleotide 
12robes in chip A 
Binding data are displayed in Table 2 and Figure 8 and were first analysed using 
Kendal's tau-a test to test for a significant drift between cycles in the magnitudes of 
bindings of oligonucleotide, probes to ECP and myoglobin, and in the differences 
between them (ECP - myoglobin). There was a significant drift between cycles of 
bindings to myoglobin only (Table 2), with a significant drift from a small net fall 
(negative 'binding') to a small net rise (positive 'binding') in the sensorgram. with each 
successive cycle of injections of probes (mean difference in 'binding' to myoglobin 
between successive cycles = 0.44 RU (95 % confidence intervals (CI) 0.14 to 0.73), p 
= 0.005, derived from data in Table 2). The cause of this significant upward drift for 
myoglobin, but not for ECP, is unclear, but may relate, in some manner, to the small, 
but progressive, fall in the baseline myoglobin sensorgram between successive cycles 
(mean (SD) change in baseline myoglobin sensorgrarn between cycles = . 4.5 (3.7), in 
comparison to ECP sensorgram. = 0.8 (2.0)) 
To allow for the drift in 'binding' to myoglobin, data from Table 2 were then analysed 
by regression with robust variance clustered by cycle in section 4.2.2. 
4.2.2 Comparison of binding of oligonucleotide Rrobes to ECP with lbindinal to 
the control 12rotein. mloglobin. In chip A 
There were significant differences for all oligonucleotide probes between binding to 
ECP and 'binding' to the control protein, myoglobin (Table 3), indicating binding to 
ECP but not to myoglobin. 
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4.2.3 COMDarison of sense with antisense oligonucleotide 'net' binding to EC 
in chip A 
In Chapter 2, a significant difference in in situ binding to eosinophils between sense and 
antisense oligonucleotide probes was demonstrated. Thus the data for in vitro binding 
to ECP in the present chapter were a prior! analysed for this comparison. The mean 
difference between ECP and myoglobin binding, termed mean net binding to ECP, for 
the sense probe was significantly greater than for the three antisense probes (mean 
difference between antisense and sense probes in net binding to ECP = 12.3 RU (CI 
10.5 to 14.1), p< 0.00 1, by regression with robust variance clustered by cycle, derived 
from data in Table 2). Thus, significantly greater in vitro binding of sense than 
antisense probes to ECP was observed, the converse of the in situ observations. 
Comparison of net binding to ECP between different antisense probes was not made, 
as this was not the original intention of the in vitro experiments and, if performed, 
would therefore have compromised the statistical analysis because of multiple 
retrospective comparisons. 
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TabIe 2. Magnitudes of bindings of different oligonucleotide probes to ECP and 
to myoglobin in chip A (data displayed in graphic fonn in Figure 8)- In each cycle, 
each probe was injected once, and the order of injections was changed between cycles. 
Means and standard deviations of magnitudes of bindings of each oligonucleotide 
probe are displayed in RU. 
bindings of 
antisense 1 (RU) 
bindings of 
antisense 2 (RU) 
bindings of 
antisense 3 (RU) 
bindings of 
sense (RU) 
cycle ECP MG ECP MG ECP MG ECP MG 
1 20.0 -1.2 15.3 -1.0 2.5 -1.1 23.4 -2.0 
2 20.0 -2.4 10.0 -1.2 2.4 -0.5 25.6 0.5 
3 18.4 0.8 11.9 -0.1 3.1 0.2 22.0 0.5 
4 17.5 0.5 13.1 0.3 3.2 0.0 23.6 0.5 
5 16.4 2.3 10.7 -0.1 3.5 1.5 22.4 -0.8 
mean 18.4 0.0 12.2 -0.4 2.9 0.0 23.4 0.3 
SD 1.6 1.8 2.1 0.7 0.5 1.0 1.4 1.1 
MG = myoglobin, ECP = eosinophil cationic protein 
binding = RU of sensorgram 80 seconds after injection - RU immediately before 
injection of oligonucleotide probe 
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Figure 8. Graph displaying means and standard deviations of magnitudes of 
bindings of different oligonucleotide probes to ECP (x) and to myoglobin (11) in 
chip A in RU (data displayed in tabulated form in Table 2). 
I 
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antisense I antisense 2 antisense 3 scnse 
TabIe 3. Differences in magnitude of binding of oligonucleotide probes to ECP 
and the control protein myoglobin (termed net bindings to ECP in text) in chip 
A. 
probe mean difference between 
binding to ECP and binding 
to myoglobin (RU) 
95 % confidence 
intervals of the 
difference (RU) 
p value* 
antisense 1 18.5 (15.3,21.6) < 0.001 
antisense 2 12.6 (10.5,14.7) < 0.001 
antisense 3 2.9 (2.4,3.5) < 0.001 
sense 23.7 (22.1,25.2) <0.001 
* analysis by regression with robust variance clustered by cycle 
4.3 Binding of different oligonucleotide probes to ECP and to 
lysozyMe in chip B 
The magnitudes of binding of antisense 1 and sense probes to ECP and lysozyme in 
chip B are displayed in Table 4. The two other probes were tested only once. 
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Table 4. Magnitudes of bindings of antisense 1 and sense oligonucleotide probes 
to ECP and to Iysozyme in Chip B. Four injections of antisense 1 were followed by 
four injections of sense probe, and means and standard deviations of magnitudes of 
bindings for each oligonucleotide probe are displayed in RU. 
magnitudes of 
bindings of 
antisense 1 (RU) 
magnitudes of 
bindings of sense 
(RU) 
ECP LYS ECP LYS 
129.7 2.4 14.3 -0.9 
75.1 3.5 12.2 2.8 
55.6 2.5 10.9 0.5 
42.7 2.1 8.4 2.1 
mean 75.7 2.6 11.5 1.1 
SD 38.3 0.6 2.5 1.7 
ECP = eosinophil cationic protein, LYS = lysozyme 
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Interestingly, in chip B, there appeared to be more binding of antisense I to ECP than of sense 
to ECP, a reverse of the findings in chip A. However, the reproducibility of bindings to ECP in 
chip B was less well established than in chip A, with a marked decay in binding with each 
successive injection of the same probe. A similar exponential decay in early bindings had been 
noted in chip A when conditions of regeneration were being established, but quantitation of 
oligonucleotide binding was not performed with this chip until the rate of decay of binding had 
fallen to an insignificant level, because of the series of experiments to establish regeneration 
conditions. However, in chip B, quantitation of oligonucleotide binding was performed, 
regrettably, without a similar 'run-in' period and, furthermore, a series of four sense probe 
bindings were performed after a series of four antisense I probe bindings, rather than in 
rotation as in chip A, and this probably accounts for the apparent reversal in the magnitudes of 
antisense I and sense bindings to ECP between the two chips. 
Tbus, because of the marked decay in bindings between successive injections, the data from 
chip B cannot be used to compare bindings of the two probes, antisense I and sense, but can be 
used to compare paired bindings of individual oligonucleotide probe injections to ECP and 
lysozyme, which occur simultaneously within the two cells of the chip. In this manner, a 
significant difference is demonstrated between binding to ECP and lysozyme for both 
oligonucleotide probes by a paired t test (mean difference in binding of antisense I probe to 
ECP and lysozyme (net binding to ECP) = 73.2 RU (CI 7.4 to 139.0), p 0.038; mean 
difference in binding of sense probe to ECP and lysozyme (net binding to ECP) 10.3 RU (CI 
4.0 to 16.7), p=0.014). 
The absolute level of 'binding' of probes to lysozyme (mean (SD) for antisense I=2.6 (0.6) 
RU, and for sense = 1.1 (1.7)) were small, indicating negligible 'binding' to lysozyme. 
170 
4.4 Kinetics of bindiniz 
The values calculated using BIA evaluation software (see section 3.6 for method) for 
association rate constants (k, ), dissociation rate constants (kd) and dissociation 
constants at equilibrium (KD) for the interaction between ECP and oligonucleotide 
probes in chip A are displayed in Table 5. 
Data for the sense oligonucleotide probe were a priori compared by regression by 
robust variance clustered by cycle with mean data for antisense oligonucleotide probes, 
when a significant difference was found only for kd, with mean kd for the sense probe 
significantly less than the mean Icd for antisense probes (Table 6), and no significant 
differences for k, and KD. 
Smaller kd implies slower dissociation of oligonucleotide probes from ECP, and 
therefore implies that the interaction between ECP and sense probe is stronger than the 
interaction between ECP and antisense probes. The potential relevance of this finding 
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Table 6. Rate and equilibrium constants for the interaction between 
oligonucleotide probes and ECP in chip A. Comparison of sense and antisense 
oligonucleotide probes (k. In M"' s*', kd in s"' and KD in M). 
mean difference between mean confidence p. value* 
of sense and mean of Intervals of the 
antisenses difference* 
k,, 0.7 x 103 (-5.3,6.6) 0.771 
kd 
-3.4 x 
10-3 (-5.3, -1.5) 0.008 
KD 
-2.2 x 
10-6 (-5.4,1.0) 0.134 
0 analysis by regression with robust variance clustered by cycle 
5. Discussion 
A method was established for measuring the in vitro interaction between probes and 
ECP or control proteins using biomolecular interaction analysis with a BiacoreXTM 
instrument. For the results to be reliable, it was necessary to regenerate the dextran- 
ligand surface to the pre-binding baseline allowing accurate reproduction of successive 
bindings of the same probe. 
The data in sections 4.2. and 4.3 demonstrate binding of oligonucleotide probes to 
ECP but not to the control proteins myoglobin and lysozyme. 
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The absence of oligonucleotide probe binding to lysozyme, which has a similar pI to 
ECP, suggests that binding to ECP is unlikely to be a charge-related effect due to its 
unusually high pl. The biological explanation for why ECP binds oligonucleotides is 
unknown, but ECP is known to have ribonuclease activity (283) and therefore may 
possess a binding site(s) for nucleic acids. 
The dissociation constant at equilibrium (KD) indicates the afýinity of an interaction and 
in section 4.4 values of the order of 10-'5 M were obtained for the interaction between 
ECP and probes. This can be compared, for instance, with a very similar value of 6.5 X 
10-6m for the interaction between major histocompatibility complex-protein conjugates 
with T-cell receptors (309), which is considered a relatively strong and specific 
biological interaction between ligand and receptor. Thus the interaction between ECP 
and probes is affinous, and likely to be of high capacity because of the abundance of 
ECP. 
The concentration of probe in the ISH solution was 833 times less than the 
concentration used during biornolecular interaction analysis (0.12 vs 100 gg nT1 
respectively), but the density of ECP on the Biosensor chip surface (0.18-0.20 pmol 
nun 2) cannot be equated to the concentration of ECP in eosinophil granules, as 
although it is known that 10's eosinophils contain 26 gg of ECP (305), the 
concentration of ECP within granules is unknown. However, this uncertainty does not 
invalidate the in vitro demonstration of binding of oligonucleotide probes to ECP, or 
comparison of binding of sense and antisense probes. 
In Chapter 2, significantly less in situ binding to eosinophils of the sense than of the 
antisense oligonucleotide probes was demonstrated (see Chapter 2, Table 2 displaying 
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quantitation of individual probe binding to eosinophils during ISH). Thus in section 
4.2.3, the data for in vitro magnitude of binding to ECP were a priori analysed for this 
comparison, and the mean net binding of the sense probe to ECP was significantly 
greater than the mean net binding of the three antisense probes, the converse of the in 
situ findings. Thus, differences in magnitude of binding of oligonucleotide probes to 
ECP in vitro, used as a marker for the strength of the probe-ECP interaction, do not 
account for differential in situ binding. 
When similar comparisons for calculated rate and equilibrium constants were made in 
section 4.4, the only significant difference was for kd, with the mean for the sense probe 
significantly less than the mean for antisense probes. STaller IQ implies slower 
dissociation of oligonucleotide probes from ECP, and therefore this finding, like the 
finding for magnitude of binding, does not account for differential in situ binding. 
However, it is possible that one or more of the properties of ECP-probe interactions 
may combine with another factor during ISH to produce the observed binding to 
eosinophils. It is hypothesised that this other factor be tissue penetration of probes, 
which is determined by their physical characteristics, particularly hydrophobicity, and in 




Using a biosensor approach with biornolecular interaction analysis, in vitro binding to 
ECP, but not to control proteins, of all tested oligonucleotide probes was 
demonstrated, which explains binding of oligonucleotide probes to eosinophils 
observed during ISH in Chapter 2. The interaction is not due to the unusually high pI 
of ECP, as no in vitro binding to the control protein lysozyme, which has a similar pI, 
was demonstrated. 
The magnitude of binding to ECP of the sense probe for IKB(x mRNA was significantly 
greater than the mean of the magnitudes of bindings of the three antisense probes, 
which is the reverse of observed binding to eosinophils during ISH. Thus, another 
factor, namely tissue penetration of probes, is hypothesised to influence the degree of 
oligonucleotide probe binding to ECP in eosinophils in tissue sections, and thus 
produce the observed differential binding of antisense and sense probes during ISH. 
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Chapter 4 
Measurement of hydrollhobicity of oligonucleotide probes 




In Chapter 2, different levels of binding of different oligonucleotide probes to 
eosinophils in sections of bowel were observed during ISH, and when binding of 
individual probes for IKB(x was quantitated, significantly less binding occurred with 
sense than the three antisense probes. In Chapter 3, binding of the same probes to ECP 
in vitro was quantitated when mean binding of sense probe was significantly greater 
than mean binding of antisense probes. Thus, the differential in vitro binding did not 
explain the differential in situ binding, and neither did the measurements of rate and 
equilibrium constants for the in vitro interaction between ECP and oligonucleotide 
probes. Thus, another factor must be involved, which is hypothesised to be tissue 
penetration. Tissue penetration by probes is determined by probe length, but in this 
instance this is the same for all probes and therefore not the factor responsible for 
differential binding in situ, and also by probe hydrophobicity/hydrophilicity. 
Hydrophobicity/hydrophilicity of oligonucleofides of the same length can be accurately 
measured by retention times in ion-pair reverse-phase high performance liquid 
chromatography (IP-RP HPLQ columns (310) and this technique was therefore 
employed. The work was kindly performed by Dr. Paul Taylor of Transgenomics 
Incorporated, Santa Clara, California, USA. 
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2. Methods 
IP-RP HPLC was used to measure the hydrophobicity/hydrophilicity of individual 
probes in a system where greater hydrophobicity results in longer retention. The IP-RP 
HPLC system comprised a Waters Action Analyser (Waters Co., Milford, MA, USA), 
a column heater (Model 105, Interaction Chromatography, San Jose, CA, USA), a 
biocompatible injection valve (Model K-1760, Rheodyne, Cotati, CA, USA), a 20 Rl 
titanium loop (Superflex, SGE Austin, TX, USA) and a5 gl syringe (Superflex) for 
sample introduction. To improve thermal equilibration of the mobile phase and the 
sample, the injection valve was mounted on the column heater with the sample loop 
inside the heater. A Waters 484 UV variable ultraviolet light monitor (Waters Co. ) was 
used for detection. 
Mobile phases were prepared using a 1M stock solution of HPLC-grade 
triethylammoniurn acetate (Transgenomic Inc., San Jose, CA, USA), pH 7.0, and 
distilled water (Wheaton Autostill, Millville, NJ, USA), with probe concentration of 
0.15 mg r'. The eluent was 25 % (v/v) acetonitrile (EM Science, San Jose, CA, USA) 
in 0.1 M triethylammoniurn acetate, and the gradient used to separate the 
oligonucleotides was from 10 to 60 % acetonitrile in fifteen minutes, then from 60 to 
100 % in one minute and back to 10 % in one minute. 
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3. Results 
Retention times for individual l1cBa oligonucleotide probes on the IP-RP HPLC 
columns are displayed in the Table. As in Chapter 3, data were a priori analysed for a 
difference between antisense and sense probes, and mean hydrophobicity of the 
antisense oligonucleotides was found to be significantly greater than for the sense 
probe (difference of means = 0.65 (95 % CI 0.63 to 0.67), p<0.00001 using a 
Student's t-test). 
Table. Retention times of Individual IlcBa oligonucleotide probes In IP-RP HPLC 
coIumns. 
run oligonucleotide probe 
antisense 1 antisense 2 antisense 3 sense 
1 8.83 8.10 8.58 7.84 
2 8.84 8.09 8.55 7.83 
3 8.83 8.08 8.57 7.85 
4 - 8.09 - - 
mean 8.83 8.09 8.57 7.84 
standard deviation 0.006 0.008 0.02 0.01 
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4. Discussion 
IP-RP HPLC was successfuUy used to measure probe hydrophobicity and provided 
data with small standard deviations and consequently highly significant differences 
between antisense and sense probes. The relationship between probe hydrophobicity, in 




An immunohistochemical studv of the activation of 
NFic1B in inflammatory bowel disease 
1. Introduction and aim 
In Chapter 2, attempts to develop an ISH method to study activation of NFO via 
expression of 10 mRNA in tissue sections were unsuccessful because of non-specific 
binding of oligonucleotide probes to eosinophils. Whilst these ISH studies were being 
conducted, an antibody, developed by Professor P. A. Baeuerle's group in Germany, 
that recognised only the activated, nuclear-translocated form of NFKB, was 
commercially manufactured by Boehringer Mannheim and became available in October 
1995 (311). The antibody recognises an epitope overlapping the nuclear location signal 
(NLS) of the p65 subunit of NFO, which is revealed when 10 is proteolytically 
degraded during activation of NFO, and so it selectively binds to the activated fonn 
(312). 
After the development of this antibody, there remained little advantage in an ISH 
method over an immunohistochemical method to study activation of NFY. B, and, 
indeed, the proposed ISH method used IKB(x mRNA expression is only a marker of 
activation of NFY. B, whereas the recently developed antibody directly detected 
activated NFkJ3. Thus, the new antibody was used to study the location and degree of 




2.1 Collection and preparation of tissues for immunostaining 
2.1.1 Tissues for validating the antibody 
To validate the specificity of the antibody for activated NFKB, experiments were 
performed using two unrelated tissues as positive controls, namely HeLa cells that 
express activated NFKB upon stimulation with phorbol 12-myristate 13-acetate (PMA) 
(Sigma Chemical Company) (2), and mouse cerebral cortex containing neurones that 
constitutively express activated NFKB (8 1). 
Unsectioned cultured cells 
HeLa Ohio cells (gift of The Imperial Cancer Research Fund, Lincoln's Inn Field, 
London, UK) were grown to confluency in 25 ml sterile culture flasks (BDH) in sterile 
tissue culture medium (TCM), consisting of Eagle's minimum essential medium with 
Hank's balanced salt solution (Life Technologies, Paisley, Scotland, UK) 
supplemented with 10 % fetal calf serum (Life Technologies), 2 mM L-glutamine 
(Life Technologies), 100 units ml-1 penicillin (Sigma Chemical Company), 100 ýtgrnl-' 
streptomycin (Sigma Chemical Company) and 50 jig ml-1 gentarnicin (Sigma 
Chemical Company). Flasks were incubated in a carbon dioxide incubator (IRE93, J 
Bio Co., San Jose, CA, USA) with a continuous supply of 5% carbon dioxide, 95 % 
4(r- at 370C. All work with cell cultures was performed in a 'Class 2' laminar flow 
cabinet (Intermed Microflow, Microflow Pathfinder Ltd., Fleet, Hampshire, UK). 
Cells were harvested using 2 ml of a solution containing 0.025 % (w/v) beef pancreas 
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trypsin (Sigma Chemical Company) and 0.02 % (w/v) EDTA (Sigma Chemical 
Company) in serum-free TCM (prepared as described above with the omission of fetal 
calf serum), and then a 0.25 ml sample of the cell culture was stained with 0.25 ml 
trypan blue (Sigma Chemical Company) and counted using a haemocytometer (BDH) 
to allow subsequent dilution to the required concentrations and to ensure non-viable 
cells were below 5% of the total cells. Cells were then seeded on to individual glass 
coverslips (Sigma Chemical Company) in each of the wells of six-well culture plates 
(Sigma Chemical Company), by pipetting 2 ml of cells suspended at 2x 104 cells ml" 
in TCM, and cultured as before for 24 hours. The medium was then removed and 
replaced with 2 ml of either TCM alone or TCM containing 50 ng ml-1 phorbol 12- 
myristate 13-acetate (PMA) (Sigma Chemical Company). Cells were incubated for one 
hour, the medium then removed, and cells fixed by filling wells with an excess of 
absolute ethanol (BDH) for two minutes followed by an excess of a solution of 3.7 % 
(v/v) formaldehyde (Sigma Chemical Company) in PBS for five minutes (311), and 
finally washed in PBS before immunostaining for activated NFKB as described below. 
The following modifications to this protocol were tested to optimise stimulation and 
immunostaining of cells: 
(i) different stimulants - cells were stimulated with both recombinant TNFa alone 
(R&D Systems), at 200 units ml-1 TCM for one hour, or a combination of PMA and 
TNFcc for one hour, which are known synergistically to stimulate NFKB (83). The 
duration of stimulation was varied over a range of 20 minutes (the shortest time 
required for marked activation NFrB (11)) to two hours; 
(ii) different fixatives - both 100 % methanol (BDH) at -20 'C for five minutes, and a 
4% (w/v) solution of paraformaldehyde (Sigma Chemical Company) in PBS, for five 
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minutes, were tested as alternatives to the ethanol/formaldehyde fixation method as 
described above; 
(iii) permeabilisation - after fixation with each of the three fixatives, half the cell 
cultures were permeabilised with a 0.2 % (v/v) solution of Triton X-100 (Sigma 
Chemical Company) in PBS for five minutes, and then 0.1 % (v/v) Triton X-100 was 
added to all immunostaining solutions; 
(iv) tumour cell type - as an alternative to HeLa Ohio cells grown in sheets onto 
coverslips, HeLa S3 cells (European Collection of Cell Cultures, Salisbury, UK) were 
grown in suspension to a concentration of 3-9 x 105 cells ml" in TCM. The 
proportion of non-viable cells was determined by trypan blue exclusion and kept 
below 5% by passaging cell cultures every 2-3 days. Before stimulation, cells 
contained in one 25 ml culture flask were washed twice in scrum-frec TCM by 
centrifuging cells into a pellet at 400g at 20" C for five minutes using a Centra-3 
centrifuge (International Equipment Company, Dunstable, UK), and then resuspending 
cells in serum-free TCM. The cells were spun into a pellet again, and then finally 
resuspended at 2x 104 cells ml" in TCM either with or without stimulant. After 
stimulation for one hour, cells were spun onto poly-L-lysine-coated microscope slides 
(Sigma Chemical Company) at 500 rpm for five minutes at room temperature using a 
Cytospin 2 centrifuge (Shandon, Runcom, Cheshire, UK), using 0.5 ml of cell 
suspension for each slide. Cell preparations were then fixed, as described above, using 
the three different protocols. 
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Frozen sections of mouse cerebral cortex 
Samples (0.25 cm cubed) of cerebral cortex from the brains of freshly killed BALB/c 
mice were rapidly dissected out and embedded in OCT compound (Sigma Chemical 
Company). Eight pra frozen sections were cut with a cryotome (Cryotome 620M, 
Anglia Scientific Instruments, Cambridge, UK) on to poly-L-lysine coated slides, air- 
dried for 30 minutes, fixed by immersion in methanol at -20 OC for five minutes, air 
dried again for ten minutes, and then stored until processed at -70 OC within 
individual packages of aluminium foil and three air-tight plastic bags. 
Paraffin-embedded sections of cells and mouse cerebral cortex 
For both unstimulated and stimulated cells, the contents of one 25 ml culture flask of 
HeLa S3 cells were spun into a pellet as described above, then fixed by resuspending 
in an excess (10 ml) of 10 % (v/v) formaldehyde in PBS for five minutes, and then 
centrifuged into gelatine (Sigma Chemical Company) and embedded in paraffin by the 
Histopathology Department, St. Thomas' Hospital. 
Samples (0.25 cm cubed) of mouse cerebral cortex were fixed overnight in a 10 % 
(v/v) solution of formaldehyde, and embedded in paraffin. 
The Histopathology Department performed sectioning of all paraffin-embedded tissue. 
Seven jim sections were floated onto water and then air-dried overnight onto poly-L- 
lysine-coated microscope slides. Paraffin was removed from sections in a standard 
manner by immersion in successive baths of xylene for two minutes, twice, 100 % 
alcohol for one minute, twice, and then successive solutions of reducing 
concentrations of alcohol for one minute each (95,70 and 50 % (v/v) solutions of 
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alcohol in distilled water). Endogenous peroxidase was blocked as for frozen sections 
(section 2.3.1), except hydrogen peroxide solution was diluted in methanol (313). 
Some paraffin-embedded sections were pre-treated to expose antigen that may have 
been hidden by the highly cross-linking fixative, formaldehyde, by either: 
(i) trypsinisation (314) - sections were incubated at 37"C in a solution of 0.1 % (w/v) 
beef pancreas trypsin and 0.1 % (w/v) calcium chloride in distilled water at pH 7.8 for 
ten minutes and then washed in PBS at room temperature, or 
(ii) microwaving (315) - sections were placed in a covered, boiling solution of 0.1 M 
tri-sodium citrate pH 6.0 (adjusted with 0.1 M acetic acid) and microwaved at 700 
Watts for ten minutes, and then rinsed once by immersion in PBS. 
2.1.2 Full thickness frozen sections of bowel from CD and control patients 
Full thickness samples of small or large bowel were taken from thirteen patients with 
active CD undergoing intestinal resection at St. Thomas' Hospital and St. Mark's 
Hospital (mean age 37 years, range 15 to 48, four male). The diagnosis of CD was 
made using conventional clinical, histological and endoscopic and/or radiographic 
criteria. Eight CD patients were receiving corticosteroid therapy (range 0-60 mg 
prednisolone per day), one azathioprine (2 mg kg") and nine aminosalicylates (Table 
1). Pairs of samples, one from a macroscopically diseased and the other from a 
macroscopically non-involved area at least five centimetres distant from the 
macroscopically inflamed area, were taken from each patient, nine pairs from the 
ileum and four from the colon. 
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Samples of bowel were also taken from two patients with ulcerative colitis undergoing 
proctectomy after previous sub-total colectomy, one patient with diverticulitis and one 
endoscopic biopsy from a patient with Wegener's granulornatosis with colonic 
vasculitis (Table 1). 
Full thickness samples of bowel were also taken from eleven patients undergoing 
intestinal resection for carcinoma of the colon to act as controls with normal bowel 
(mean age 72 years, range 38 to 84, eight male) (Table 2). Samples, at least five 
centimetres from the margins of the carcinoma, were taken from the small bowel in 
four patients and from the large bowel in seven. Control patients were taking no 
corticosteroids, 5-ASA compounds or aspirin, but received a single dose of intravenous 
metronidazole and a cephalosporin antibiotic at induction for anaesthesia. 
The protocol for the study was approved by The Research Ethics Committee of St. 
Thomas' Hospital and The Research Ethics Committee of Northwick Park and St. 
Mark's Hospitals National Health Service Trust. 
Biopsy specimens of bowel were frozen in OCT compound and sectioned and fixed in 
methanol as described for mouse cerebral cortex (see section 2.1.1). 
2.1.3 Formaldehyde-rixed. paraffln-embedded full thickness biopsy sRecimens of 
bowel from CD patients 
To test use of the antibody on formaldehyde-fixed, paraffin-embedded sections, 
samples from small bowel resection specimens from five patients with CD were 
obtained from the library of paraffin-embedded specimens in the Histopathology 
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Table 2. Clinical details of control patients from whom operative resection 
specimens were collected for immunostaining of frozen sections. 
Control 
patient 
Diagnosis Age Sex Location 
1 carcinoma 80 F colon 
2 carcinoma 75 M terminal ileum 
3 carcinoma 38 M colon 
4 carcinoma 84 F colon 
5 carcinoma 78 M terminal ileum 
6 carcinoma 79 M colon 
7 carcinoma 78 F colon 
8 carcinoma 67 M colon 
9 carcinoma 73 F terminal ileum 
10 carcinoma 69 F terminal ileum 
carcinoma 68 M colon 
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2.2 Histological grading of inflammation 
Four different sections of the same biopsy specimens immunostained for activated 
NFr, B, from patients with CD, were stained with haernatoxylin and eosin (see 
Appendix II) and assessed by an histopathologist (Dr John Goodlad, Senior Registrar 
in Histopathology, St. Thomas' Hospital) who was blind to the patient status. 
Inflammation was graded using a previously validated scoring system according to the 
cellularity of the mucosa and the severity of changes in the enterocytes and crypts 
(316) (Table 3). In this system, grade 0 represents no inflammation, termed 'non- 
inflamed', and grades 1 to 3 represent increasing degrees of inflammation, together 
termed 'inflamed' (Table 4). Any samples from macroscopically non-involved areas 
that showed evidence of microscopic inflammation were excluded from analysis. 
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Table 3. Scanning system for histological assessment of biopsy specimens. An 
inflammatory score was calculated by adding the scores from four categories, namely 
enterocytes, mononuclear cells, crypts and neutrophils. Four sections from each biopsy 
specimen were examined and scored, and the mean of these scores allocated as the final 
inflammatory score for the specimen. 
EPITHELIUM LAMINA PROPRIA 
Enterocytes Mononuclear cells 
Normal 0 Normal 0 
Loss of single cells 1 Slight increase I 
Loss of groups of cells 2 Moderate increase 2 
Frank ulceration 3 Marked increase 3 
Crypts Neutrophils 
Normal 0 Normal 0 
Single inflammatory cells 1 Slight increase I 
Cryptitis 2 Moderate increase 2 
Crypt abscesses 3 Marked increase 3 
Table 4. Conversion of histological scores to grades, and categorisation into 
inflamed and non-inflamed specimens. 
Grade Totaiscore 
Non-inflamed 0 0 





2.3.1 Immunostaining of frozen sections of mouse cerebral cortex 
Stored slides and coverslips were brought to room temperature and pre-treated by 
immersion into a 0.18 % (v/v) solution of hydrogen peroxide (Sigma Chemical 
Company) in PBS for five minutes to block endogenous peroxidase by providing an 
excess of substrate. Sections and cells were then covered with a5% (v/v) solution of 
rabbit serum in phosphate-buffered saline (PBS) (Oxoid, Unipath Ltd., Basingstoke, 
UK) and incubated for ten minutes to block non-specific binding sites for the 
secondary antibody (serum from the species in which the secondary antibody is raised, 
maximally blocks non-specific binding of the secondary antibody). The excess of the 
solution of rabbit serum was then carefully removed from the sections with a pipette, 
and the sections then completely covered with 50 ýd of aI in 200 dilution of mouse 
anti-p65 primary antibody (Boehringer Mannheim, Lewes, East Sussex, UK) and 
incubated for one hour in a moist chamber followed by two, five minute washes in 
PBS. A 50ýd aliquot of aI in 300 dilution of the secondary, biotinylated, rabbit anti- 
mouse IgG antibody (Dako Ltd., High Wycombe, Hertfordshire, UK) was applied and 
the slides incubated for 35 minutes, followed by two washes by immersion in a bath of 
PBS containing a magnetic stirrer. All antibodies were diluted in aI% (w/v) solution 
of blocking agent in PBS (constituents not released by Boehringer Mannheim) and 
incubations performed at room temperature. 
A 50 ýd aliquot of aI in 500 dilution of streptavidin-peroxidase conjugate (Dako Ltd. ) 
was applied as a tertiary layer, the slides incubated at room temperature for 45 minutes 
and washed twice in PBS. The sections were covered with an excess of the 
chromogen, imidazole-enhanced diaminobenzidine (317) (a 1M solution of imidazole 
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(Sigma Chemical Company) in 0.1 M Tris buffer (Sigma Chemical Company) at pH 
7.6, was diluted 1: 100 with a solution of 0.5 mg ml" diaminobenzidine (Grade 2, 
Sigma Chemical Company) in 0.1 M Tris buffer at pH 7.6 with 0.03 % (v/v) hydrogen 
peroxide). After incubation at room temperature for ten minutes, slides were washed 
for ten minutes, twice, in PBS. Sections were counterstained with Mayer's 
haernatoxylin (Sigma Chemical Company) for two minutes, washed in tap water, and 
then dehydrated in serial, graded alcohols (successive solutions of 90,95 and 99 % 
(v/v) alcohol in distilled water), air-dried for fifteen minutes, mounted in Ralmount 
(BDH) and finally covered with a coverslip. As negative-staining controls, sections of 
the same specimens prepared in an identical manner were processed by the same 
method except with PBS substituted for the primary antibody. 
The above protocol was finally determined after several experiments to determine the 
ideal experimental conditions for frozen sections of mouse cerebral cortex: 
different fixatives, namely acetone at -20*C, which resulted in poorer quality 
immunostaining than with use of methanol at -20'C in the above protocol; 
use of varying dilutions of blocking rabbit serum from 0 to 100 % at different 
points in the immunohistochernistry protocol, namely, before application of the 
primary antibody, before application of the secondary antibody, or both, and with 
and without a PBS wash before application of the subsequent antibody. Least 
background staining was obtained when a5% solution was applied only before 
application of the primary antibody, and not followed by a PBS wash and this was 
thus used in the above protocol; 
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* without dilution of antibodies in blocking solution, which increased background 
staining, and therefore blocking solution was included in the above protocol; 
two 'chequer-boards' of ranges of dilutions of primary (from 1 in 50 to 1 in 400) 
and secondary antibodies (from 1 in 100 to 1 in 600) were immunostained, one 
chequer-board with a tertiary layer dilution of 1 in 100 and the other with 1 in 300, 
to choose the combination of dilutions of antibodies that resulted in the best signal 
and least background staining. Results from this experiment demonstrated the 
optimal dilutions to be 1 in 200,1 in 300 and 1 in 500 for the primary, secondary 
and tertiary layers respectively, which were therefore used in the above protocol. 
2.3.2 Modifleations in immunostaining protocol for unsectioned cultured cells 
and frozen sections of bowel 
Immunostaining was performed for aU tissues as described above (section 2.3.1) for 
mouse cerebral cortex except: 
(i) Immunostaining of cultured cells 
Blocking of endogenous peroxidase was omitted, as none is present in cultured HeLa 
cells. 
(ii) frozen sections of bowel 
When a peroxidase-based. detection system was used on sections of bowel, despite 
steps in the protocol to block endogenous peroxidase, numerous positive cells were 
seen that were recognised to be due to non-specific staining because the negative 
control, namely when PBS was substituted for the primary antibody, showed similar 
staining. Furthermore, when PBS was substituted for the primary, secondary and 
tertiary layers and only the chromogen-peroxidase solution added, a similar pattern of 
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staining was seen, thus strongly suggesting endogenous peroxidase activity, and the 
appearances of dark brown, granular staining were characteristic (1061). 
Further methods to block endogenous peroxidase activity, such as increasing the pre- 
treatment concentration of hydrogen peroxide to 0.3 % (v/v), and pre-treatment with 6 
% (v/v) hydrogen peroxide followed by 2.5 % (v/v) periodic acid and finally 0.02 % 
sodium borohydride (106 1), were unsuccessful. 
Therefore, an alkaline phosphatase-based detection system was used instead of a 
peroxidase-based system. Thus, a tertiary layer of a1 in 200 dilution of streptavidin- 
alkaline phosphatase conjugate (Dako Ltd. ) was applied for one hour, followed by two, 
five minute washes in PBS. The substrate, VectorRed alkaline phophatase substrate 
(VectorLabs, Peterborough, UK), prepared as recommended by the manufacturer with 
the addition of one drop of levamisole solution (VectorLabs) to block non-intestinal, 
endogenous alkaline phosphatase activity, was applied to sections and incubated for a 
further twelve minutes before two final washes in PBS. Brush border intestinal alkaline 
phosphatase, which is not blocked by this concentration of levarnisole (higher 
concentrations will block intestinal enzyme, but also block the chromogen reaction and 
are therefore not used), was clearly seen as a continuous red line on the luminal surface 
of the epithelium, and was disregarded. 
2.4 Photography 
Microscopy and photography was performed with the apparatus described in Chapter 
2, section 2.6. 
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2.5 Quantitation of cells immunostaining positive for activated NFKB 
and statistical analysis 
Each section of bowel wall was subdivided into muscle, submucosa and mucosal layers. 
Each level was assessed separately for cells staining positive for activated NFKB and 
quantitation undertaken using a point counting technique as used by others for 
quantitating cells staining positive for cytokines in IBD (318). Briefly, ten high- 
powered fields (x 400) were chosen at random and the positive cells that lay under a 
Lennox graticule (Graticules Ltd, Tonbridge, UK) point counted (319), and counts of 
any endogenously-positive cells in the matched negative control slides (see Appendix 
III) subtracted. Cell counts were converted to tissue-densities, expressed as number of 
positive cells per MM2 of tissue section, by multiplication by a factor (26.5) provided by 
the manufacturer of the graticule. As assessed by others, reproducibility of counts was 
evaluated by repeating counts on sections to which the assessor was blinded (318). The 
difference was always less than ten percent of the mean of the scores (mean difference 
6.7 %, standard deviation 1.6 %) (see Appendix IV). 
Data were analysed using the Mann-Whitney U-test and Spearman's method of 
correlation, and 95 % confidence intervals of the ratio of medians of unpaired samples 
were calculated in the conventional manner with replacement of a value of zero with a 
value of one, to avoid ratios of infinity. This method of calculating confidence intervals 
is equivalent to confidence intervals of the logged difference of medians, and was 
performed because the distributions were log-normal. 
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3. Results 
3.1 Validation of the antibody using frozen sections of mouse cerebral 
cortex and unsectioned HeLa cells 
Stimulated HeLa cells, fixed in ethanol/formaldehyde, showed densely staining nuclei, 
representing activated, nuclear-translocated NFYB, in contrast to unstimulated. ceRs 
(Figure 1). However, only small numbers of cells stained positive for activated NF1cB 
and were seen only in some areas of the stimulated culture, and so quantitation of the 
difference in numbers of positive cells between unstimulated and stimulated cultures 
was not possible. Modifications to methods (see section 2.1.1.1) of stimulation, 
perineabilisation, and tumour cell type had no effect on the results. 
Mouse cerebral cortex showed staining related to the nuclei of most neurones (Figure 
3), as expected from previous studies (8 1). The nuclear localisation of the antibody 
confirmed its specificity for activated, nuclear-translocated NFO. 
The negative controls, with PBS substituted for the primary antibody, showed no 
positive cells in either stimulated HeLa cells (Figure 2) or mouse cerebral cortex 
(Figure 3), confirining that non-specific binding was not occurring . 
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Figure 1. Photomicrographs (magnification x 1000) of unstimulated (above) and 
stimulated (below) HeLa Ohio cells grown onto cover slips and immunostained for 
activated NFKB. Cells were stimulated with TNFcc and PMA and fixed in 
ethanol/formaldehyde. The stimulated cell shows dense nuclear staining (brown, 
peroxidase-based detection system). The results show, together with results displayed 
in Figures 2 and 3, that the antibody binds to the nuclei of stimulated cells, which is 
consistent with its proposed specificity for activated NFKB. 
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Figure 2. Photomicrographs (magnification x 1000) of negative controls of 
unstimulated (above) and stimulated (below) HeLa Ohio cells grown onto cover slips 
and immunostained with substitution of PBS for the primary (anti-p65 NFKB) 
antibody (brown, peroxidase-based detection system). Cells were stimulated with 
TNFcc and PMA and fixed in ethanol/formaldehyde. The absence of staining confirms 
that the staining in Figure 1, with use of the primary antibody, is not due to non- 
specific binding of secondary or tertiary layers of immunostaining, or due to 
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Figure 3. Photomicrographs, (magnification x 400) of a frozen section of mouse 
cerebral cortex immunostained for activated NFKB (above) showing nuclear staining, 
and negative control (below) immunostained in the same manner with PBS substituted 
for the primary antibody (brown, peroxidase-based detection system) and 
counterstained with Mayer's haernatoxylin. Neurones in mouse cerebral cortex are 
known to constitutively express activated NFKB, and so the results are consistent with 
the proposed specificity of the primary antibody. 
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3.2 Frozen sections of bowel from Crohn's disease and control patients 
Positive staining of cells for nuclear, activated NFKB, similar to that seen with the stimulated 
HeLa cells, was seen in sections of bowel from CD patients (Figures 4,5 and 6). Some cells 
showed a peri-nuclear ring of staining, particularly in the muscle layer, which may possibly 
represent cytoplasmic, activated NFKB. Negative staining controls, with PBS substituted for 
the primary antibody, gave no positively stained cells, but minimal areas of background 
staining (Figure 7), which was quantitated and subtracted from the positive cell count (see 
Appendix III), as performed by others (318). Cells positive for activated NFicB were 
predominantly large, mononuclear, macrophage-like cells, although a few small, mononuclear, 
lymphocyte-like cells, were also observed in the mucosa. 
In all CD patients, and the majority of control patients (Figure 8), at least some cells staining 
positive for activated NFKB were observed in all layers, namely the mucosa, submucosa and 
muscle, although the number of positive cells was lower in control patients. There were, 
however, no cells positive for activated NFKB in the epithelium or endothelium. of CD or 
control patients. 
In all three layers, the tissue-density of positively-stained cells was significantly (p = 0.001) 
greater in inflamed areas of CD, compared to normal bowel from controls (Figure 9) (95 % 
confidence intervals of the ratio of medians of inflamed CD to controls: mucosa 2.6-23.5; 
submucosa 3.0-41.5; muscle 10.7-95.8). 
In non-inflamed areas of CD, only in the submucosa was there a significantly (p = 0.009) 
greater tissue-density of activated NFKB positive cells compared to normal bowel from controls 
(95 % confidence intervals of the ratio of the medians of non-inflamed areas to controls: 1.36- 
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Figure 4. Photomicrographs of the mucosa of a frozen section (above, magnification x 
100; below, magnification x 400) of inflamed CD bowel (patient 10) immunostained 
for activated NFKB and counterstained with Mayer's haematoxylin, showing scattered 




Figure 5. Photomicrographs of the submucosa of a frozen section (above, 
magnification x 100; below, magnification x 400) of inflamed bowel from a patient 
with CD (patient 10) immunostained for activated NFKB and counterstained with 
Mayer's haernatoxylin, showing scattered cells positive for activated NFKB (red, 














Figure 6. Photomicrographs of the muscle layer of a frozen section (above, 
magnification x 100; below, magnification x 400) of inflamed bowel from a patient 
with CD (patient 10) immunostained for activated NFKB and counterstained with 
Mayer's haematoxylin, showing scattered cells positive for activated NFKB (red, 




Figure 7. Photomicrographs (magnification x 200) of a frozen section (above, 
mucosa; middle, submucosa; below, muscle) of inflamed bowel from a patient with 
CD (patient 10) immunostained for activated NFKB with PBS substituted for the 
primary antibody as a negative control. The sections were not counterstained with 
Mayer's haernatoxylin to ensure background staining was not obscured. No positive 
cells and minimal background staining is observed (red, alkaline phosphatase-based 
detection system). The results demonstrate that the positive cells in Figures 4,5 and 6 
were not due to non-specific binding of the secondary or tertiary layers of 










Figure 8. Photomicrograph of a frozen section (magnification x 100) of normal bowel 
from a control patient (control 6) immunostained for activated NFKB and 
counterstained with Mayer's haernatoxylin, showing few cells positive for activated 






















































































































3.3 Correlation of activation of NFicB with inflammatory scores 
Moderately significant correlations between inflammatory score and tissue-density of 
ceRs positive for activated NFO were seen in the mucosa (r = 0.67, p=0.003 (Figure 
10)) and muscle (r = 0.5 8, p=0.0 18 (Figure 12)), but not in the submucosa (r = 0.16, 
p=0.57 (Figure 11)). 
3.4 Effect of corticosteroids on activation of NFicB 
Although corticosteroids inhibit activation of NFO in vitro, in no layer of sections 
from inflamed bowel was there a correlation between tissue-density of positive cells 
and corticosteroid dose (r = -0.36,0.06 and 0.32, for mucosa, submucosa and muscle 
respectively). The degree of inflammation is a possible confounding factor on this 
correlation, and so tissue-density of positive cells was divided by inflammatory score, 
hence giving a figure representing amount of activated NFicB corrected for degree of 
inflammation, but still no correlation with dose of steroid was found (r = -0.28, -0.27 
and -0.25 for mucosa, submucosa and muscle respectively) 
3.5 Ulcerative colitis and inflammator: K controls 
There were increased numbers of cells staining for activated NFO in sections from 
both patients with ulcerative colitis and from two inflammatory controls, although 
numbers were insufficient to perform significance testing (see Appendix HI). 
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3.6 Paraffin-embedded sections 
No staining was seen when formaldehyde-fixed, paraffin-embedded sections of mouse 
cerebral cortex, HeLa cells and CD bowel received either no pre-treatment or were 
pre-treated with trypsin. However, with microwave pre-treatment, the following 
staining was observed: 
1. cytoplasmic staining of neurones in mouse cerebral cortex, and in some areas clear 
nuclear staining (Figure 13); 
2. in HeLa cells, possible nuclear staining in one experiment, but this is likely to 
represent artefact, because of the irregular contour of the nuclear staining and difficulty 
in reproducing these appearances (Figure 14), and 
3. in sections from patients with CD, cytoplasmic staining of large mononuclear cells, 
possibly plasma cells, but no nuclear staining (Figure 15). 
Thus, no unequivocal nuclear staining was observed in paraffin-embedded sections and 
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Figure 13. Photomicrographs of formaldehyde-fixed, paraffin-embedded sections of mouse 
cerebral cortex pre-treated by microwaving, and then immunostained for activated NFKB 
(above and middle), showing cytoplasmic staining of neurones within an area of the section 
(above, magnification x 400), and nuclear staining in another area of the section (middle, 
magnification x 200), (brown, peroxidase-based detection system). Negative control section 
(below, magnification x 200) immunostained in the same manner with PBS substituted for the 
primary antibody showing no positive cells. Sections were counterstained with Mayer's 
haematoxylin. Results are difficult to interpret, but suggest that when used in microwave pre- 
treated, paraffin-embedded tissue, the primary antibody is not specific for activated NFKB. 
Alternatively, the microwave pre-treatment may have altered cytoplasmic stores of NFICB, 
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Figure 14. Photomicrographs (magnification x 400) of formaldehyde-fixed, paraffin- 
embedded sections of HeLa S3 cells pre-treated by microwaving, and then immunostained for 
activated NFKB (brown, peroxidase-based detection system). Cells treated with PMA to 
activate NFxB (above) show nuclear staining most likely to represent artefact, as suggested 
by the irregular contour of the nuclear staining and difficulty in reproducing these 
appearances. Unstimulated cells (middle) show cytoplasmic staining, but no nuclear staining. 
Negative control section (below) of stimulated cells immunostained in the same manner, but 
with PBS substituted for the primary antibody, showing no staining. Sections were 
counterstained with Mayer's haernatoxylin. 
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Figure 15. Photornicrographs (magnification x 400) of fonnaldehyde-fixed, paraffin- 
embedded sections of inflamed small bowel from a patient with CD, pre-treated by 
microwaving and then immunostained for activated NFKB (above), showing 
cytoplasmic staining of large mononuclear cells, but no nuclear staining (brown, 
peroxidase-based detection system). Exclusive cytoplasmic staining suggests that in 
sections of bowel prepared in this way, staining of cells containing nuclear- 
translocated, activated NFKB did not occur. Negative control section (below) 
immunostained in the same manner with PBS substituted for the primary antibody 
showing no positive cells. Sections were counterstained with Mayer's haematoxylin. 
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4. Discussion 
4.1 Paraffin-embedded sections 
Paraffin-embedded sections offer considerable advantages of good morphology, easy 
handling and access to historical specimens in libraries. There have been no previous 
publications using anti-p65 NFO antibody manufactured by Boehringer Mannheim on 
paraffin-embedded tissue sections. 
In the present chapter, the staining in paraffin-embedded sections of bowel, pre-treated 
by microwaving, was exclusively cytoplasmic. This was difficult. to interpret given the 
specificity of the antibody for activated NFKB and the known nuclear localisation of 
the activated form, and occurred in mononuclear cells of one type, probably plasma 
cells. Some activated NFO may be present within the cytoplasm (3), but in paraffin- 
embedded sections of bowel, exclusive cytoplasmic, with no nuclear, staining was seen. 
It is possible that in cytoplasmic pools of inactive, IKB-bound NFKB, the process of 
microwaving may have revealed the epitope to which the antibody binds, thus falsely 
resulting in staining, but a greater number of positive cells, and of different 
morphologies, might have been expected if this had occurred, as many different cell 
types contain the p65 subunit of NFic]B (see section 4.2). 
In paraffin-embedded sections of mouse cerebral cortex, pre-treated with microwaving, 
cytoplasmic staining was seen in some areas, but definite nuclear staining in others. In 
paraffin-embedded sections of stimulated HeLa cells, no convincing staining was seen. 
Thus, the findings in paraffin-embedded sections were difficult to interpret and work 
therefore concentrated on frozen sections and unsectioned cultured cells grown on to 
cover-slips. 
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4.2 Frozen sections and unsectioned cultured cells 
The nuclear staining seen in positive controls of activated HeLa cells and mouse 
cerebral cortex is consistent with the specificity of the antibody and the rapid 
translocation of activated NFKB to the nucleus. Similar staining was seen in sections of 
bowel, but cytoplasmic, peri-nuclear staining was seen in some cells in all layers, but 
particularly in the muscle layer, which may represent activated, cytoplasmic NF1cB (3). 
Previous studies have shown that in HeLa cells stimulated for thirty minutes, all 
activated, nuclear-translocated NFrB is inactivated by newly synthesised 10 widiin 
eight hours of the original stimulus (320), which suggests that the activation of NF1cB 
in the present study in bowel reflects recent events. 
Immunohistochemical staining revealed a significantly greater tissue-density of cells 
expressing activated NFkB in the inflamed bowel in CD compared to normal bowel 
from controls, and expression was highest in the mucosa and muscle layers. 
In all three layers of the bowel wall, expression of activated NFxB in CD patients was 
mainly restricted to large mononuclear cells, morphologically suggestive of 
macrophages, suggesting these are a major cell-type involved in propagating 
inflammation in CD. 
This is comparable to findings from two previous studies using the same antibody in 
rheumatoid arthritis (RA) and osteoarthritis (106) and in atherosclerosis (105). In the 
study in arthritis, patients with chronic joint disease had increased activation of NFkB 
within the synovial lining, specifically in cells of a macrophage lineage, the type A 
synoviocytes. As in the present study, there was a low level of activation of NFO in 
normal control subjects. Interestingly, in arthritis patients with acute disease, but not 
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those with chronic disease, there was increased activation of NFYB in endothelial 
cells, an event not found in the present study, possibly due to the chronic nature of 
CD in the patients studied. 
In the study in atherosclerosis, activation of NFrB was found in macrophages, 
fibroblasts and endothelial cells in the active atherosclerotic lesion. 
In another study, increased activation of NFKB was demonstrated by electrophoretic 
mobility shift assay in macrophage-enriched mucosa mononuclear cells from mice 
with 2,4,6, -trinitrobenzene sulfonic acid (TNBS)-induced granulomatous colitis, and 
the active form of NFKB contained both p5O and p65 subunits (321). Using Western 
blotting, this study demonstrated a significant increase in p65 levels in nuclear 
extracts from macrophage-enriched mucosa mononuclear cells from patients with CD 
as compared to controls. These findings were confirmed in another study using both 
Western blotting and EMSA of nuclear extracts of endoscopic biopsy specimens from 
inflamed CD bowel (322), and are consistent with the findings in this chapter. in the 
second study (322), reduction in levels of activated NFicB were demonstrated from 
before, to after, treatment of patients with corticosteroids. In the present Chapter, no 
correlation between corticosteroid dose and activation of NFKB was found. 
Activated NFKB controls transcription of the gene for the cytokine TNFcc, and TNFcc 
activates NFYB; hence NFYB plays an essential role in the regulation of TNFa and 
could form a positive feedback mechanism (3). Studies using immunohistochernistry 
(318) and in situ hybridisation (221) have found that expression of TNFa in CD is 
restricted to a small number of macrophages and some lymphocytes, mainly in the 
lamina propria, with no expression in the epithelium, and fewer positive cells in 
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normal bowel from control patients. This is similar to the pattern of NFicB activation 
seen in the present study. It is thus possible that there is a direct relationship between 
TNFcc expression and activation of NFKB in the bowel. However, co-staining studies 
are required to detennine whether expression of TNFcc and activated NFYB occurs 
within the same macrophages. 
NFKB is expressed in a wide variety of cell types in vitro including T cells, B cells, 
monocytes/macrophages, neurones, colonic epithelial cells, endothelial cells and 
connective tissue cells, and its most important role is in cells of the immune system 
(3). Unexpectedly, in the present study, activation in many different cell types in 
inflamed tissue was not seen, with only mononuclear cells staining positive for 
activated NFicB. As has been suggested to explain similar results in the joint, this may 
be because other cell types may use alternative forms of the NFKB heterodimer (e. g. 
p5O-p5O heterodimer) that do not contain the p65 (Rel A) subunit, which is the 
epitope for the antibody used in the present study, such as the pSO-Rel-B heterodimer 
(106). 
The greater tissue-density of cells expressing activated NFYB in inflamed CD could 
simply reflect the increase of a particular cell type in inflamed areas. However, in 
view of the central role that NF1cB plays in many inflammatory events, a functional 
increase in its activation is more likely. Furthermore, as stated above, in RA it is clear 
that increased activation, rather than changes in cell number, causes the observed 
increase in expression of activated NFKB during inflammation. The few cells positive 
for activated NFicB found in normal bowel from controls may represent normal 
immunological activity in the mucosa., for instance, the continual process of antigen 
sampling and consequent immunological reaction. 
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There was a significantly greater tissue-density of cells expressing activated NFicB in 
the submucosa, but not in the mucosa or muscle layers, of macroscopically and 
microscopically non-inflamed CD bowel compared to normal bowel from controls. 
The absence of a significant difference between non-inflamed areas and control 
specimens in the mucosa and muscle layers may be a correct finding or may be due to 
a type II sampling error, particularly as only small numbers of non-inflamed 
specimens were collected (microscopically normal areas of resection specimens were 
difficult to accumulate and several specimens from macroscopically normal areas 
showed microscopic evidence of inflammation, and were not included in either group 
since they were not completely non-inflamed and specimens from macroscopically 
(and microscopically) inflamed areas from these patients were already included in the 
inflamed group). However, the difference observed in the submucosa strongly 
suggests that the apparently non-inflamed bowel in CD is more immunologically 
active than completely normal bowel from controls. 
A moderately significant correlation between inflammatory score and number of cells 
staining for activated NFKB was seen in the mucosa and muscle layer, but not in the 
submucosa. This supports an hypothesis that the increased levels of activation of 
NFKB in the submucosa do not simply reflect inflammation and, together with the 
observation of increased expression of activated NFicB in the submucosa of non- 
inflamed specimens, suggests that a process independent of inflammation may occur 
there. However, it could be hypothesised that the absence of a correlation in the 
submucosa may simply reflect inclusion of data from specimens scored as non- 
inflamed, but which contained increased numbers of cells positive for activated NFYB 
in the submucosa (for whatever reason) and which, in the submucosa, diluted a 
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significant correlation that existed in inflamed specimens. When the non-inflamed 
specimens are removed from the analysis of correlation, there is still no significant 
correlation in the submucosa (r = 0.17, p=0.62), but a weak correlation just persists 
at significant levels in the mucosa (r = 0.62, p=0.03), but not in the muscle layer (r = 
0.45, p=0.13). However, the small numbers of patients may miss real correlations 
due to type II sampling effors. 
Other studies have demonstrated subtle abnormalities in CD bowel that is normal by 
macroscopic and microscopic criteria, namely changes in: immunohistochemically 
demonstrated plasma cells (323); immunohistochemically demonstrated nerve fibres 
(324) and axonal necrosis of nerves by electron microscopy (325); vasoactive 
intestinal polypeptide containing nerves (326,327); nerves positive for major 
histocompatibility complex class II antigen (328); T cells and macrophages (329), and 
in intercellular adhesion molecule-I (330). Such changes in non-inflamed areas in CD 
may predate overt inflammation and further study of these areas, rather than those that 
are already inflamed and possess a compromised mucosal barrier, may reveal more 
about the early events that generate inflammation in CD. 
Comparisons were not made between non-inflamed and inflamed areas as this was not 
the original aim of the study, and because of advice from the statistician, that such 
multiple significance testing would require a Bonferroni correction that would reduce 
the power of the data. 
Although corticosteroids inhibit activation of NFKB in vitro, which explains their 
diverse anti-inflammatory effects in vivo (127,128), in the present study ex vivo, there 
was no correlation between the current dose of corticosteroid and activation of NFr. B, 
despite correcting for the degree of inflammation as a confounding factor. This might 
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be explained by the use of resection tissue from patients who, by definition, were 
unresponsive to corticosteroids and hence required surgery, i. e. these patients may 
have possessed corticosteroid resistance. Alternatively, the severity of the underlying 
disease may have overridden the inhibitory effects of corticosteroids on NFYB 
activation. 
It was not possible to collect many full-thickness operative specimens from patients 
with ulcerative colitis, as most operations are unplanned, and are becoming less 
common with improvements in medical therapy. Endoscopic biopsy specimens are 
more easily obtained and were collected, but good quality staining with low 
background staining was difficult to obtain, as indicated by the high background 
count obtained in the only endoscopic biopsy included for analysis, from a patient 
with Wegener's granulomatosis (see Appendix III). Furthermore, endoscopic biopsy 
specimens contain only mucosa and occasionally submucosa, but no muscle layer. In 
the two patients with UC from whom full thickness specimens were collected, cells 
positive for NFicB were plentiful, particularly in the mucosa and submucosa, 
consistent with the pathology of UC as a disease affecting predominantly the mucosa, 
extending into the deeper layers only in more active disease. 
In inflammatory controls with diverticulitis and vasculitis, many cells positive for 
activated NFicB were also seen, and so increased activation of NFKB in bowel is not 
confined to CD. 
A large increase in activation of NFicB in inflamed areas of CD bowel was 
demonstrated. NFicB is activated by diverse stimuli and it is unclear whether this 
increase in activation is in response to a causal agent e. g. viruses, to reactive oxygen 
species, or to increased immunological signalling. Recently, antagonists of NFicB 
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activation that specifically inhibit the proteasome that degrades IKB have been shown 
to be effective in treating chronic granulornatous colitis in rats (124) and local 
administration of antisense oligonucleotides improves both TNBS-induced 
granulomatous colitis in mice and colitis in EL-10 deficient mice (321). This suggests 
that activation of NFYB, and hence the cells expressing it, are fundamental to the 
process of inflammation in the bowel. NFKB thus represents a potent target for new 
anti-inflammatory agents in CD. 
5. Conclusion 
In this chapter, an immunohistochemical method to study activation of NFlcB in 
frozen sections of bowel was established. Increased tissue-density of cells positive for 
activated NFYB was demonstrated in sections of bowel from patients with CD in all 
layers of inflamed areas in comparison to sections of bowel from control patients. 
Activation was restricted mainly to large mononuclear cells, morphologically 
suggestive of macrophages, suggesting that these are a major cell type involved in 
propagating inflammation in CD. 
A greater tissue density of cells expressing activated NFKB was found in the 
submucosa, but not in the mucosa or muscle layers, of macroscopically and 
microscopically non-inflamed CD bowel compared to normal bowel from controls, 
which suggests that the apparently non-inflamed bowel in CD may be more 
immunologically active than completely normal bowel from controls, consistent with 
other studies that have demonstrated subtle abnormalities in these areas. The first 
molecular inflammatory events of CD may therefore occur in the submucosa. 
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Chapter 6 




In Chapter 4, immunohistochemistry was used to investigate the activation of NFlcB 
in sections of bowel using an antibody that was specific for the activated form of 
NFxB. The antibody was validated using sections of mouse cerebral cortex and 
cultured HeLa cells grown on to coverslips, immunostained with a peroxidase-based 
system. 
In the present chapter, a method to measure activation of NFicB by flow cytometry, 
which has not previously been published, is developed. The reasons for developing a 
method were: 
e immunocytochernistry allows in situ identification and quantitation of cells staining 
positive for NFrB, but definitive identification of the cell-type(s) staining positive 
requires double staining, which is technically difficult and often unsuccessful, 
whereas 
* flow cytometry allows rapid measurement of antibody staining of large numbers of 
cells, and allows sorting of cells into different populations. Once a method was 
established, these characteristics would be used in two ways: 
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1. to measure activation of NFic-B in isolated lamina propria cells from patients with 
inflammatory bowel disease and controls, and to identify sub-populations of cells 
containing activated NFKB, and 
2. it is known that NFicB plays an essential role in silica-induced inflammatory 
mediator production in macrophages (331,332), and flow cytometry would be used to 
measure activation of NFxB in cultured cells stimulated with solutions of inorganic 
sub-micron particles with bioactive bacterial products adsorbed onto their surface, 
thus linking with other work within The Gastrointestinal Laboratory examining the 
potency, and mechanism of action, of these particles in inducing inflammatory 
responses, and their possible role in the aetiology of Crohn's disease. 
1.2 Description of flow cytometrv 
Flow cytometry measures the properties of individual cells or particles as they move, 
or flow, in liquid suspension. Measurements are made separately on each particle 
within the suspension in turn and not simply as a total value for the whole population. 
A laser emits an intense beam of monochromatic light that falls on individual cells, or 
particles, moving singly through the viewing field at rates of up to several thousand 
cells per second. Light is scattered by particles in cells and is measured by highly 
sensitive light detectors, called photomultiplier tubes, which are located both opposite 
and to one side of the laser and measure forward and side light scatter, respectively. 
Forward light scatter provides infonnation on the relative size of individual cells, 
whereas side light scatter provides information on the relative granularity of individual 
cells. Additional photomultiplier tubes measure light emitted at a different wavelength 
by fluorescent labels in, or on, cells, with incident light removed by filters. 
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Since all measurements are made on each cell simultaneously, one or two 
measurements, usually forward and side scatter, can be used to select a subset of cells 
for study using another measurement, usually light from a fluorophore. 
1.3 Proposed methods 
in previous studies of flow cytometric measurement of other nuclear antigens, 
numerous techniques for fixation and permeabilisation of cell suspensions have been 
used, and when using a new antibody, it is difficult to predict which will result in 
optimal results, and so a range of methods need to be tested (333). Alcohol fixation 
has previously been extensively used in flow cytometry and it both fixes and 
permeabilises cells by dissolving lipids in the cell membrane, which allows 
penetration of antibodies. Other techniques use cross-linking fixatives such as 
paraformaldehyde, which preserve structure well, but may reduce permeability, and 
are hence often combined with permeabilising agents such as Triton X- 100. 
Camplejohn (333) has categorised four basic methods, namely: 70 % ethanol at 4"C; 
absolute methanol at -20OC; paraformaldehyde fixation followed by permeabilisation, 
and detergent enucleation followed by alcohol fixation. In this chapter, five fixation 
methods, that were previously tested by Landberg et al (334) for analysis by flow 
cytometry of a nuclear antigen, proliferating cell nuclear antigen, were used plus a 
further commercially available method, Ortho Permeafix, (composition withheld by 
the manufacturer). 
One of these methods, detergent enucleation, involves removal of the cytoplasm of 
cells with a solution of detergent, and was therefore of particular interest as it would 
prevent any possibility of staining of inactive, cytoplasmic NFKB. For this reason, an 
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antibody that is not specific for the activated form of NFr. B, namely an anti-p65 NFxB 
antibody manufactured by Santa Cruz (335), could also be tested to measure only 
activated, nuclear-translocated NFxB. It was desirable to test more than one antibody, 
because it is known that antibodies that are successfully used for 
immunohistochernistry, as the Boehringer antibody was in Chapter 5, are not always 
successfully applied to flow cytometry (333). 
Immunostaining techniques can be single-layer methods, where the fluorophore is 
directly attached to the primary antibody, or, as used here, two or three layer 
techniques, where the fluorophore is attached to the final layer, which increase 
sensitivity. 
Thus, a range of fixation techniques were combined with a range of immunostaining 
protocols and two primary antibodies, to optimise results. 
To allow identification of'flow cyiometry protocols that succeeded in accurately 
measuring activation of NFYB from the results of mean levels of activation of NFKB 
within cell suspensions, tumour cell lines in four different states of stimulation were 
tested, namely: 
1. untreated cell suspensions that were termed 'unstimulated' and should contain only 
a minority of cells containing activated NFKB; 
2. cell suspensions stimulated with a combination of PMA and TNFa, which are 
known to synergistically activate NFKB (83), termed 'stimulated'; 
3. cell suspensions incubated with an agent that inhibits activation of NFKB, termed 
'inhibited'. Pyrrolidine dithiocarbarnate (PDTC) is such an agent, which inhibits 
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activation of NFrB because of antioxidant properties that inhibit the ROI-induced 
activation of NFicB (34) (see Chapter 1, section 3.6); 
4. cell suspensions incubated with PDTC to inhibit activation of NFKB, and then 
stimulated with TNFa and PMA, termed 'inhibited, then stimulated'. This group 
was included to demonstrate that any increased levels of activated NFKB measured 
in the 'stimulated' suspension, returned to baseline levels (similar to the level of 
activation in the 'inhibited' suspensions) when activation of NFKB was inhibited 
prior to stimulation. Thus, alternative hypotheses for increased levels of activated 
NFY, B in the stimulated suspensions, such as increased non-specific binding to 
proteins other than activated NFKB because of increased total cellular protein 
content in stimulated cells, could be excluded. 
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2. Methods 
2.1 Cell culture 
HeLa S3 cells were grown in suspension as described in Chapter 4. Jurkat T cells (gift 
of Dr. G. A. Limb, Department of Immunology, The Rayne Institute, St. Thomas' 
Hospital) were cultured in a similar manner except with replacement of Eagle's 
minimum essential medium containing Hank's balanced salt solution with Roswell 
Park Memorial Institute 1640 culture medium (Life Technologies, Paisley, Scotland, 
LJK). 
2.2 Stimulation of cells 
As in Chapter 4, cells were washed twice in serum-free tissue culture medium (TCM), 
stained with trypan blue and then counted to ensure non-viable cells were below 5 
Cells were then resuspended in TCM at 2x 10 6 cells ml"' and, as described in section 
1.3, divided into four suspensions in separate culture flasks: 
1. to be left unstimulated for 2 hours (tenned 'unstimulated); 
2. to be left for one hour and then stimulated with a combination of TNFcc and PMA 
(200 units ml" and 50 ng ml" respectively) for one hour (termed 'stimulated'); 
3. to be left for one hour and then cultured for one hour with 100 gM PDTC (Sigma 
Chemical Company) (termed 'inhibited'), and 
4. to be cultured with PDTC for one hour and then TNFcc and PMA added for one 
hour (termed 'inhibited, then stimulated'). 
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Aliquots of 1.5 xlO 6 cells were pipetted into flow cytometry tubes (Sigma Chemical 
Co. Ltd. ) and then washed once in serum-free TCM, as described in Chapter 5, and 
once in PBS, and fixed and immunostained using the following methods. 
2.3 Fixation 
In the following methods, whole cells were centrifuged at 400g for five minutes and 
nuclei at 640g for ten minutes. 
Method A. Stimulation, enucleation and fixation in 100 % methanol. 
1. Cells were centrifuged at 4 *C and the supernatant decanted, and then resuspended 
in the residual volume by shaking the tube. 
2. To each tube, 500 pl of enucleating/lysing solution (0.5 % (v/v) Triton X-100,0.2 
gg ml" EDTA in PBS) was added, mixed gently and then incubated on ice for fifteen 
minutes. 
3. To each tube, 3 mls of 100 % methanol at - 20 "C was slowly added while 
agitating vigorously by hand. 
4. Cells were vortexed and stored at - 20 'C. 
Method B. Stimulation and fixation of whole cells in 70 % ethanol. 
1. Cells were centrifuged at 4 'C and the supernatant decanted, and then resuspended 
in 200ýd of PBS. 
2. To each tube, 2.8 mls of a 70 % (v/v) solution of ethanol in distilled water at 4"C 
was added while agitating vigorously by hand, and then stored at 4"C. 
Method C. Fixation of whole cells in 100 % methanol. 
1. Cells were centrifuged at 4 'C and the supernatant decanted, and then resuspended 
in 200pl of PBS. 
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2.2.8 mls of 100 % methanol at - 20'C was added while agitating vigorously by 
hand. 
3. Cells were cooled to -20'C for five minutes, and I ml of distilled water added to 
each tube. Cells were then mixed and stored at 4C. 
Method D. Fixation of whole cells in paraformaldehyde/Triton X-100. 
1. Cells were centrifuged at 4 *C and the supernatant decanted, and then resuspended 
in 200pl of PBS. 
2. To each tube, I ml of aI% (w/v) solution of paraformaldehyde in PBS was added 
and incubated at room temperature for fifleen minutes. 
3. To each tube, I ml of a 0.2 % (v/v) solution of Triton X-100 in PBS was added to 
the paraformaldehyde/cell mixture. Cells were then mixed and stored at 4 *C. 
Method E. Fixation of whole cells in Triton X-100/ paraformaldehyde. 
1. Cells were centrifuged and the supernatant decanted, and then resuspended in the 
residual volume. 
2. To each tube, I ml of a 0.1 % (v/v) solution of Triton X- 100 in PB S was added and 
incubated at room temperature for fifteen minutes. 
3. To each tube, I ml of a2% (w/v) solution of paraformaldehyde in PBS at 4 "C was 
added, and then cells stored at 4 T. 
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Method F. Stimulation and fixation of whole cells in Ortho Permeafix (Ortho 
Diagnostic Systems, Raritan, New Jersey, USA) (as per manufacturer's instructions). 
1. Cells were centrifuged at 4 "C and the supernatant decanted, and then resuspended 
in 2 ml of Ortho Permeafix and incubated at room temperature for forty minutes. 
3. Cells were then centrifuged, the supernatant decanted, and then resuspended in the 
residual volume. 
4. To each tube, 2 ml of wash buffer (5 % (v/v) fetal calf serum, 1.5 % (v/v) bovine 
serum albumin (BSA) (Sigma Chemical Company) and 0.005 % (w/v) EDTA in PBS) 
was added, and then incubated at room temperature for ten minutes. 
S. Cells were centrifuged at 4 OC, the supernatant decanted, and then resuspended in 
the residual volume and immediately immunostained with a two layer technique (see 
section 2.4.3). 
2.4 Immunostainini! 
2.4.1 Immunostaining of nuclei using a three layer technigLie. 
1. Clumped nuclei were separated by passing forcefully through a 16 gauge needle 
(Sigma Chemical Company) with aI ml syringe (Sigma Chemical Company). 
2. Nuclei were washed twice, by centrifuging at 4 *C, decanting the supernatant, and 
then adding 2 ml of enucleating/lysing solution. The supernatant was then again 
decanted and the nuclei resuspended in the residual volume, and one of two tested 
primary antibody layers (A and B below) added and incubated at room temperature 
for one hour. In all experiments, as a negative control, to a second tube prepared in an 
identical manner, was added an isotype control antibody (C below) in place of the 
primary antibody. 
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A: I OOpI of a solution of Boehringer Mannheim anti-p65 NFxB antibody diluted I in 
50 in enucleating/lysing solution. 
B: 100pl of a solution of Santa Cruz anti-p65 NFKB antibody (335) (Santa Cruz 
Biotechnology, Inc., Autogen Bioclear, Devizes, Wiltshire, UK) diluted I in 20 in 
enucleating/lysing solution. 
C: 100pl of a solution of mouse IgG3r, isotype control antibody (Sigma Chemical 
Company) diluted I in 100 in enucleating/lysing solution. 
3. Nuclei were washed twice with enucleating/lysing solution, as before. The 
supernatant was then decanted and the nuclei resuspended in the residual volume. 
4. The secondary antibody appropriate to the primary antibody was then added, mixed 
gently and incubated at room temperature for one hour as follows: 
For primary antibody A and C: 100gl of a solution of biotinylated, rabbit anti-mouse 
antibody (Dako Ltd. ) diluted I in 100 in enucleating/lysing solution. 
For primary antibody B: 100gl of a solution of biotinylated, goat anti-rabbit antibody 
(Sigma Chemical Company) diluted I in 100 in enucleating/lysing solution. 
5. Nuclei were washed twice with enucleating/lysing solution as before, and the 
tertiary layer, 100 pl of a solution of Extravidin TM -FITC (Sigma Chemical Company) 
diluted I in 200 in enucleating/lysing solution, added and incubated at room 
temperature for one hour. 
6. Nuclei were washed twice with antibody diluent. The supernatant was then 
decanted and the nuclei resuspended in the residual volume. 
7. For identification, nuclei were stained with 200 pl propidium iodide (PI) solution, 
which stains PI (336) (10 pg ml"' PI (Sigma Chemical Company), 1.8 Kunitz units 
ml" RNase, 0.5 % (v/v) Nonidet P-40 (Sigma Chemical Company) in PBS), then 
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resuspended by passing forcefully through a 16 gauge needle prior to analysis by flow 
cytometry. 
2.4.2 Immunostaining of nuclei using a two layer technique 
1. Steps I and 2 of method I were performed using only Boehringer Mannheim anti- 
p65 NFKB and isotype control antibody. 
2. Nuclei were washed twice with enucleating/lysing solution as before. The 
supernatant was then decanted and the nuclei resuspended in the residual volume. 
3. A solution of secondary antibody, FITC-labelled rabbit anti-mouse antibody (Dako 
Ltd. ) diluted I in 10 in enucleating/lysing solution was applied and incubated at room 
temperature for 45 minutes. 
4. Nuclei were washed twice with antibody diluent as before. The supernatant was 
then decanted and the nuclei resuspended in the residual volume. 
S. Nuclei were stained with 200 pI PI solution, then resuspended by passing forcefully 
through a 16 gauge needle prior to analysis by flow cytometry. 
2.4.3 Immunostaining of whole cells using a two layer technique. 
1. Cells were washed once, as before, with wash buffer (5 % (v/v) fetal calf serum, 
1.5 % (v/v) BSA and 0.005 % (w/v) EDTA in PBS). 
2. The supernatant was decanted, and the cells then resuspended in the residual 
volume. and the primary antibody applied (100pl of a solution of Boehringer 
Mannheim anti- p65 NFxB antibody diluted I in 50 in enucleating/lysing solution, or 
100gl of a solution of isotype control antibody diluted I in 100 in enucleating/lysing 
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solution). Cells were then mixed gently by hand and incubated at room temperature for 
one hour. 
3. Cells were washed twice with wash buffer, as before, and the supernatant decanted 
and the cells then resuspended in the residual volume. 
4. The secondary antibody, I 00ýd of a solution of FITC-labelled rabbit anti-mouse 
antibody diluted I in 10 in wash buffer, was then added and incubated at room 
temperature for 45 minutes. 
5. Cells were washed twice with wash buffer as before, and finally resuspended in 200 
ýtl of wash buffer prior to analysis by flow cytometry. 
2.5 Flow cvtometr_V analvsis 
Fixed and immunostained suspensions of cells and nuclei were analysed by flow 
cytometry using a Becton Dickinson FACScan (Becton Dickinson, Mountain View, 
California, USA) and LYSIS II software package (Becton Dickinson), simultaneously 
measuring forward scatter, side scatter, FITC fluorescence (detected by fluorochrome 
I photomultiplier tube), and for suspensions of nuclei, PI fluorescence (detected by 
fluorochrome 2 photomultiplier tube). Data were then analysed using a Personal 
Computer (PC) and Windows multiple document interface software package, version 
2.7 (Microsoft Corporation, Redmond, WA, USA), that is specifically designed for 
analysis of flow cytometry data. 
When suspensions of nuclei were stained with two fluorophores, analysis was adjusted 
for spectral overlap of FITC and PI immunofluorescence by electronic spectral overlap 
correction. Furthermore, control samples of nuclei labelled only with 
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FITC, were analysed in the PI spectrum, and vice versa, to confirm that no significant 
spectral overlap occurred. 
2.5.1 Selection of populations of cells 
Whole cells within cell suspensions were defined by forward- and side-scatter 
characteristics: a 'dot-plot' of forward versus side-scatter was created, and an area 
selected, terined a 'gate' (RI, Figure 1), such that particles at the extremes of forward- 
or side- scatter, that might represent fragments or small clumps of cells respectively, 
were excluded from subsequent recording of fluorescence. The same gate was used 
within individual experiments, to allow direct comparison of stimulated and 
unstimulated states, but varied slightly between experiments, because different cell 
cultures had slightly differing forward- and side-scatter characteristics. 
eg 
. 0. . 







Figure 1. An example of a dotplot of forward scatter versus side scatter characteristics of HeLa 
cells, showing a gated area, R1, that is designated as representing whole cells. Similar dotplots were 
obtained for Jurkat T cells. 
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2.5.2 Selection of populations of nuclei 
To create a gate for selection of a population of single nuclei, a DNA histogram 
(Figure 2) was created by plotting number of nuclei against log PI fluorescence. The 
DNA histograin represents a range of quantity of DNA within different nuclei, with 
the first peak (A) representing nuclei from cells in the G, phase of the cell cycle when 
division is first triggered, and the second peak (B) representing nuclei from cells in 
the G2 phase, when the DNA content is doubled immediately pnor to mitosis (336). 
The population of single nuclei to be analysed was defined by a gate (MI) applied to 
the DNA histogram, so excluding, for instance, clumped nuclei that have a combined 
DNA content higher than single nuclei from cells in the G2 phase and small fragments 
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Figure 2. An example of a DNA histogram. A plot of number of nuclei versus PI 
fluorescence for a suspension of HeLa cell nuclei. A region, MI, is gated and used for 






Figure 3. An example of a histogram of number of HeLa cells versus log FITC- 
fluorescence. Population A is stained with anti-p65 NFKB antibody (Boehringer 
Mannheim) and population B with isotype control antibody. The region MI represents 
fluorescence intensity above the 95th centile of fluorescence intensity of the isotype 
control antibody-stained population. Similar histograms were obtained for whole 
Jurkat T cells and suspensions of nuclei of both cell types. 
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2.5.3 Assessment of data 
Once the population of cells or nuclei to be analysed had been defined, staining of the 
population with anti-p65 NFicB antibody was measured by plotting a histogram of 
number of cells against fluorescence of the FITC label (Figure 3). The FITC- 
fluorescence of an identical cell population stained with isotype control antibody was 
overlaid on this histogram to allow derivation of the following data: 
mean fluorescence intensity (NEI) of cells or nuclei immunostained with anti-p65 
NFKB antibody (termed 'NFKB' in the Results tables); 
2. NEI of cells or nuclei immunostained with isotype control antibody (termed 
'isotype' in the Results tables); 
3.1 minus 2, to control for non-specific binding of antibody to nuclei or cells (termed 
'NFKB - isotype' in the Results tables); 
4. a ratio of I divided by 2, as used by others (334) as a further measure to control for 
non-specific factors influencing the intensity of staining (termed 'NFKB / isotype' in 
the Results tables); 
5. NEI of the population of cells or nuclei stained with anti-p65 NFKB antibody that 
fluoresced with greater intensity than the fluorescence of the 95th centile of the 
isotype control antibody-stained population (termed 'NFKB > 95 W in the Results 
tables). This analysis was chosen to detennine the Nff I of cells or nuclei that had 
'significantly' stained with anti-p65 NFicB antibody, and 
6. percentage of the population of cells or nuclei stained with anti-p65 NFKB antibody 
that fluoresced with greater intensity than the fluorescence of the 95th centile of the 
isotype control antibody-stained population (termed '% positive cells' in the Results 
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tables). This analysis was chosen to determine a percentage of cells or nuclei that had 
'significantly' stained with anti-p65 NFKB antibody. 
The data for each of the experimental protocols, manipulated in the ways described 
above (1-6), were assessed for biological plausibility of the results, to identify a 
protocol that succeeded in staining cells containing activated NFKB. Thus, the 
expected order of ranking of magnitude of data was: 
stimulated > unstimulated > inhibited then stimulated ýt inhibited. 
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4. Results 




Unstimulated Stimulated Inhibited Inhibited then 
stimulated 
NFKB 115 99 113 94 
Isotype 46 44 46 42 
NFicB-isotype 69 55 67 52 
NFKB Asotype 2.5 2.3 2.2 2.4 
NFKB > 95% 
isotype 
148 111 107 123 
% positive 
cells 
65 84 88 80 
Table 1. Results of experiment where whole HeLa cells were fixed in 70 % 
ethanol (fixation method B) and then immunostained with anti-p65 NFKB 
antibody (Boehringer Mannheim) and isotype control antibody (immunostaining 
method 3, two-layer technique). NffIs are displayed. None of the different types of 
analysis of the data (far left column) produced the expected order of ranking of 
magnitude for different cell treatments, and it was therefore concluded that the 





Unstimulated Stimulated Inhibited Inhibited then 
stimulated 
NFKB 105 109 122 67 
Isotype 49 57 45 59 
NFKB-isotype 56 52 77 8 
NFKB /isotype 2.1 1.9 2.7 1.1 
NFKB > 95% 
isotype 
ý10 227 166 1088 
% positive 
cells 
I 44 I 31 I 63 2 
Table 2. Results of experiment where whole Jurkat T cells were fixed in 100 % 
methanol (fixation method Q and then immunostained with anti-p65 NFjcB 
antibody (Boehringer Mannheim) and isotype control antibody (immunostaining 
method 3, two-layer technique). NgIs are displayed. None of the different types of 
analysis of the data (far left column) resulted in the expected order of ranking of 
magnitude for different cell treatments, and it was therefore concluded that the 




Unstimulated Stimulated Inhibited Inhibited then 
stimulated 
NFxB 88 86 91 67 
Isotype 36 53 62 37 
NFKB-isotype 52 33 29 30 
NFKB /isotype 2.4 1.6 1.5 1.8 
NFKB > 95% 
isotype 
115 150 320 148 
% positive 
cells 
I 59 I 30 I 10 
Table 3. Results of experiment where whole HeLa cells were fixed in 100 % 
methanol (fixation method Q and then immunostained with anti-p65 NFxB 
antibody (Boehringer Mannheim) and isotype control antibody (immunostaining 
method 3, two-layer technique). NgIs are displayed. None of the different types of 
analysis of the data (far left column) resulted in the expected order of ranking of 
magnitude for different cell treatments, and it was therefore concluded that the 





Unstimulated Stimulated Inhibited Inhibited then 
stimulated 
NFKB 199 210 107 181 
Isotype 115 143 155 131 
NFKB-isotype 
_84 
67 -48 50 
NFKB Asotype 1.7 1.5 0.7 1.4 
NFKB > 95% 
isotype 
666 784 507 1388 
% positive 
cells 
19 14 1 16 
Table 4. Results of experiment where whole HeLa cells were fixed in PFA/Triton-X 
(fixation method D) and then immunostained with anti-p65 NFicB antibody 
(Boehringer Mannheim) and isotype control antibody (immunostaining method 2). 
NFIs are displayed. None of the different types of analysis of the data (far left column) 
resulted in the expected order of ranking of magnitude for different cell treatments, and it 





Unstimulated Stimulated Inhibited Inhibited then 
stimulated 
NFKB 33 25 31 24 
Isotype 40 49 33 45 
NFKB-isotype -7 -24 -2 -21 
NFKB /isotype 0.8 0.5 0.9 0.5 
NFKB > 95% 
isotype 
386 640 260 873 
% positive 
cells 
I 4.0 I 2.7 I 7.3 1.4 
Table 5. Results of experiment where whole Jurkat T cells were fixed in Triton- 
X/PFA (fixation method E) and then immunostained with anti-p65 NFxB 
antibody (Boehringer Mannheim) and isotype control antibody (immunostaining 
method 3, two-layer technique). NffIs are displayed. None of the different types of 
analysis of the data (far left column) resulted in the expected order of ranking of 
magnitude for different cell treatments, and it was therefore concluded that the 





Unstimulated Stimulated Inhibited Inhibited then 
stimulated 
NFKB 594 612 602 611 
Isotype 669 623 -57 689 
NFKB-isotype -75 -11 -57 -129 
NFKB /isotype 0.9 1.0 0.9 0.8 
NFKB > 95% 
isotype 
ý107 1875 2038 2189 
% positive 
cells I 
4.3 I 4.6 
I 
3.9 I 
Table 6. Results of experiment where whole HeLa cells were fixed in Ortho 
Permeafix (fixation method F) and then immunostained with anti-p65 NFxB 
antibody (Boehringer Mannheim) and isotype control antibody (immunostaining 
method 3, two-layer technique). Nff Is are displayed. None of the different types of 
analysis of the data (far left column) resulted in the expected order of ranking of 
magnitude for different cell treatments, and it was therefore concluded that the 




Unstimulated Stimulated Inhibited Inhibited then 
stimulated 
NF1cB 665 543 727 697 
lsotype 640 738 619 826 
NFicB-isotype 25 -195 108 -129 
NFKB Asotype 1.0 0.7 1.2 0.8 
NFKB > 95% 
isotype 
4239 5088 4333 8908 
% positive 
cells 
I 4.6 I 3.2 I 8.5 3.0 I 
Table 7. Results of experiment where whole Jurkat T cells were fixed in Ortho 
Permearix (fixation method F) and then immunostained with anti-p65 NFicB 
antibody (Boehringer Mannheim) and isotype control antibody (immunostaining 
method 3, two-layer technique). Nff Is are displayed. None of the different types of 
analysis of the data (far left column) resulted in the expected order of ranking of 
magnitude for different cell treatments, and it was therefore concluded that the 





Unstimulated Stimulated Inhibited Inhibited then 
stimulated 
A B A B A B A B 
NFKB 457 471 549 517 - 532 472 254 
Isotype 208 254 213 193 - 217 158 244 
NFKB-isotype 249 213 336 324 - 315 314 10 
NFKB /isotype 2.2 1.9 2.6 2.7 - 2.5 3.0 1.0 
NF1cB > 95% 
isotype 











78 88 5 
A and B= repeated experiments - 
Table 8. Results of experiments where HeLa cells were fixed and enucleated in 
100 % methanol (fixation method A) and then immunostained with anti-p65 
NFicB antibody (Boehringer Mannheim) and isotype control antibody 
(immunostaining method 1, three-layer technique). NUIs are displayed. All the 
analyses (far left column) of the data from experiment A, except the '% positive cells' 
analysis, are consistent with the expected order of ranking of magnitude for different 
cell treatments. However, when the experiment was repeated in B, the order was no 
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Unstimulated Stimulated Inhibited then 
stimulated 
NFKB 691 702 584 
Isotype 208 213 158 
NFKB - 
isotype 
483 489 426 
NFKB /isotype 3.3 3.3 3.7 
NFxB > 95% 
isotype 
724 731 601 
% positive 
cells I 
92 94 98 
I 
Table 10. Results of experiment where HeLa cells were fixed and enucleated in 
100 % methanol (fixation method A) and then immunostained with anti-p65 
NFicB antibody (Santa Cruz) and isotype control antibody (immunostaining 
method 1, three-layer technique). NEIs are displayed. None of the different types of 
analysis of the data (far left column) resulted in the expected order of ranking of 
magnitude for different cell treatments, and it was therefore concluded that the 
protocol had not resulted in successful staining of activated NFYB. 
5. Discussion 
None of the experiments gave a clear, unequivocal result suggesting a successful 
method for measurement of activated NFKB by flow cytometry. The most promising 
results were those displayed in Table 8, in a repeated experiment where enucleated 
HeLa cells were fixed in 100 % methanol and stained with the Boehringer Mannheim 
antibody using a three layer technique. In the first of these experiments (Table 8, 
experiment A), all the analyses of the data, except the '% positive cells' analysis, are 
consistent with the expected order of ranking of magnitude for different cell 
treatments. 
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In this experiment, the data analysis termed 'NFKB' (Table 8, experiment A) for 
unstimulated and stimulated states is displayed in Figure 4 in overlaid histograms of 
number of cells versus FITC-fluorescence intensity. The difference between these 
histograms for stimulated and unstimulated nuclei is accentuated by integrating the 
percentage of the total population of analysed nuclei and plotting this against FITC- 
fluorescence intensity of anti-p65 NF1cB antibody staining (Figure 5). Subtraction of 
the resulting two curves produces the curve in Figure 6, which may represent a 
method of detecting activation of NFKB within suspensions of nuclei by flow 
cytometry. 
However, in the repeat of the experiment (Table 8, experiment B), although the 
findings for stimulated and unstimulated nuclei were similar to those in the first 
experiment (Table 8, experiment A), for all data analyses (far left column), the Nff I 
for the 'inhibited ' nuclei is larger than for the 'stimulated' nuclei. 
Furthermore, in Table 9, the same methods were employed using Jurkat T cells and 
although, in experiments A and B in this table, Nff I of the stimulated nuclei is larger 
than that with other cell treatments, this is not repeated in experiments C and D. Thus 
considerable doubt exists as to whether this is a reliable method of measuring 
activation of NFKB by flow cytometry. 
Finally, staining of suspensions of nuclei with the Santa Cruz anti-p65 NFKB antibody 
(Table 10) did not result in the expected order of ranking of magnitude for different 
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Figure 4. Overlaid histograms of number of cells versus FITC-fluorescence intensity 
for Boehringer Mannheim anti-p65 NFrB antibody staining of stimulated and 
unstimulated suspensions of nuclei from HeLa cells prepared and fixed by fixation 












Figure 5. Graph displaying integrated percentage of the total analysed population of 
stimulated and unstimulated suspensions of nuclei from HeLa cells, prepared and 
fixed by fixation method A, and stained by immunostaining method 1, versus the 
FITC-fluorescence intensity of anti-p65 NFKB antibody staining. Subtraction of these 
curves results in the graph displayed in Figure 6. 
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FITC fluorescence intensity of anti-p65 NFkB antibody staining 
Figure 6. Graph displaying the result of subtraction of the curve for unstimulated 
nuclei from the curve for stimulated nuclei in Figure 5. Thus, difference in cumulative 
percentage of nuclei is plotted against FITC-fluorescence intensity of anti-p65 NFKB 
antibody staining. The curve may represent measurement of activation of NFKB (see 
section 4.2). 
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RTC fluorcscerice hftnsity of anfi-p65 NFkB argibody stahng 
6. Conclusion 
A standard range of fixation methods of suspensions of cells and nuclei, different 
staining protocols and two different antibodies were tested to develop a method of 
measuring activation of NFKB by flow cytometry. No method was conclusively 
successful, but the best results were obtained by enucleation of HeLa cells, followed 
by fixation in 100 % methanol, with immunostaining with the Boehringer Mannheim 
anti-p65 NFxB antibody using a triple layer technique. The technique was not 
sufficiently reliable to apply to the investigations outlined in the section 1.1, and 
further experiments are required to investigate the method further before it can be 
used. Nevertheless, the experiments show that it should be possible to develop such a 
method, and this would allow measurement of NFicB activation in subpopulations of 
suspensions of large numbers of cells. 
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Chapter 7. Discussion and future work 
In Chapter 2, while developing an ISH method to study in situ activation of NFxB, 
non-specific binding of oligonucleotide probes to eosinophils in sections of bowel was 
demonstrated. On review of the literature, a similar effect was observed between 
longer (400-mer) DNA probes and eosinophils in bone marrow (285) smears, and 
between riboprobes and eosinophils in sections of bowel (286). However, there were 
no similar reports of this effect occurring during oligonucleotide ISH, including 
studies using it in bowel. 
Non-specific binding of probes was successfully prevented by pre-treatment of 
sections with dithiothreitol and iodoacetamide followed by high stringency washes. 
Hybridisation of poly-d(T) probe to the polyriboadenosine tail on all mRNA within 
cells was demonstrated when low stringency post-hybridisation washes were used, but 
non-specific binding to eosinophils returned when low stringency washes were used, 
despite pre-treatment of sections with DTT and iodoacetamide. It is therefore 
concluded that oligonucleotide probes cannot be used to investigate gene expression 
in the lamina propria of bowel, unless other blocking manoeuvres are developed, as 
non-specific binding of probe to eosinophils appears identical to the appearances of 
probe genuinely hybridised to target mRNA. Furthermore, this phenomenon occurred 
in sections of nasal polyp that are rich in eosinophils, and therefore probably occurs in 
other eosinophil-containing tissues, such as lung. 
In addition, there was greater non-specific binding of the antisense probe cocktail for 
lr, Bcc to eosinophils than of an equivalent concentration of a single sense probe. 
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Experiments with in&vidual IKBot probes confirmed significantly less non-specific 
binding of sense than all antisense probes to eosinophils. This effect, of differential 
binding of different oligonucleotide probes, may explain why non-specific binding to 
eosinophils has not been reported in previous publications using oligonucleotide ISH 
in bowel, as it was presumably mistaken for genuine hybridisation to target mRNA. 
In Chapter 3, the mechanism of non-specific binding of oligonucleotide probes to 
eosinophils was explored. Using biomolecular interaction analysis with a BiacoreXTm 
instrument, a method was established for measuring the in vitro interaction between 
probes and eosinophilic cationic protein, which was hypothesised to be the agent 
within eosinophils binding oligonucleotide probes, or control proteins. Binding of all 
oligonucleotide probes to ECP, but not to the control proteins, myoglobin and 
lysozyme, was demonstrated. The absence of binding to lysozyme, which has a 
similar pI to ECP, suggests that binding to ECP is unlikely to be a charge-related 
effect due to its unusually high pl. The reason that ECP binds oligonucleotide probes 
is unclear, but it possesses ribonuclease activity (283) and may therefore contain a 
binding site(s) for nucleic acids. 
The dissociation constant at equilibrium indicates the affinity of an interaction and 
values obtained for the interaction between probes and ECP were of the order of 10-6 
K indicating moderate affinity, although the interaction is likely to be of high 
capacity because of the abundance of ECP. 
In vitro binding of antisense and sense oligonucleotide probes for IKBct mRNA were 
compared using four parameters, namely magnitude of total binding, association rate 
constant (kj, dissociation rate constant (kd) and dissociation constant at equilibrium 
254 
(KD)- Significant differences between values for sense and antisense oligonucleotides 
were found for magnitude of binding and kd, with the differences in both parameters 
consistent with more binding of sense than antisense oligonucleotides, the converse of 
the in situ observations. Thus, these in vitro differences do not alone explain the 
observation of less non-specific binding of sense than antisense oligonucleotide 
probes to eosinophils during ISH. It is possible that an undetected, real difference in 
k,, and KD, which might explain the differential in situ binding, may have been missed 
due to a type 11 statistical error. However, it is probable that the property of the in 
vitro probe-ECP interaction that is most relevant to the in situ binding of probes to 
eosinophils is the dissociation constant, kd, as although equilibrium between 
association and dissociation will probably be reached during overnight incubation of 
the sections of bowel with the hybridisation solution containing the probes, during 
subsequent washes, which determine the amount of probe left on the sections, only 
dissociation of probes from eosinophils into the wash solution will occur, with 
virtually no association. 
Therefore, another factor must be the major determinant of the observed differential 
in situ binding of oligonucleotide probes, and this was hypothesised to be differential 
tissue penetration of probes, determined by their physical characteristics, particularly 
hydrophobicity. In Chapter 4, reverse-phase ion-pair liquid chromatography was used 
to measure hydrophobicity of oligonucleotide probes, when the antisense probes for 
Ir, Bcc mRNA were found to be significantly more hydrophobic than the sense probe. 
Hydrophobic probes will penetrate tissue sections more easily, and so the findings for 
oligonucleotide probe hydrophobicity are consistent with the observed greater in situ 
non-specific binding to eosinophils by antisense than by sense probes, and suggests 
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the amount of individual probe binding non-specifically to eosinophils in situ is 
determined predominantly by probe hydrophobicity, which limits tissue penetration 
and so limits the amount of probe available to bind to ECP in eosinophils. 
In early experiments, oligonucleotide probe bound non-specifically to eosinophils was 
retained after washes that removed poly-d(T) probe hybridised to the 
polyriboadenosine tail on all mRNA, which suggests that hybridisation of poly-d(T) 
probe to the polyriboadenosine tail on all mRNA is weaker than the interaction 
between oligonucleotide probes and ECP. As stated above, the amount of probe bound 
to ECP within eosinophils was determined predominantly by probe hydrophobicity, 
and it is likely that hybridisation of oligonucleotide probes to mRNA is affected by 
probe hydrophobicity to a similar or, more likely (because the interaction is weaker), a 
greater degree. There has been no previous investigation of this effect, which may be 
vitally important in establishing the validity of sense negative controls, which are 
widely used and rely on differential binding to target mRNA between sense and 
antisense probes. 
Hence, it may be important to match hydrophobicity of sense and antisense probes 
when choosing gene sequences for design of oligonucleotide probes. This effect is less 
likely to be important for longer probes, such as riboprobes or long cDNA probes, 
because long antisense and sense probes are statistically more likely to possess similar 
hydrophobicities. 
Previous studies using IP-RP-HPLC to detennine the contribution of individual bases 
to the total hydrophobicity of oligonucleotides have established the order of 
hydrophobicity of individual bases as C<G<A<T for the bulk of the 
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oligonucleotide, and C<G<T<A for the 3' terminal base (310). Approximate 
matching of probe hydrophobicity may be achieved without resorting to measurement 
by IP-RP-HPLC by calculating a proposed 'hydrophobicity score', where one point is 
allocated for an A at the 3' terminal and one point for each T in the rest of the 
oligonucleotide. In the present study, there was a strong correlation (r = 0.97 by 
Pearson's method of correlation, see Figure) between the measured hydrophobicity of 
the four probes and their respective calculated hydrophobicity scores. 
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Figure. Measured hydrophobicity (retention time in RP-IP HPLC columns in minutes) 
versus calculated hydrophobicity score of the four oligonucleotide probes for IKB(x. 






As stated above, IKB(x antisense probes were more hydrophobic than the sense probe, 
and tberefore penetrated sections better and bound in greater quantities to eosinophils 
than the sense probe. Was it by chance that the sequence chosen for the IKBct mRNA 
sense probe was less hydrophobic than the antisense probes? This question is 
important, because the use of sense probes in ISH is based on the premise that the 
chosen sequence renders them statistically unlikely to hybridise to mRNA vvithin 
cells. Thus, if, as proposed above, matching of hydrophobicity is important for parity 
in tissue penetration and subsequent opportunity to hybridise to target mRNA, or not 
hybridise in the case of sense probes, then a systematic bias in the sequences chosen 
for antisense vs sense probes that resulted in greater hydrophobicity of antisense than 
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sense probes would be of enormous significance, as it would bias the opportunity for 
hybridisation towards antisense probes. 
To help determine whether a systematic bias exists, hydrophobicity scores from the 
published sequences chosen for oligonucleotide antisense and sense probes in 
previous studies using oligonucleotide ISH were therefore calculated (Appendix V). 
In these studies, the mean (SD) calculated hydrophibicity score for antisense probes 
(9.1 (3.0)) was significantly greater (p = 0.047, compared using a paired t-test) than 
the mean for sense probes (6.4 (2.9)). 
Calculated hydrophobicity scores are predominantly dependent on the number of 
thymidine bases within the probe and, based on the calculated hydrophobicity scores 
of probes used in the literature, a systematic bias for selection of thymidine bases in 
antisense probes may exist. Potential explanations for this bias include: 
ea systematic bias in the method of selection of oligonucleotide probe antisense 
sequences towards choice of thymidine bases, thus concomitantly biasing towards 
fewer thymidine bases in the mirror-image sense probes. The principles and 
method of sequence selection are described in Chapter 2, section 2.4.1. No 
potential explanation for a systematic bias in this process could be suggested by an 
expert in the method (Dr. Steve Jones, Retinitis Pigmentosa Laboratory, The 
Rayne Institute, St. Thomas' Hospital), and 
9a relative excess of thymidine bases in the human genome. Relative nucleotide 
content of genomes varies between species, but in humans is approximately 30 % 
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A, 30% T, 20 %G and 20 % C. The relative nucleotide content of DNA in the 
genome of human liver, sperm and thymus is displayed in Appendix 6. Antisense 
oligonucleotide probes, which hybridise in ISH experiments to target mRNA, are 
of identical sequence to DNA coding for mRNA, and will therefore contain a mean 
of 30 % thymidine bases. However, because there is also an equal percentage of 
adenosine bases in DNA (and antisense probes), which are transcribed to thymidine 
bases in sense probes, the percentage of thymidine bases in sense probes will be 
similar to that in antisense probes. Therefore, the mean base constitution of the 
human genome will not result in a systematic bias in the hydrophobicity of probes. 
Thus, the explanation for the apparent difference in mean hydrophobicities of 
antisense and sense probes remains unclear. It may be that the difference in 
hydrophobicities of antisense and sense probes in this thesis occurred by chance, and 
that the difference observed in the published literature is due to a type I sampling 
error of the literature. 
Thus, attempts to develop an ISH method to detect activation of NFYB in sections of 
bowel were unsuccessful, but lead to important observations on the technique of 
oligonucleotide ISH. 
Whilst perforining this work, an antibody that is specific for the activated form of 
NFicB became commercially available and, in Chapter 5, this antibody was used to 
demonstrate a greater tissue-density of cells expressing activated NFxB in all layers of 
inflamed bowel from patients with CD compared to normal bowel from controls. 
Activation was restricted mainly to large mononuclear cells, morphologically 
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suggestive of macrophages, suggesting that these are a major cell involved in 
propagating inflammation in CD. Interestingly, a greater tissue-density of cells 
expressing activated NFKB was found in the submucosa, but not in the lamina propria 
or muscle layers, of macroscopically and microscopically non-inflamed CD bowel 
compared to normal bowel from controls, which suggests that the apparently non- 
inflamed bowel in CD may be more immunologically active than completely normal 
bowel from controls, consistent with other studies that have demonstrated subtle 
abnormalities in these areas. Such changes in non-inflamed areas in CD may predate 
overt inflammation and further study of these areas, rather than those that are already 
inflamed and possess a compromised mucosal barrier, may reveal more about the 
early events that generate inflammation in CD. 
In Chapter 6, a method to study the activation of NFKB with flow cytometry was 
proposed and investigated. A range of methods were tested, but only a method using 
enucleation of cells and subsequent fixation in 100 % methanol, followed by 
immunostaining with a three-layer technique, produced promising results. 
Unfortunately, results were not reliably reproduced in the time available for this 
project, and further work is required before this method can be utilised. Such a 
method would be a powerful tool that could be applied to many experiments. For 
instance, activation of NFicB in large numbers of cultured cells could be rapidly 
quantitated, and while this can already be assessed by existing methods such as 
EMSA, activation in subsets of cells, for instance subsets of isolated LPMNCs and 
PBMNCs, could also be quantitated. Such information might provide important 
insights into activation of subsets of cells of the immune system in IBD. 
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Future work 
1. To develop additional manoeuvres that more effectively block binding of 
oligonucleotide probes to eosinophils during ISH. These manoeuvres could be 
developed in vitro using biomolecular interaction analysis with ECP and 
oligonucleoticle probes, and then applied to ISH. 
2. To investigate further the relationship between oligonucleoticle probe 
hydrophobicity, tissue penetration and non-specific binding to eosinophils in 
sections of bowel with further experiments using new oligonucleotide probes of 
different base composition. 
3. To confirm the hypothesis that probe hydrophobicity is relevant to hybridisation of 
oligonucleotide probes to target mRNA, by performing ISH experiments using a 
range of different oligonucleotide probes, with differing base sequences, for the 
same target mRNA (using non-eosinophil-containing tissue, such as brain, as the 
problem of successful hybridisation without concomitant non-specific binding to 
eosinophils in sections of bowel is, as yet, unsolved). 
4. To confirm increased activation of NFKB in the submucosa of macroscopically and 
microscopically non-inflamed specimens of resected bowel from a larger group of 
patients. If the possibility of a type II sampling error could be more definitely 
excluded, then this important finding would concentrate future work on the 
submucosa of non-inflamed areas as the site of early changes in CD. Furthermore, 
262 
it would be interesting to correlate the activation of NF1cB with other previously 
documented subtle changes in these areas, such as neural changes (324,325), and to 
investigate the activation of other early response genes such as c-fos and c-jun. 
5. To perform immunohistochernical co-staining to confirm the identity of the cell 
type(s) expressing activated NFlcB in CD. 
6. To develop further the initial promising results using flow cytometry to measure 
activation of NFKB, and to apply this technique to measure and quantitate 
activation of NF1cB in isolated lamina propria mononuclear cells from patients with 
inflammatory bowel disease and controls, and to identify sub-populations of cells 
containing activated NFxB. Furthermore, this method could be used to measure 
activation of NFicB in cultured cells stimulated with solutions of inorganic sub- 
micron particles with bioactive bacterial products adsorbed onto their surface, thus 
linking with work within The Gastrointestinal Laboratory examining the potency, 
and mechanism of action, of these particles in inducing inflammatory responses, 
and their possible role in the aetiology of Crohn's disease (337,338). 
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AppendiX I 
Establishment of conditions for regeneration of dextran-ligand 
surfaces in the Biocore XTm cbi: p 
Ideal regeneration of the dextran-ligand surfaces of the chips in the Biocore Xrm in 
Chapter 3 results in reproducible bindings of analyte to the ligands (ECP and control 
proteins). For this to be achieved, the sensorgram should return after each 
regeneration injection to the level prior to binding of analyte, resulting in a small 
change in the baseline sensorgram, and suggesting complete removal of the analyte 
from the dextran-ligand surface without stripping of any ligand from the dextran. In 
addition, there should be reproducible magnitudes of binding of the probe analytes. 
The results in the Table and Figure represent a step-wise evolution of the constitution 
of the regeneration injection, where the constitution of the next injection to be tested 
was chosen after assessing the results obtained from the previous injection. 
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Table. Establishing regeneration conditions. Effect of injection of different volumes of regeneration solutions A to C on 
the magnitude of binding, in RU, of oligonucleotide I to ECP and myoglobin in chip A, and on regeneration of the dextran- 
ligand surface in each cell of the chip. Magnitude of binding is calculated as the change of the sensorgram, in RU, from before 
injection of probe to 80 seconds after injection (columns 2 and 4). Regeneration is assessed by change in the baseline sensorgrwn 
from before injection to after regeneration (columns 3 and 5). The aim is to establish reproducible magnitudes of binding with 
little change in the baseline sensorgram. The results represent a step-wise evolution of the constitution of the regeneration 
injection, where the constitution of the next regeneration injection (see section 3.5, Chapter 3 for constitution of solutions A. B 
and C) to be tested was chosen after assessing the results obtained from the previous regeneration irýection. Injections 12-20 are 
repeated injections of the same volume of the same regeneration solution to verify its reproducibility. Conclusions drawn from 
these data are discussed below, and the same data are displayed in graphs in the Figure, to allow easy identification of trends. 
Regeneration 
Injection (volume of 
regeneration 
solution) 
Magnitude of binding 
or probe to ECP (RQ 
following different 
regeneration injections 
Change in baseline 
ECP sensorgram from 
before injection of 
probe to after 
regeneration (RLT) 
Magnitude of binding 




Change in baseline 
myoglobin sensorgram 
from before injection of 
probe to after 
regeneration (RU) 
injection 1 (10 pJ A) 92.7 -149.1 1.7 -68.3 
injection 2 (5 p] A) 115.0 -35.4 -0.4 0.7 
injection 3 (1 p. 1 A) 106.3 -13.3 -3.2 -4.3 
injection 4 (1 pJ B) 94.8 19.0 -1.2 -3.2 
injection 5 (5 pl B) 76.8 -21.1 -0.5 3.9 
injection 6 (5 Id B) 87.6 0.3 -1.6 . 2.2 
Injection 7 (4 p] B) 80.6 6.2 . 0.3 1.0 
Injection 8 (5 pJ B) 64.3 -10.4 0.5 7.5 
injection 9 (10 pl Q 23.8 -10.0 -1.9 . 20.0 
injection 10 (2 Id Q 19.1 -9.7 0.1 . 12.3 
injection II (10 Q 24.2 3.3 -1.2 -10.6 
Injection 12 (2 ILI Q 21.9 -4.6 1.4 -9.3 
injection 13 (2 Id Q 17.9 . 4.2 -1.8 . 6.9 
injection 14 (2 pJ Q 19.4 0.3 0.9 0.2 
Injection 15 (2 pi Q 17.5 -0.5 -1.4 -5.1 
injection 16 (2 p1 Q 20.0 1.7 -1.2 -2.5 
Injection 17 (2 pi Q 20.0 4.7 -2.4 -2.0 
Injection IS (2 p] Q 19.4 -3.0 0.8 -6.3 
injection 19 (2 pi Q 17.5 2.8 0.3 -1.9 

































Figure. Establishing regeneration conditions. Effect of different volumes of regeneration solutions A 
to C (regeneration injections 1-20, see Table) on the magnitude of binding (displayed in black in RU) of 
oligonucleotide I to ECP (above) and myoglobin (below), and on regeneration of the dextran-ligand 
surface, as assessed by change in the sensorgrarn from before injection of probe to after regeneration 
(displayed in red in RU). The data plotted in these graphs are also displayed in the Table. the graphs 
allow easy identification of trends, particularly the approximately exponential decay in magnitude of 
binding of probe to ECP with successive bindings, at least until regeneration solution C is used (starting 
at regeneration injection 9), while the numerical data in the Table explain conclusions drawn below. 
Regeneration injections 12-20 are repeated injections of the same volume of the same regeneration 
solution to verify its properties. 
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Regeneration injection (we Table) 
Regeneration injection (see Table) 
The findings in the Table and Figure suggest the following conclusions about the 
regeneration injections: 
s there was an approximately exponential decay in magnitude of binding of probe to 
ECP (regeneration injections 1-8), at least until regeneration solution C was used 
(regeneration injections 9-20); 
9 the smallest injectable quantity (I gl) of solution A (regeneration injection 3) 
caused a fall in baseline ECP sensorgram from before injection of probe to after 
regeneration, suggesting stringent removal of probe bound to ECP in the previous 
cycle and possibly removal of ECP from dextran, but despite this apparently 
stringent regeneration, there was still a reduction in magnitude of subsequent probe 
binding to ECP; 
95 pl of solution B (regeneration injection 8) caused a fall in baseline ECP 
sensorgram from before injection of probe to after regeneration, but 4 pl 
(regeneration injection 7) caused a rise in baseline, suggesting inadequate 
regeneration of the dextran-ECP surface; 
* 10 gl of solution C (regeneration injection 9) caused a fall in baseline ECP 
sensorgram from before injection of probe to after regeneration, suggesting 
stringent removal of probe bound to ECP in the previous cycle and possibly 
removal of ECP from dextran, but despite this apparently stringent regeneration, 
there was still a reduction in magnitude of subsequent probe binding to ECP, and 
92 jil of solution C (regeneration injections 12-20) produced reproducible 
oligonucleotide binding to ECP and little change in the baseline sensorgrarn (mean 
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binding to ECP 18.8 RU, SD 1.7; mean change in baseline ECP sensorgram from 
before injection of probe to after regeneration 0.4 RU, SD 3.3). Furthermore, the 
magnitude of 'binding' to the control protein, myoglobin, varied little, and there 
were also only small changes in the baseline sensorgrarn (mean 'binding' to 
myoglobin -0.1 RU, SD 1.6; mean change in baseline myoglobin sensorgram. from 
before injection of probe to after regeneration -3.4 RU, SD 3.8). 
It was hypothesised that the decay in the magnitude of oligonucleotide probe binding 
to ECP with each successive binding indicated that either some probe was left bound 
to ECP after each regeneration injection, or that ECP poorly bound to the dextran 
matrix was shed during initial injections, or a combination of the two. 
Alternatively, the decay in the magnitude of oligonucleotide probe binding to ECP 
with successive binding might have been caused by a constituent of the running 
buffer. To exclude the possibility that EDTA in the running buffer, HBS, was 
stripping Zný+ from ECP and so altering its affinity for the probe, two experiments to 
replenish the putatively chelated Zn 2+ were performed: 
9a 10 gl bolus of 10 gM zinc chloride (BDH) was injected, followed by a change in 
the running buffer to HBS without EDTA, and 
* similarly, the running buffer was changed to HBS without EDTA but containing 
additional 10 gM ZnC12. 
Neither experiment had an effect on the underlying decay in magnitude of successive 
bindings of oligonucleotide probe to ECP, which suggested that EDTA within the 
running buffer was not stripping Zn2+ from ECP to cause this decay. 
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No matter the cause, the decay in magnitude of oligonucleotide probe binding to ECP 
was exponential and a sufficiently flat portion of the curve could be used to compare 
bindings of different probes, particularly if the four probes were bound in succession, 
i. e. antisense 1, antisense 2, antisense 3 and then sense, and then repeated in cycles in 
different order. 
Thus, 2 pl of solution C was chosen as the regeneration injection and HBS was used 
as the running buffer. 
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Appendix 11 
Protocol for staining of frozen sections with haematoxylin and eosin 
1. Stain sections by immersion in a bath of Mayer's haematoxylin (Sigma Chemical 
Company) for five minutes. 
2. 'Blue' sections by immersion in a bath of tap water for 2 minutes. 
3. Stain sections by immersion, for two minutes, in a bath of aI% (w/v) solution of 
eosin (Sigma Chemical Company) in a 95 % (v/v) solution of alcohol (BDH) in 
distilled water. 
4. Dehydrate sections by immersion, for two minutes, in successive baths of solutions 
of 95 % (v/v) alcohol in distilled water, twice, and then absolute alcohol, twice. 
5. Finally, immerse sections in baths of xylene (BDH) for two minutes, twice, and air 
dry sections for fifteen minutes. 
Apply a single drop of Ralmount (Sigma Chemical Company), cover with a coverslip 
(Sigma Chemical Company) and leave overnight. 
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Appendix III 
Quantitation of immunphistochemical staining for activated NFr. B 
Table 1. Number of hits counted per mm 2 using a Lennox graticule on sections of 
inflamed bowel immunostained for activated NFKB (+ve) and the negative control 
with PBS substituted for the primary antibody (-ve). In patients with CD, the 
differences between these counts (A) are displayed in a scattergram in Figure 9, 
Chapter 5. 
Patient Diagnosis Inflammato 
ry scorl? 
Number of positive cells per mmý of tissue 
lamina propria submucoss muscle 
+ve -ve +VC -Ve A +ve -ve A 
I CD 10 132 7 125 53 7 46 46 0 46 
2 CD 10 0 5 0* 10 
0 0 349 9 340 
3 CD 2 29 3 26 15 10 5 31 0 31 
4 CD 9 263 11 252 60 5 55 35 0 35 
5 CD 5 68 0 68 158 0 158 96 0 96 
6 CD 9 128 8 120 174 15 159 103 2 101 
7 CD 4 147 10 137 31 12 1 19 51 1 0 51 
8 CD 3 41 2 39 0 0 0 26 2 24 
9 CD 9 102 2 100 82 5 77 84 0 84 
10 CD 8 114 5 109 91 3 88 87 21 85 
11 CD 10 208 1 6 202 60 31 1 29 6 8 0* 
12 CD 2 39 2 37 73 0 73 53 0 53 
13 CD 8 333 0 333 285 0 285 
14 UC - 82 12 70 1 69 14 55 5 0 5 
15 UC 50 1 8 42 - - 15 2 13 
16 Wegener's 185 
17 Diverticulifis 93 83 9 74 
*where the count on the control (-ve) section was greater than the count on the section stained 
with the primary antibody (+ve), a value of 0 was allocated for the difference between them 
(A). 
*inflammatory score of the inflamed specimens. Non-inflamed specimens were obtained from 
patients 1,2,4,6 and 12, and had inflammatory scores of 0. 
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Table 111. Number of hits counted per mm 2 using a Lennox graticule on sections of 
non-inflamed bowel immunostained for activated NFKB (+ve) and the negative 
control with PBS substituted for the primary antibody (-ve). The differences between 
these counts (A) are displayed in a scattergram in Figure 9, Chapter 5. 
patient diagnosis Number of positive cells per mm' of tissue 
lamina propria submucosa muscle 
+ve -ve A +ve -ve A +ve -ve A 
I CD 53 6 47 29 0 29 8 0 8 
2 CD 108 5 103 175 25 150 - - 
4 CD 90 8 82 27 0 27 0 0 0 
6 CD 37 12 25 63 0 63 29 0 29 
10 CD 8 3 5 43 3 40 26 0 26 
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Table M. Number of hits counted per mm 2 using a Lennox graticule on sections of 
bowel from control patients immunostained for activated NFYB (+ve) and the 
negative control with PBS substituted for the primary antibody (-ve). The differences 
between these counts (A) are displayed in a scattergram in Figure 9, Chapter 5. 
control 
patient 
diagnosis Number of positive cells per meof tissue 
lamina propria submucosa muscle 
+ve -ve A +ve -ve A +ve -ve A 
I carcinoma 85 0 85 6 8 0* 21 0 21 
2 carcinoma 15 9 6 7 12 0* 0 0 0 
3 carcinoma 29 11 18 29 0 29 3 0 3 
4 carcinoma 52 4 48 32 3 29 3 0 3 
5 carcinoma 53 0 53 3 0 3 53 0 53 
6 carcinoma 32 16 16 11 16 0* 8 0 8 
7 carcinoma 53 0 53 32 3 29 0 0 0 
8 carcinoma 5 0 5 2 0 2 0 0 0 
9 carcinoma 33 4 29 12 2 10 5 1 4 
10 carcinoma 5 0 5 0 0 0 0 0 0 
11 carcinoma 9 6 3 8 3 5 3 0 3 
*where the count on the control (-ve) was greater than the count with the primary 
antibody (+ve), a value of 0 was allocated for the difference between them (A). 
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Appendix IV 
Reproducibilfty of counts of immunohistochemical stainin 
Table. Assessment of reproducibility of counts of cells immunostaining positive for 
activated NFKB. 
first count second count difference difference as 
(cells mmy (cells mmý between counts % of mean 
count 
patient 1 116 126 10 8.3 
lamina propria 
patient 1 50 48 2 4.1 
submucosa 
patient 1 48 52 4 8 
muscle 
patient 5 85 77 7 8.6 
lamina propria 
patient 5 154 143 11 7.4 
submucosa 
patient 5 93 98 5 5.2 
muscle 
patient 6 128 122 6 4.8 
lamina propria 
patient 6 151 162 11 7.0 
submucosa 







Calculated hydrophobiciiy scores for oligonucleotide probes 
Table. Hydrophobicity scores calculated from sequences for oligonucleotide antisense and sense 
probes used in previous publications. Publications were chosen using a Medline search for 
publications using oligonucleotide ISH on frozen sections of intestinal tract, and only those 
publications that included the sequence of oligonucleotide probes were included. 
Publication target mRNA Probetype 
antisense sense 
Kontakou M et al (291) interferon y 9 11 
11 6 
3 14 
TNF(x 9 5 
7 6 
5 9 
IL-6 12 3 
12 4 
10 4 
Beckett CG et al (289) IL-4 12 6 
13 4 
11 6 
IL-10 9 7 
2 
13 4 
Limb ct al(279) IL-1 P 9 9 
7 6 
5 7 
mean (SD) 9.1(3.0) 6.4(2.9) 
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Appendix VI 
Mean nucleotide base content of the human genome 
Table. Mean percentage nucleotide base content of human liver, sperm and thymus 
(294). 
% nucleotide base composition 
A T G C 
liver 30.3 30.3 19.5 19.9 
sperm 30.7 31.2 19.3 18.8 
thymus 30.9 29.4 19.9 19.8 
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